0001164888
false
Q2
--03-31
2022
0001164888
2021-04-01
2021-09-30
0001164888
2021-11-15
0001164888
2021-09-30
0001164888
2021-03-31
0001164888
us-gaap:SeriesAPreferredStockMember
2021-09-30
0001164888
us-gaap:SeriesAPreferredStockMember
2021-03-31
0001164888
us-gaap:SeriesBPreferredStockMember
2021-09-30
0001164888
us-gaap:SeriesBPreferredStockMember
2021-03-31
0001164888
2021-07-01
2021-09-30
0001164888
2020-07-01
2020-09-30
0001164888
2020-04-01
2020-09-30
0001164888
us-gaap:PreferredStockMember
2021-06-30
0001164888
KBPH:PreferredStockBMember
2021-06-30
0001164888
us-gaap:CommonStockMember
2021-06-30
0001164888
us-gaap:AdditionalPaidInCapitalMember
2021-06-30
0001164888
us-gaap:RetainedEarningsMember
2021-06-30
0001164888
2021-06-30
0001164888
us-gaap:PreferredStockMember
2021-07-01
2021-09-30
0001164888
KBPH:PreferredStockBMember
2021-07-01
2021-09-30
0001164888
us-gaap:CommonStockMember
2021-07-01
2021-09-30
0001164888
us-gaap:AdditionalPaidInCapitalMember
2021-07-01
2021-09-30
0001164888
us-gaap:RetainedEarningsMember
2021-07-01
2021-09-30
0001164888
us-gaap:PreferredStockMember
2021-09-30
0001164888
KBPH:PreferredStockBMember
2021-09-30
0001164888
us-gaap:CommonStockMember
2021-09-30
0001164888
us-gaap:AdditionalPaidInCapitalMember
2021-09-30
0001164888
us-gaap:RetainedEarningsMember
2021-09-30
0001164888
us-gaap:PreferredStockMember
2021-03-31
0001164888
KBPH:PreferredStockBMember
2021-03-31
0001164888
us-gaap:CommonStockMember
2021-03-31
0001164888
us-gaap:AdditionalPaidInCapitalMember
2021-03-31
0001164888
us-gaap:RetainedEarningsMember
2021-03-31
0001164888
us-gaap:PreferredStockMember
2021-04-01
2021-09-30
0001164888
KBPH:PreferredStockBMember
2021-04-01
2021-09-30
0001164888
us-gaap:CommonStockMember
2021-04-01
2021-09-30
0001164888
us-gaap:AdditionalPaidInCapitalMember
2021-04-01
2021-09-30
0001164888
us-gaap:RetainedEarningsMember
2021-04-01
2021-09-30
0001164888
us-gaap:PreferredStockMember
2020-06-30
0001164888
KBPH:PreferredStockBMember
2020-06-30
0001164888
us-gaap:CommonStockMember
2020-06-30
0001164888
us-gaap:AdditionalPaidInCapitalMember
2020-06-30
0001164888
us-gaap:RetainedEarningsMember
2020-06-30
0001164888
2020-06-30
0001164888
us-gaap:PreferredStockMember
2020-07-01
2020-09-30
0001164888
KBPH:PreferredStockBMember
2020-07-01
2020-09-30
0001164888
us-gaap:CommonStockMember
2020-07-01
2020-09-30
0001164888
us-gaap:AdditionalPaidInCapitalMember
2020-07-01
2020-09-30
0001164888
us-gaap:RetainedEarningsMember
2020-07-01
2020-09-30
0001164888
us-gaap:SeriesBPreferredStockMember
2020-09-30
0001164888
us-gaap:PreferredStockMember
2020-09-30
0001164888
KBPH:PreferredStockBMember
2020-09-30
0001164888
us-gaap:CommonStockMember
2020-09-30
0001164888
us-gaap:AdditionalPaidInCapitalMember
2020-09-30
0001164888
us-gaap:RetainedEarningsMember
2020-09-30
0001164888
2020-09-30
0001164888
us-gaap:PreferredStockMember
2020-03-31
0001164888
KBPH:PreferredStockBMember
2020-03-31
0001164888
us-gaap:CommonStockMember
2020-03-31
0001164888
us-gaap:AdditionalPaidInCapitalMember
2020-03-31
0001164888
us-gaap:RetainedEarningsMember
2020-03-31
0001164888
2020-03-31
0001164888
us-gaap:PreferredStockMember
2020-04-01
2020-09-30
0001164888
KBPH:PreferredStockBMember
2020-04-01
2020-09-30
0001164888
us-gaap:CommonStockMember
2020-04-01
2020-09-30
0001164888
us-gaap:AdditionalPaidInCapitalMember
2020-04-01
2020-09-30
0001164888
us-gaap:RetainedEarningsMember
2020-04-01
2020-09-30
0001164888
KBPH:AbferoPharmaceuticalsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueDecemeberTwoThousandTwentyTwoMember
2021-09-30
0001164888
KBPH:AbferoPharmaceuticalsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueDecemeberTwoThousandTwentyTwoMember
2021-04-01
2021-09-30
0001164888
KBPH:AcheliosTherapeuticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:AcheliosTherapeuticsIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneOneMember
2021-04-01
2021-09-30
0001164888
KBPH:AcheliosTherapeuticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneOneMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:AcheliosTherapeuticsIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneTwoMember
2021-04-01
2021-09-30
0001164888
KBPH:AcheliosTherapeuticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneTwoMember
2021-09-30
0001164888
KBPH:AcheliosTherapeuticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSidecarTwentyFivePercentageDiscountNoInterestMember
2021-09-30
0001164888
KBPH:AOADXIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteFourPercentageDueMayTwoThousandTwentyFourMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:AOADXIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteFourPercentageDueMayTwoThousandTwentyFourMember
2021-04-01
2021-09-30
0001164888
KBPH:AvisiTechnologiesIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueJulyTwoThousandTwentyTwoMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:AvisiTechnologiesIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteEightPercentageDueJulyTwoThousandTwentyTwoMember
2021-04-01
2021-09-30
0001164888
KBPH:BasepawsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteOnePercentageDueAprilTwoThousandTwentyMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:BasepawsIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteOnePercentageDueAprilTwoThousandTwentyMember
2021-04-01
2021-09-30
0001164888
KBPH:BeamSemiConductorIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyTwoMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:BeamSemiConductorIncMember
KBPH:TechnologyMember
KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyTwoMember
2021-04-01
2021-09-30
0001164888
KBPH:BeamSemiConductorIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueMarchTwoThousandTwentyOneMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:BeamSemiConductorIncMember
KBPH:TechnologyMember
KBPH:ConvertibleNoteEightPercentageDueMarchTwoThousandTwentyOneMember
2021-04-01
2021-09-30
0001164888
KBPH:BeamSemiConductorIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueMarchTwoThousandTwentyTwoMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:BeamSemiConductorIncMember
KBPH:TechnologyMember
KBPH:ConvertibleNoteEightPercentageDueMarchTwoThousandTwentyTwoMember
2021-04-01
2021-09-30
0001164888
KBPH:CoLabsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueFebruaryTwoThousandTwentyThreeMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:CoLabsIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteSixPercentageDueFebruaryTwoThousandTwentyThreeMember
2021-04-01
2021-09-30
0001164888
KBPH:CorinnovaIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyFourMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:CorinnovaIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyFourMember
2021-04-01
2021-09-30
0001164888
KBPH:CorinnovaIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyFourOneMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:CorinnovaIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyFourOneMember
2021-04-01
2021-09-30
0001164888
KBPH:CyberdonticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueSeptemberTwoThousandTwentyTwoMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:CyberdonticsIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteEightPercentageDueSeptemberTwoThousandTwentyTwoMember
2021-04-01
2021-09-30
0001164888
KBPH:CyberdonticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueFebruaryTwoThousandTwentyThreeMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:CyberdonticsIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteEightPercentageDueFebruaryTwoThousandTwentyThreeMember
2021-04-01
2021-09-30
0001164888
KBPH:CyberdonticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteZeroPercentageOnDueDateMember
2021-09-30
0001164888
KBPH:DeepBlueMedicalAdvancesIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueJuneTwoThousandTwentyTwoMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:DeepBlueMedicalAdvancesIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteSixPercentageDueJuneTwoThousandTwentyTwoMember
2021-04-01
2021-09-30
0001164888
KBPH:EveryKeyIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteFivePercentageDueDecemberTwoThousandTwentyThreeMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:EveryKeyIncMember
KBPH:TechnologyMember
KBPH:ConvertibleNoteFivePercentageDueDecemberTwoThousandTwentyThreeMember
2021-04-01
2021-09-30
0001164888
KBPH:IdenticalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteTwoPercentageDueMayTwoThousandTwentyTwoMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:IdenticalIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteTwoPercentageDueMayTwoThousandTwentyTwoMember
2021-04-01
2021-09-30
0001164888
KBPH:INBayTechnonlogyIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteTwelvePercentageDueOctoberTwoThousandTwentyMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:INBayTechnonlogyIncMember
KBPH:TechnologyMember
KBPH:ConvertibleNoteTwelvePercentageDueOctoberTwoThousandTwentyMember
2021-04-01
2021-09-30
0001164888
KBPH:INBayTechnonlogyIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteTwelvePercentageDueJulyTwoThousandTwentyOneMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:INBayTechnonlogyIncMember
KBPH:TechnologyMember
KBPH:ConvertibleNoteTwelvePercentageDueJulyTwoThousandTwentyOneMember
2021-04-01
2021-09-30
0001164888
KBPH:INBayTechnonlogyIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteTwelvePercentageDueFebruaryTwoThousandTwentyTwoMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:INBayTechnonlogyIncMember
KBPH:TechnologyMember
KBPH:ConvertibleNoteTwelvePercentageDueFebruaryTwoThousandTwentyTwoMember
2021-04-01
2021-09-30
0001164888
KBPH:INBayTechnonlogyIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyTwoMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:INBayTechnonlogyIncMember
KBPH:TechnologyMember
KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyTwoMember
2021-04-01
2021-09-30
0001164888
KBPH:INBayTechnonlogyIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyThreeMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:INBayTechnonlogyIncMember
KBPH:TechnologyMember
KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyThreeMember
2021-04-01
2021-09-30
0001164888
KBPH:IrisRAndDGroupIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueMayTwoThousandTwentyThreeMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:IrisRAndDGroupIncMember
KBPH:TechnologyMember
KBPH:ConvertibleNoteEightPercentageDueMayTwoThousandTwentyThreeMember
2021-04-01
2021-09-30
0001164888
KBPH:KianaAnalyticsMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteThreePercentageDueDecemberTwoThousandTwentyTwoMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:KianaAnalyticsMember
KBPH:TechnologyMember
KBPH:ConvertibleNoteThreePercentageDueDecemberTwoThousandTwentyTwoMember
2021-04-01
2021-09-30
0001164888
KBPH:KiotechMedicalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:KiotechMedicalIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember
2021-04-01
2021-09-30
0001164888
KBPH:KiotechMedicalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueNovemberTwoThousandTwentyTwoMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:KiotechMedicalIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteSixPercentageDueNovemberTwoThousandTwentyTwoMember
2021-04-01
2021-09-30
0001164888
KBPH:LifewaveBiomedicalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:LifewaveBiomedicalIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember
2021-04-01
2021-09-30
0001164888
KBPH:LifewaveBiomedicalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyOnlyMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:LifewaveBiomedicalIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyOnlyMember
2021-04-01
2021-09-30
0001164888
KBPH:LifewaveBiomedicalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyOneMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:LifewaveBiomedicalIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyOneMember
2021-04-01
2021-09-30
0001164888
KBPH:LowellTherapeuticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageNoDueDateMember
2021-09-30
0001164888
KBPH:MMTronIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteFourPercentageDueAprilTwoThousandTwentyThreeMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:MMTronIncMember
KBPH:TechnologyMember
KBPH:ConvertibleNoteFourPercentageDueAprilTwoThousandTwentyThreeMember
2021-04-01
2021-09-30
0001164888
KBPH:NavauxIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyThreeMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:NavauxIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyThreeMember
2021-04-01
2021-09-30
0001164888
KBPH:NeuroFoutyTwoIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyThreeMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:NeuroFoutyTwoIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyThreeMember
2021-04-01
2021-09-30
0001164888
KBPH:OctagonTherapeuticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:OctagonTherapeuticsIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneMember
2021-04-01
2021-09-30
0001164888
KBPH:OctagonTherapeuticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneOnlyMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:OctagonTherapeuticsIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneOnlyMember
2021-04-01
2021-09-30
0001164888
KBPH:PerikineticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueMayTwoThousandTwentyTwoMember
2021-09-30
0001164888
KBPH:PerikineticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueMayTwoThousandTwentyTwoMember
2021-04-01
2021-09-30
0001164888
KBPH:PreviewMedicalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSevenPercentageDueJanuaryTwoThousandTwentyThreeMember
2021-09-30
0001164888
KBPH:PreviewMedicalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSevenPercentageDueJanuaryTwoThousandTwentyThreeMember
2021-04-01
2021-09-30
0001164888
KBPH:PromaxoIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteFivePercentageDueJulyTwoThousandTwentyTwoMember
2021-09-30
0001164888
KBPH:PromaxoIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteFivePercentageDueJulyTwoThousandTwentyTwoMember
2021-04-01
2021-09-30
0001164888
KBPH:RheosIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueAugustTwoThousandTwentySixMember
2021-09-30
0001164888
KBPH:RheosIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueAugustTwoThousandTwentySixMember
2021-04-01
2021-09-30
0001164888
KBPH:SaccharoIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSevenPercentageDueSeptemberTwoThousandTwentyTwoMember
2021-09-30
0001164888
KBPH:SaccharoIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSevenPercentageDueSeptemberTwoThousandTwentyTwoMember
2021-04-01
2021-09-30
0001164888
KBPH:SageMedicCorpMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyOnePlusWarrantsMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:SageMedicCorpMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyOnePlusWarrantsMember
2021-04-01
2021-09-30
0001164888
KBPH:SageMedicCorpMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyTwoPlusWarrantsMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:SageMedicCorpMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyTwoPlusWarrantsMember
2021-04-01
2021-09-30
0001164888
KBPH:SensingElectromagneticPlusCorpMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteFullyReservedMember
2021-09-30
0001164888
KBPH:SensingElectromagneticPlusCorpMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteFullyReservedOneMember
2021-09-30
0001164888
KBPH:SinglePassIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageAprilTwoThousandTwentyFourMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:SinglePassIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteSixPercentageAprilTwoThousandTwentyFourMember
2021-04-01
2021-09-30
0001164888
KBPH:ValfixMedicalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDecemberTwoThousandTwentyOneMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ValfixMedicalIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteEightPercentageDecemberTwoThousandTwentyOneMember
2021-04-01
2021-09-30
0001164888
KBPH:XpanIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageMarchTwoThousandTwentyTwoMember
2021-09-30
0001164888
KBPH:XpanIncMember
KBPH:LifeScienceMember
us-gaap:CorporateNoteSecuritiesMember
KBPH:ConvertibleNoteEightPercentageMarchTwoThousandTwentyTwoMember
2021-09-30
0001164888
us-gaap:CorporateNoteSecuritiesMember
KBPH:XpanIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteEightPercentageMarchTwoThousandTwentyTwoMember
2021-04-01
2021-09-30
0001164888
KBPH:XpanIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:XpanIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoMember
2021-04-01
2021-09-30
0001164888
KBPH:XpanIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoOnlyMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:XpanIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoOnlyMember
2021-04-01
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
country:US
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
country:CA
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:RestOfWorldMember
2021-09-30
0001164888
KBPH:AltisBiosystemsMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
2021-09-30
0001164888
KBPH:AltisBiosystemsMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
2021-04-01
2021-09-30
0001164888
KBPH:AstrocytePharmaceuticalsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2021-09-30
0001164888
KBPH:AstrocytePharmaceuticalsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2021-04-01
2021-09-30
0001164888
KBPH:CnoteGroupIncMember
KBPH:FintechMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedTwoPreferredMember
2021-09-30
0001164888
KBPH:CnoteGroupIncMember
KBPH:FintechMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedTwoPreferredMember
2021-04-01
2021-09-30
0001164888
KBPH:CnoteGroupIncMember
KBPH:FintechMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedThreePreferredMember
2021-09-30
0001164888
KBPH:CnoteGroupIncMember
KBPH:FintechMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedThreePreferredMember
2021-04-01
2021-09-30
0001164888
KBPH:CoLabsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredMember
2021-09-30
0001164888
KBPH:CoLabsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredMember
2021-04-01
2021-09-30
0001164888
KBPH:ConnectusServicesLtdMember
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
2021-09-30
0001164888
KBPH:ConnectusServicesLtdMember
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
2021-04-01
2021-09-30
0001164888
KBPH:DeepBlueMedicalAdvancesIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2021-09-30
0001164888
KBPH:DeepBlueMedicalAdvancesIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2021-04-01
2021-09-30
0001164888
KBPH:EumentisThereapeuticsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2021-09-30
0001164888
KBPH:EumentisThereapeuticsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2021-04-01
2021-09-30
0001164888
KBPH:FemtoDXIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2021-09-30
0001164888
KBPH:FemtoDXIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2021-04-01
2021-09-30
0001164888
KBPH:HealionicsCorporationMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredMember
2021-09-30
0001164888
KBPH:HealionicsCorporationMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredMember
2021-04-01
2021-09-30
0001164888
KBPH:ILumenScientificIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredPlusWarrantsMember
2021-09-30
0001164888
KBPH:ILumenScientificIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredPlusWarrantsMember
2021-04-01
2021-09-30
0001164888
KBPH:ILumenScientificIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredPlusWarrantsOneMember
2021-09-30
0001164888
KBPH:ILumenScientificIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredPlusWarrantsOneMember
2021-04-01
2021-09-30
0001164888
KBPH:InhalonBiopharmaIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
2021-09-30
0001164888
KBPH:InhalonBiopharmaIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
2021-04-01
2021-09-30
0001164888
KBPH:LightLineMedicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteMember
2021-09-30
0001164888
KBPH:LightLineMedicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteMember
2021-04-01
2021-09-30
0001164888
KBPH:LightLineMedicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteOneMember
2021-09-30
0001164888
KBPH:LightLineMedicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteOneMember
2021-04-01
2021-09-30
0001164888
KBPH:LightLineMedicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
2021-09-30
0001164888
KBPH:LightLineMedicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
2021-04-01
2021-09-30
0001164888
KBPH:LightLineMedicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredPlusWarrantsMember
2021-09-30
0001164888
KBPH:LightLineMedicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredPlusWarrantsMember
2021-04-01
2021-09-30
0001164888
KBPH:LowellTherapeuticsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2021-09-30
0001164888
KBPH:LowellTherapeuticsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2021-04-01
2021-09-30
0001164888
KBPH:LowellTherapeuticsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredStockOneMember
2021-04-01
2021-09-30
0001164888
KBPH:LowellTherapeuticsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesBPreferredStockMember
2021-09-30
0001164888
KBPH:LowellTherapeuticsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesBPreferredStockMember
2021-04-01
2021-09-30
0001164888
KBPH:MakaniScienceIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
2021-09-30
0001164888
KBPH:MakaniScienceIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
2021-04-01
2021-09-30
0001164888
KBPH:MicronicTechnologiesIncMember
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedOnePreferredPlusWarrantsMember
2021-09-30
0001164888
KBPH:MicronicTechnologiesIncMember
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedOnePreferredPlusWarrantsMember
2021-04-01
2021-09-30
0001164888
KBPH:NeuroflowIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedTwoPreferredMember
2021-09-30
0001164888
KBPH:NeuroflowIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedTwoPreferredMember
2021-04-01
2021-09-30
0001164888
KBPH:NeuroflowIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesBPreferredStockMember
2021-09-30
0001164888
KBPH:NeuroflowIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesBPreferredStockMember
2021-04-01
2021-09-30
0001164888
KBPH:NewViewSurgicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredMember
2021-09-30
0001164888
KBPH:NewViewSurgicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredMember
2021-04-01
2021-09-30
0001164888
KBPH:NewViewSurgicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredOneMember
2021-09-30
0001164888
KBPH:NewViewSurgicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredOneMember
2021-04-01
2021-09-30
0001164888
KBPH:OrionBiotechnologyIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2021-09-30
0001164888
KBPH:OrionBiotechnologyIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2021-04-01
2021-09-30
0001164888
KBPH:OtomagneticsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredPlusWarrantsMember
2021-09-30
0001164888
KBPH:OtomagneticsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredPlusWarrantsMember
2021-04-01
2021-09-30
0001164888
KBPH:PartheousIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2021-09-30
0001164888
KBPH:PartheousIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2021-04-01
2021-09-30
0001164888
KBPH:PromaxolIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesBOnePreferredConvertedNoteMember
2021-09-30
0001164888
KBPH:PromaxoIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesBOnePreferredConvertedNoteMember
2021-04-01
2021-09-30
0001164888
KBPH:SealRockTherapeuticsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteMember
2021-09-30
0001164888
KBPH:SealRockTherapeuticsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteMember
2021-04-01
2021-09-30
0001164888
KBPH:ShyftFKACraterGroupIncMember
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredMember
2021-09-30
0001164888
KBPH:ShyftFKACraterGroupIncMember
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredMember
2021-04-01
2021-09-30
0001164888
KBPH:ShyftFKACraterGroupIncMember
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2021-09-30
0001164888
KBPH:ShyftFKACraterGroupIncMember
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredConvertedNoteMember
2021-04-01
2021-09-30
0001164888
KBPH:ShyftFKACraterGroupIncMember
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredConvertedNoteMember
2021-09-30
0001164888
KBPH:ShyftFKACraterGroupIncMember
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredConvertedNoteMember
2021-04-01
2021-09-30
0001164888
KBPH:TrellisBioscienceLLCMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesBPreferredPlusWarrantsMember
2021-09-30
0001164888
KBPH:TrellisBioscienceLLCMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesBPreferredPlusWarrantsMember
2021-04-01
2021-09-30
0001164888
KBPH:TrellisBioscienceLLCMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesBPreferredPlusWarrantsOneMember
2021-09-30
0001164888
KBPH:TrellisBioscienceLLCMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesBPreferredPlusWarrantsOneMember
2021-04-01
2021-09-30
0001164888
KBPH:TrellisBioscienceLLCMember
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesBPreferredPlusWarrantsTwoMember
2021-09-30
0001164888
KBPH:TrellisBioscienceLLCMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesBPreferredPlusWarrantsTwoMember
2021-04-01
2021-09-30
0001164888
KBPH:ValfixMedicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
2021-09-30
0001164888
KBPH:ValfixMedicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
2021-04-01
2021-09-30
0001164888
KBPH:VesteckIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2021-09-30
0001164888
KBPH:VesteckIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredConvertedNoteMember
2021-04-01
2021-09-30
0001164888
KBPH:VisgenxIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedOnePreferredConvertedNoteMember
2021-09-30
0001164888
KBPH:VisgenxIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedOnePreferredConvertedNoteMember
2021-04-01
2021-09-30
0001164888
KBPH:VisgenxIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteMember
2021-09-30
0001164888
KBPH:VisgenxIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteMember
2021-04-01
2021-09-30
0001164888
KBPH:VisgenxIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteOneMember
2021-09-30
0001164888
KBPH:VisgenxIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteOneMember
2021-04-01
2021-09-30
0001164888
KBPH:PreferredInvestmentsMember
2021-09-30
0001164888
KBPH:PreferredInvestmentsMember
country:US
2021-09-30
0001164888
KBPH:PreferredInvestmentsMember
country:CA
2021-09-30
0001164888
KBPH:PreferredInvestmentsMember
KBPH:RestOfWorldMember
2021-09-30
0001164888
KBPH:BendaRXCorpMember
KBPH:LifeScienceMember
KBPH:CommonStockInvestmentsMember
us-gaap:CommonStockMember
2021-09-30
0001164888
KBPH:BendaRXCorpMember
KBPH:LifeScienceMember
KBPH:CommonStockInvestmentsMember
us-gaap:CommonStockMember
2021-04-01
2021-09-30
0001164888
KBPH:BendaRXCorpMember
KBPH:LifeScienceMember
KBPH:CommonStockInvestmentsMember
KBPH:CommonStockOneMember
2021-09-30
0001164888
KBPH:BendaRXCorpMember
KBPH:LifeScienceMember
KBPH:CommonStockInvestmentsMember
KBPH:CommonStockOneMember
2021-04-01
2021-09-30
0001164888
KBPH:BoardwalkTechMember
KBPH:TechnologyMember
KBPH:CommonStockInvestmentsMember
us-gaap:CommonStockMember
2021-09-30
0001164888
KBPH:BoardwalkTechMember
KBPH:TechnologyMember
KBPH:CommonStockInvestmentsMember
us-gaap:CommonStockMember
2021-04-01
2021-09-30
0001164888
KBPH:BoardwalkTechMember
KBPH:TechnologyMember
KBPH:CommonStockInvestmentsMember
KBPH:CommonStockOneMember
2021-09-30
0001164888
KBPH:BoardwalkTechMember
KBPH:TechnologyMember
KBPH:CommonStockInvestmentsMember
KBPH:CommonStockOneMember
2021-04-01
2021-09-30
0001164888
KBPH:KuantsolIncMember
KBPH:TechnologyMember
KBPH:CommonStockInvestmentsMember
us-gaap:CommonStockMember
2021-09-30
0001164888
KBPH:KuantsolIncMember
KBPH:TechnologyMember
KBPH:CommonStockInvestmentsMember
us-gaap:CommonStockMember
2021-04-01
2021-09-30
0001164888
KBPH:CommonStockInvestmentMember
2021-09-30
0001164888
KBPH:CommonStockInvestmentsMember
country:US
2021-09-30
0001164888
KBPH:CommonStockInvestmentsMember
country:CA
2021-09-30
0001164888
KBPH:CommonStockInvestmentsMember
KBPH:RestOfWorldMember
2021-09-30
0001164888
KBPH:CommonStockInvestmentsMember
2021-09-30
0001164888
KBPH:InfinidomeLtdMember
KBPH:TechnologyMember
KBPH:SafeInvestmentsMember
KBPH:SafeMember
2021-09-30
0001164888
KBPH:InfinidomeLtdMember
KBPH:TechnologyMember
KBPH:SafeInvestmentsMember
KBPH:SafeOneMember
2021-09-30
0001164888
KBPH:MadorraIncMember
KBPH:SafeInvestmentsMember
KBPH:SafeInvestmentsMember
KBPH:SafeMember
2021-09-30
0001164888
KBPH:MitreMedicalCorpMember
KBPH:LifeScienceMember
KBPH:SafeInvestmentsMember
KBPH:SafeMember
2021-09-30
0001164888
KBPH:MitreMedicalCorpMember
KBPH:LifeScienceMember
KBPH:SafeInvestmentsMember
KBPH:SafeOneMember
2021-09-30
0001164888
KBPH:OrionBiotechnologyIncMember
KBPH:LifeScienceMember
KBPH:SafeInvestmentsMember
KBPH:SafeMember
2021-09-30
0001164888
KBPH:PolymertalIncMember
KBPH:TechnologyMember
KBPH:SafeInvestmentsMember
KBPH:SafeMember
2021-09-30
0001164888
KBPH:SafeInvestmentsMember
2021-09-30
0001164888
KBPH:SafeInvestmentsMember
country:US
2021-09-30
0001164888
KBPH:SafeInvestmentsMember
country:CA
2021-09-30
0001164888
KBPH:SafeInvestmentsMember
KBPH:RestOfWorldMember
2021-09-30
0001164888
KBPH:EnduralockLLCMember
KBPH:TechnologyMember
KBPH:OtherInvestmentMember
KBPH:SeriesAOneOwnershipUnitsMember
2021-09-30
0001164888
KBPH:EnduralockLLCMember
KBPH:TechnologyMember
KBPH:OtherInvestmentMember
KBPH:SeriesAOneOwnershipUnitsMember
2021-04-01
2021-09-30
0001164888
KBPH:EnduralockLLCMember
KBPH:TechnologyMember
KBPH:OtherInvestmentMember
KBPH:SeriesAOneOwnershipUnitsOneMember
2021-09-30
0001164888
KBPH:EnduralockLLCMember
KBPH:TechnologyMember
KBPH:OtherInvestmentMember
KBPH:SeriesAOneOwnershipUnitsOneMember
2021-04-01
2021-09-30
0001164888
KBPH:ExodosLifeSciencesLPMember
KBPH:LifeScienceMember
KBPH:OtherInvestmentMember
KBPH:SeriesAOneOwnershipUnitsMember
2021-09-30
0001164888
KBPH:GreenSunMedicalLLCMember
KBPH:LifeScienceMember
KBPH:OtherInvestmentMember
KBPH:ClassAOnePreferredOwnershipUnitsMember
2021-09-30
0001164888
KBPH:GreenSunMedicalLLCMember
KBPH:LifeScienceMember
KBPH:OtherInvestmentMember
KBPH:ClassAOnePreferredOwnershipUnitsMember
2021-04-01
2021-09-30
0001164888
KBPH:GreenSunMedicalLLCMember
KBPH:LifeScienceMember
KBPH:OtherInvestmentMember
KBPH:ClassAOnePreferredOwnershipUnitsOneMember
2021-09-30
0001164888
KBPH:GreenSunMedicalLLCMember
KBPH:LifeScienceMember
KBPH:OtherInvestmentMember
KBPH:ClassAOnePreferredOwnershipUnitsOneMember
2021-04-01
2021-09-30
0001164888
KBPH:GreenSunMedicalLLCMember
KBPH:LifeScienceMember
KBPH:OtherInvestmentMember
KBPH:ClassAOnePreferredOwnershipUnitsTwoMember
2021-09-30
0001164888
KBPH:GreenSunMedicalLLCMember
KBPH:LifeScienceMember
KBPH:OtherInvestmentMember
KBPH:ClassAOnePreferredOwnershipUnitsTwoMember
2021-04-01
2021-09-30
0001164888
KBPH:GreenSunMedicalLLCMember
KBPH:LifeScienceMember
KBPH:OtherInvestmentMember
KBPH:ClassAOnePreferredOwnershipUnitsThreeMember
2021-09-30
0001164888
KBPH:GreenSunMedicalLLCMember
KBPH:LifeScienceMember
KBPH:OtherInvestmentMember
KBPH:ClassAOnePreferredOwnershipUnitsThreeMember
2021-04-01
2021-09-30
0001164888
KBPH:RisoCapitalFundILPMember
KBPH:TechnologyMember
KBPH:OtherInvestmentMember
KBPH:OwnershipUnitsMember
2021-09-30
0001164888
KBPH:RisoCapitalFundILPMember
KBPH:TechnologyMember
KBPH:OtherInvestmentMember
KBPH:OwnershipUnitsOneMember
2021-09-30
0001164888
KBPH:OtherInvestmentMember
2021-09-30
0001164888
KBPH:OtherInvestmentMember
country:US
2021-09-30
0001164888
KBPH:OtherInvestmentMember
country:CA
2021-09-30
0001164888
KBPH:OtherInvestmentMember
KBPH:RestOfWorldMember
2021-09-30
0001164888
country:US
2021-09-30
0001164888
country:CA
2021-09-30
0001164888
KBPH:RestOfWorldMember
2021-09-30
0001164888
KBPH:AcheliosTherapeuticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneMember
2021-03-31
0001164888
KBPH:AcheliosTherapeuticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneMember
2020-04-01
2021-03-31
0001164888
KBPH:AcheliosTherapeuticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneOneMember
2021-03-31
0001164888
KBPH:AcheliosTherapeuticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneOneMember
2020-04-01
2021-03-31
0001164888
KBPH:AcheliosTherapeuticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneTwoMember
2021-03-31
0001164888
KBPH:AcheliosTherapeuticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneTwoMember
2020-04-01
2021-03-31
0001164888
KBPH:AvisiTechnologiesIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueJulyTwoThousandTwentyTwoMember
2021-03-31
0001164888
KBPH:AvisiTechnologiesIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueJulyTwoThousandTwentyTwoMember
2020-04-01
2021-03-31
0001164888
KBPH:BasepawsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteOnePercentageDueAprilTwoThousandTwentyMember
2021-03-31
0001164888
KBPH:BasepawsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteOnePercentageDueAprilTwoThousandTwentyMember
2020-04-01
2021-03-31
0001164888
KBPH:BeamSemiConductorIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyTwoMember
2021-03-31
0001164888
KBPH:BeamSemiConductorIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyTwoMember
2020-04-01
2021-03-31
0001164888
KBPH:BeamSemiConductorIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueMarchTwoThousandTwentyOneMember
2021-03-31
0001164888
KBPH:BeamSemiConductorIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueMarchTwoThousandTwentyOneMember
2020-04-01
2021-03-31
0001164888
KBPH:CorinnovaIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyFourMember
2021-03-31
0001164888
KBPH:CorinnovaIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyFourMember
2020-04-01
2021-03-31
0001164888
KBPH:CyberdonticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueSeptemberTwoThousandTwentyTwoMember
2021-03-31
0001164888
KBPH:CyberdonticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueSeptemberTwoThousandTwentyTwoMember
2020-04-01
2021-03-31
0001164888
KBPH:CyberdonticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueFebruaryTwoThousandTwentyThreeMember
2021-03-31
0001164888
KBPH:CyberdonticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueFebruaryTwoThousandTwentyThreeMember
2020-04-01
2021-03-31
0001164888
KBPH:CyberdonticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteZeroPercentageOnDueDateMember
2021-03-31
0001164888
KBPH:DeepBlueMedicalAdvancesIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueJuneTwoThousandTwentyTwoMember
2021-03-31
0001164888
KBPH:DeepBlueMedicalAdvancesIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueJuneTwoThousandTwentyTwoMember
2020-04-01
2021-03-31
0001164888
KBPH:EveryKeyIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteFivePercentageDueDecemberTwoThousandTwentyThreeMember
2021-03-31
0001164888
KBPH:EveryKeyIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteFivePercentageDueDecemberTwoThousandTwentyThreeMember
2020-04-01
2021-03-31
0001164888
KBPH:IdenticalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteTwoPercentageDueMayTwoThousandTwentyTwoMember
2021-03-31
0001164888
KBPH:IdenticalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteTwoPercentageDueMayTwoThousandTwentyTwoMember
2020-04-01
2021-03-31
0001164888
KBPH:INBayTechnonlogyIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteTwelvePercentageDueOctoberTwoThousandTwentyMember
2021-03-31
0001164888
KBPH:INBayTechnonlogyIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteTwelvePercentageDueOctoberTwoThousandTwentyMember
2020-04-01
2021-03-31
0001164888
KBPH:INBayTechnonlogyIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteTwelvePercentageDueJulyTwoThousandTwentyOneMember
2021-03-31
0001164888
KBPH:INBayTechnonlogyIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteTwelvePercentageDueJulyTwoThousandTwentyOneMember
2020-04-01
2021-03-31
0001164888
KBPH:INBayTechnonlogyIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteTwelvePercentageDueFebruaryTwoThousandTwentyTwoMember
2021-03-31
0001164888
KBPH:INBayTechnonlogyIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteTwelvePercentageDueFebruaryTwoThousandTwentyTwoMember
2020-04-01
2021-03-31
0001164888
KBPH:INBayTechnonlogyIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyTwoMember
2021-03-31
0001164888
KBPH:INBayTechnonlogyIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyTwoMember
2020-04-01
2021-03-31
0001164888
KBPH:KianaAnalyticsMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteThreePercentageDueDecemberTwoThousandTwentyTwoMember
2021-03-31
0001164888
KBPH:KianaAnalyticsMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteThreePercentageDueDecemberTwoThousandTwentyTwoMember
2020-04-01
2021-03-31
0001164888
KBPH:KiotechMedicalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember
2021-03-31
0001164888
KBPH:KiotechMedicalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember
2020-04-01
2021-03-31
0001164888
KBPH:KiotechMedicalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueNovemberTwoThousandTwentyTwoMember
2021-03-31
0001164888
KBPH:KiotechMedicalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueNovemberTwoThousandTwentyTwoMember
2020-04-01
2021-03-31
0001164888
KBPH:LifewaveBiomedicalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember
2021-03-31
0001164888
KBPH:LifewaveBiomedicalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember
2020-04-01
2021-03-31
0001164888
KBPH:LifewaveBiomedicalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyOnlyMember
2021-03-31
0001164888
KBPH:LifewaveBiomedicalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyOnlyMember
2020-04-01
2021-03-31
0001164888
KBPH:NavauxIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyThreeMember
2021-03-31
0001164888
KBPH:NavauxIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyThreeMember
2020-04-01
2021-03-31
0001164888
KBPH:NeuroFoutyTwoIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyThreeMember
2021-03-31
0001164888
KBPH:NeuroFoutyTwoIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyThreeMember
2020-04-01
2021-03-31
0001164888
KBPH:OctagonTherapeuticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneMember
2021-03-31
0001164888
KBPH:OctagonTherapeuticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneMember
2020-04-01
2021-03-31
0001164888
KBPH:OctagonTherapeuticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneOnlyMember
2021-03-31
0001164888
KBPH:OctagonTherapeuticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneOnlyMember
2020-04-01
2021-03-31
0001164888
KBPH:PerikineticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueMayTwoThousandTwentyTwoMember
2021-03-31
0001164888
KBPH:PerikineticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueMayTwoThousandTwentyTwoMember
2020-04-01
2021-03-31
0001164888
KBPH:PreviewMedicalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSevenPercentageDueJanuaryTwoThousandTwentyThreeMember
2021-03-31
0001164888
KBPH:PreviewMedicalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSevenPercentageDueJanuaryTwoThousandTwentyThreeMember
2020-04-01
2021-03-31
0001164888
KBPH:SageMedicCorpMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyOnePlusWarrantsMember
2021-03-31
0001164888
KBPH:SageMedicCorpMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyOnePlusWarrantsMember
2020-04-01
2021-03-31
0001164888
KBPH:SageMedicCorpMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyTwoPlusWarrantsMember
2021-03-31
0001164888
KBPH:SageMedicCorpMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyTwoPlusWarrantsMember
2020-04-01
2021-03-31
0001164888
KBPH:SensingElectromagneticPlusCorpMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteFullyReservedMember
2021-03-31
0001164888
KBPH:SensingElectromagneticPlusCorpMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteFullyReservedOneMember
2021-03-31
0001164888
KBPH:ValfixMedicalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDecemberTwoThousandTwentyOneMember
2021-03-31
0001164888
KBPH:ValfixMedicalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDecemberTwoThousandTwentyOneMember
2020-04-01
2021-03-31
0001164888
KBPH:XpanIncMember
KBPH:LifeScienceMember
us-gaap:CorporateNoteSecuritiesMember
KBPH:ConvertibleNoteEightPercentageMarchTwoThousandTwentyTwoMember
2021-03-31
0001164888
KBPH:XpanIncMember
KBPH:LifeScienceMember
us-gaap:CorporateNoteSecuritiesMember
KBPH:ConvertibleNoteEightPercentageMarchTwoThousandTwentyTwoMember
2020-04-01
2021-03-31
0001164888
KBPH:XpanIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoMember
2021-03-31
0001164888
KBPH:XpanIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoMember
2020-04-01
2021-03-31
0001164888
KBPH:XpanIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoOnlyMember
2021-03-31
0001164888
KBPH:XpanIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoOnlyMember
2020-04-01
2021-03-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
2021-03-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
country:US
2021-03-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
country:CA
2021-03-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:RestOfWorldMember
2021-03-31
0001164888
KBPH:AltisBiosystemsMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
2020-04-01
2021-03-31
0001164888
KBPH:AltisBiosystemsMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
2021-03-31
0001164888
KBPH:AstrocytePharmaceuticalsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2020-04-01
2021-03-31
0001164888
KBPH:AstrocytePharmaceuticalsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2021-03-31
0001164888
KBPH:CnoteGroupIncMember
KBPH:FintechMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedTwoPreferredMember
2020-04-01
2021-03-31
0001164888
KBPH:CnoteGroupIncMember
KBPH:FintechMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedTwoPreferredMember
2021-03-31
0001164888
KBPH:CnoteGroupIncMember
KBPH:FintechMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedThreePreferredMember
2020-04-01
2021-03-31
0001164888
KBPH:CnoteGroupIncMember
KBPH:FintechMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedThreePreferredMember
2021-03-31
0001164888
KBPH:CoLabsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredMember
2020-04-01
2021-03-31
0001164888
KBPH:CoLabsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredMember
2021-03-31
0001164888
KBPH:ConnectusServicesLtdMember
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
2020-04-01
2021-03-31
0001164888
KBPH:ConnectusServicesLtdMember
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
2021-03-31
0001164888
KBPH:DeepBlueMedicalAdvancesIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2020-04-01
2021-03-31
0001164888
KBPH:DeepBlueMedicalAdvancesIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2021-03-31
0001164888
KBPH:EumentisThereapeuticsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2020-04-01
2021-03-31
0001164888
KBPH:EumentisThereapeuticsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2021-03-31
0001164888
KBPH:FemtoDXIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2020-04-01
2021-03-31
0001164888
KBPH:FemtoDXIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2021-03-31
0001164888
KBPH:ILumenScientificIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredPlusWarrantsMember
2020-04-01
2021-03-31
0001164888
KBPH:ILumenScientificIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredPlusWarrantsMember
2021-03-31
0001164888
KBPH:ILumenScientificIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredPlusWarrantsOneMember
2020-04-01
2021-03-31
0001164888
KBPH:ILumenScientificIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredPlusWarrantsOneMember
2021-03-31
0001164888
KBPH:InhalonBiopharmaIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
2020-04-01
2021-03-31
0001164888
KBPH:InhalonBiopharmaIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
2021-03-31
0001164888
KBPH:LightLineMedicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteMember
2020-04-01
2021-03-31
0001164888
KBPH:LightLineMedicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteMember
2021-03-31
0001164888
KBPH:LightLineMedicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteOneMember
2020-04-01
2021-03-31
0001164888
KBPH:LightLineMedicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteOneMember
2021-03-31
0001164888
KBPH:LightLineMedicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
2020-04-01
2021-03-31
0001164888
KBPH:LightLineMedicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
2021-03-31
0001164888
KBPH:LightLineMedicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredPlusWarrantsMember
2020-04-01
2021-03-31
0001164888
KBPH:LightLineMedicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredPlusWarrantsMember
2021-03-31
0001164888
KBPH:LowellTherapeuticsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2020-04-01
2021-03-31
0001164888
KBPH:LowellTherapeuticsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2021-03-31
0001164888
KBPH:LowellTherapeuticsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredStockOneMember
2020-04-01
2021-03-31
0001164888
KBPH:LowellTherapeuticsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredStockOneMember
2021-03-31
0001164888
KBPH:MicronicTechnologiesIncMember
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedOnePreferredPlusWarrantsMember
2020-04-01
2021-03-31
0001164888
KBPH:MicronicTechnologiesIncMember
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedOnePreferredPlusWarrantsMember
2021-03-31
0001164888
KBPH:NeuroflowIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedTwoPreferredMember
2020-04-01
2021-03-31
0001164888
KBPH:NeuroflowIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedTwoPreferredMember
2021-03-31
0001164888
KBPH:NeuroflowIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesBPreferredStockMember
2020-04-01
2021-03-31
0001164888
KBPH:NeuroflowIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesBPreferredStockMember
2021-03-31
0001164888
KBPH:NewViewSurgicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredMember
2020-04-01
2021-03-31
0001164888
KBPH:NewViewSurgicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredMember
2021-03-31
0001164888
KBPH:OtomagneticsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredPlusWarrantsMember
2020-04-01
2021-03-31
0001164888
KBPH:OtomagneticsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredPlusWarrantsMember
2021-03-31
0001164888
KBPH:PromaxoMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesBOnePreferredConvertedNoteMember
2020-04-01
2021-03-31
0001164888
KBPH:PromaxoMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesBOnePreferredConvertedNoteMember
2021-03-31
0001164888
KBPH:SealRockTherapeuticsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteMember
2020-04-01
2021-03-31
0001164888
KBPH:SealRockTherapeuticsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteMember
2021-03-31
0001164888
KBPH:ShyftFKACraterGroupIncMember
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredMember
2020-04-01
2021-03-31
0001164888
KBPH:ShyftFKACraterGroupIncMember
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredMember
2021-03-31
0001164888
KBPH:ShyftFKACraterGroupIncMember
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredConvertedNoteMember
2020-04-01
2021-03-31
0001164888
KBPH:ShyftFKACraterGroupIncMember
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredConvertedNoteMember
2021-03-31
0001164888
KBPH:ShyftFKACraterGroupIncMember
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredConvertedNoteMember
2020-04-01
2021-03-31
0001164888
KBPH:ShyftFKACraterGroupIncMember
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredConvertedNoteMember
2021-03-31
0001164888
KBPH:TrellisBioscienceLLCMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesBPreferredPlusWarrantsMember
2020-04-01
2021-03-31
0001164888
KBPH:TrellisBioscienceLLCMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesBPreferredPlusWarrantsMember
2021-03-31
0001164888
KBPH:TrellisBioscienceLLCMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesBPreferredPlusWarrantsOneMember
2020-04-01
2021-03-31
0001164888
KBPH:TrellisBioscienceLLCMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesBPreferredPlusWarrantsOneMember
2021-03-31
0001164888
KBPH:TrellisBioscienceLLCMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesBPreferredPlusWarrantsTwoMember
2020-04-01
2021-03-31
0001164888
KBPH:TrellisBioscienceLLCMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesBPreferredPlusWarrantsTwoMember
2021-03-31
0001164888
KBPH:ValfixMedicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
2020-04-01
2021-03-31
0001164888
KBPH:ValfixMedicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
2021-03-31
0001164888
KBPH:VisgenxIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedOnePreferredConvertedNoteMember
2020-04-01
2021-03-31
0001164888
KBPH:VisgenxIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedOnePreferredConvertedNoteMember
2021-03-31
0001164888
KBPH:VisgenxIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteMember
2020-04-01
2021-03-31
0001164888
KBPH:VisgenxIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteMember
2021-03-31
0001164888
KBPH:VisgenxIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteOneMember
2020-04-01
2021-03-31
0001164888
KBPH:VisgenxIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteOneMember
2021-03-31
0001164888
KBPH:PreferredInvestmentsMember
2021-03-31
0001164888
KBPH:PreferredInvestmentsMember
country:US
2021-03-31
0001164888
KBPH:PreferredInvestmentsMember
country:CA
2021-03-31
0001164888
KBPH:PreferredInvestmentsMember
KBPH:RestOfWorldMember
2021-03-31
0001164888
KBPH:BendaRXCorpMember
KBPH:LifeScienceMember
KBPH:CommonStockInvestmentsMember
us-gaap:CommonStockMember
2020-04-01
2021-03-31
0001164888
KBPH:BendaRXCorpMember
KBPH:LifeScienceMember
KBPH:CommonStockInvestmentsMember
us-gaap:CommonStockMember
2021-03-31
0001164888
KBPH:BendaRXCorpMember
KBPH:LifeScienceMember
KBPH:CommonStockInvestmentsMember
KBPH:CommonStockOneMember
2020-04-01
2021-03-31
0001164888
KBPH:BendaRXCorpMember
KBPH:LifeScienceMember
KBPH:CommonStockInvestmentsMember
KBPH:CommonStockOneMember
2021-03-31
0001164888
KBPH:BoardwalkTechMember
KBPH:LifeScienceMember
KBPH:CommonStockInvestmentsMember
us-gaap:CommonStockMember
2020-04-01
2021-03-31
0001164888
KBPH:BoardwalkTechMember
KBPH:LifeScienceMember
KBPH:CommonStockInvestmentsMember
us-gaap:CommonStockMember
2021-03-31
0001164888
KBPH:CommonStockInvestmentsMember
2021-03-31
0001164888
KBPH:CommonStockInvestmentsMember
country:US
2021-03-31
0001164888
KBPH:CommonStockInvestmentsMember
country:CA
2021-03-31
0001164888
KBPH:CommonStockInvestmentsMember
KBPH:RestOfWorldMember
2021-03-31
0001164888
KBPH:InfinidomeLtdMember
KBPH:TechnologyMember
KBPH:SafeInvestmentsMember
KBPH:SafeMember
2021-03-31
0001164888
KBPH:InfinidomeLtdMember
KBPH:TechnologyMember
KBPH:SafeInvestmentsMember
KBPH:SafeOneMember
2021-03-31
0001164888
KBPH:MitreMedicalCorpMember
KBPH:LifeScienceMember
KBPH:SafeInvestmentsMember
KBPH:SafeMember
2021-03-31
0001164888
KBPH:MitreMedicalCorpMember
KBPH:LifeScienceMember
KBPH:SafeInvestmentsMember
KBPH:SafeOneMember
2021-03-31
0001164888
KBPH:OrionBiotechnologyIncMember
KBPH:LifeScienceMember
KBPH:SafeInvestmentsMember
KBPH:SafeMember
2021-03-31
0001164888
KBPH:SafeInvestmentsMember
2021-03-31
0001164888
KBPH:SafeInvestmentsMember
country:US
2021-03-31
0001164888
KBPH:SafeInvestmentsMember
country:CA
2021-03-31
0001164888
KBPH:SafeInvestmentsMember
KBPH:RestOfWorldMember
2021-03-31
0001164888
KBPH:EnduralockLLCMember
KBPH:TechnologyMember
KBPH:OtherInvestmentMember
KBPH:SeriesAOneOwnershipUnitsMember
2020-04-01
2021-03-31
0001164888
KBPH:EnduralockLLCMember
KBPH:TechnologyMember
KBPH:OtherInvestmentMember
KBPH:SeriesAOneOwnershipUnitsMember
2021-03-31
0001164888
KBPH:EnduralockLLCMember
KBPH:TechnologyMember
KBPH:OtherInvestmentMember
KBPH:SeriesAOneOwnershipUnitsOneMember
2020-04-01
2021-03-31
0001164888
KBPH:EnduralockLLCMember
KBPH:TechnologyMember
KBPH:OtherInvestmentMember
KBPH:SeriesAOneOwnershipUnitsOneMember
2021-03-31
0001164888
KBPH:ExodosLifeSciencesLPMember
KBPH:LifeScienceMember
KBPH:OtherInvestmentMember
KBPH:ClassAOnePreferredOwnershipUnitsMember
2021-03-31
0001164888
KBPH:GreenSunMedicalLLCMember
KBPH:LifeScienceMember
KBPH:OtherInvestmentMember
KBPH:ClassAOnePreferredOwnershipUnitsMember
2020-04-01
2021-03-31
0001164888
KBPH:GreenSunMedicalLLCMember
KBPH:LifeScienceMember
KBPH:OtherInvestmentMember
KBPH:ClassAOnePreferredOwnershipUnitsMember
2021-03-31
0001164888
KBPH:GreenSunMedicalLLCMember
KBPH:LifeScienceMember
KBPH:OtherInvestmentMember
KBPH:ClassAOnePreferredOwnershipUnitsOneMember
2020-04-01
2021-03-31
0001164888
KBPH:GreenSunMedicalLLCMember
KBPH:LifeScienceMember
KBPH:OtherInvestmentMember
KBPH:ClassAOnePreferredOwnershipUnitsOneMember
2021-03-31
0001164888
KBPH:GreenSunMedicalLLCMember
KBPH:LifeScienceMember
KBPH:OtherInvestmentMember
KBPH:ClassAOnePreferredOwnershipUnitsTwoMember
2020-04-01
2021-03-31
0001164888
KBPH:GreenSunMedicalLLCMember
KBPH:LifeScienceMember
KBPH:OtherInvestmentMember
KBPH:ClassAOnePreferredOwnershipUnitsTwoMember
2021-03-31
0001164888
KBPH:RisoCapitalFundILPMember
KBPH:TechnologyMember
KBPH:OtherInvestmentMember
KBPH:OwnershipUnitsMember
2021-03-31
0001164888
KBPH:OtherInvestmentMember
2021-03-31
0001164888
KBPH:OtherInvestmentMember
country:US
2021-03-31
0001164888
KBPH:OtherInvestmentMember
country:CA
2021-03-31
0001164888
KBPH:OtherInvestmentMember
KBPH:RestOfWorldMember
2021-03-31
0001164888
country:US
2021-03-31
0001164888
country:CA
2021-03-31
0001164888
KBPH:RestOfWorldMember
2021-03-31
0001164888
2018-03-31
0001164888
srt:MaximumMember
2021-09-30
0001164888
srt:ChiefExecutiveOfficerMember
2021-01-01
2021-01-02
0001164888
srt:ChiefExecutiveOfficerMember
2021-05-01
2021-05-31
0001164888
srt:ChiefExecutiveOfficerMember
2021-07-01
2021-09-30
0001164888
srt:ChiefExecutiveOfficerMember
2021-04-01
2021-09-30
0001164888
srt:ChiefExecutiveOfficerMember
2020-04-01
2020-09-30
0001164888
2021-10-01
0001164888
KBPH:ConsultantsAndAdvisorsMember
2021-07-01
2021-09-30
0001164888
KBPH:ConsultantsAndAdvisorsMember
2020-07-01
2020-09-30
0001164888
KBPH:ConsultantsAndAdvisorsMember
2021-04-01
2021-09-30
0001164888
KBPH:ConsultantsAndAdvisorsMember
2020-04-01
2020-09-30
0001164888
KBPH:CommonStockIssuedMember
2021-07-01
2021-09-30
0001164888
KBPH:CommonStockIssuedMember
2021-04-01
2021-09-30
0001164888
KBPH:CommonStockSubscribedNotIssuedMember
2021-07-01
2021-09-30
0001164888
KBPH:CommonStockSubscribedNotIssuedMember
2021-04-01
2021-09-30
0001164888
KBPH:SeriesAPreferredStocksMember
2021-07-01
2021-09-30
0001164888
KBPH:SeriesAPreferredStocksMember
2021-04-01
2021-09-30
0001164888
KBPH:SeriesBPreferredStocksMember
2021-07-01
2021-09-30
0001164888
KBPH:SeriesBPreferredStocksMember
2021-04-01
2021-09-30
0001164888
us-gaap:EmployeeStockOptionMember
2021-07-01
2021-09-30
0001164888
us-gaap:EmployeeStockOptionMember
2021-04-01
2021-09-30
0001164888
us-gaap:WarrantMember
2021-07-01
2021-09-30
0001164888
us-gaap:WarrantMember
2021-04-01
2021-09-30
0001164888
KBPH:CommonStockIssuedMember
2020-07-01
2020-09-30
0001164888
KBPH:CommonStockIssuedMember
2020-04-01
2020-09-30
0001164888
KBPH:SeriesAPreferredStocksMember
2020-07-01
2020-09-30
0001164888
KBPH:SeriesAPreferredStocksMember
2020-04-01
2020-09-30
0001164888
KBPH:SeriesBPreferredStocksMember
2020-07-01
2020-09-30
0001164888
KBPH:SeriesBPreferredStocksMember
2020-04-01
2020-09-30
0001164888
us-gaap:EmployeeStockOptionMember
2020-07-01
2020-09-30
0001164888
us-gaap:EmployeeStockOptionMember
2020-04-01
2020-09-30
0001164888
us-gaap:WarrantMember
2020-07-01
2020-09-30
0001164888
us-gaap:WarrantMember
2020-04-01
2020-09-30
0001164888
us-gaap:PreferredStockMember
2021-09-30
0001164888
us-gaap:PreferredStockMember
2021-03-31
0001164888
us-gaap:CommonStockMember
2021-09-30
0001164888
us-gaap:CommonStockMember
2021-03-31
0001164888
KBPH:SafeMember
2021-09-30
0001164888
KBPH:SafeMember
2021-03-31
0001164888
KBPH:OtherOwnershipUnitsMember
2021-09-30
0001164888
KBPH:OtherOwnershipUnitsMember
2021-03-31
0001164888
KBPH:InvestmentFairValueMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:BasepawsIncMember
2021-09-30
0001164888
KBPH:InvestmentFairValueMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:BasepawsIncMember
2021-07-01
2021-09-30
0001164888
KBPH:InvestmentFairValueMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:PromaxoIncMember
2021-09-30
0001164888
KBPH:InvestmentFairValueMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:PromaxoIncMember
2021-07-01
2021-09-30
0001164888
srt:WeightedAverageMember
KBPH:PromaxoIncMember
KBPH:InvestmentFairValueMember
us-gaap:ConvertibleDebtSecuritiesMember
2021-09-30
0001164888
KBPH:InvestmentFairValueMember
KBPH:ConvertibleDebtSecuritiesOtherMember
2021-09-30
0001164888
KBPH:InvestmentFairValueMember
KBPH:ConvertibleDebtSecuritiesOtherMember
2021-07-01
2021-09-30
0001164888
srt:MinimumMember
KBPH:InvestmentFairValueMember
KBPH:ConvertibleDebtSecuritiesOtherMember
2021-09-30
0001164888
srt:MaximumMember
KBPH:InvestmentFairValueMember
KBPH:ConvertibleDebtSecuritiesOtherMember
2021-09-30
0001164888
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesMember
KBPH:ShyftMovingIncMember
2021-09-30
0001164888
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesMember
KBPH:ShyftMovingIncMember
2021-07-01
2021-09-30
0001164888
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesMember
KBPH:SealRockTherapeuticsIncMember
2021-09-30
0001164888
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesMember
KBPH:SealRockTherapeuticsIncMember
2021-07-01
2021-09-30
0001164888
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesMember
KBPH:FemtoDXIncMember
2021-09-30
0001164888
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesMember
KBPH:FemtoDXIncMember
2021-07-01
2021-09-30
0001164888
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesMember
KBPH:PromaxoIncMember
2021-09-30
0001164888
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesMember
KBPH:PromaxoIncMember
2021-07-01
2021-09-30
0001164888
srt:MinimumMember
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesMember
KBPH:PromaxoIncMember
2021-09-30
0001164888
srt:MaximumMember
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesMember
KBPH:PromaxoIncMember
2021-09-30
0001164888
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesOtherMember
2021-09-30
0001164888
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesOtherMember
2021-07-01
2021-09-30
0001164888
KBPH:InvestmentFairValueMember
KBPH:CommonStockInPrivateCompaniesMember
2021-09-30
0001164888
KBPH:InvestmentFairValueMember
KBPH:CommonStockInPrivateCompaniesMember
2021-07-01
2021-09-30
0001164888
KBPH:InvestmentFairValueMember
KBPH:SafeMember
2021-09-30
0001164888
KBPH:InvestmentFairValueMember
KBPH:SafeMember
2021-07-01
2021-09-30
0001164888
KBPH:InvestmentFairValueMember
us-gaap:OtherInvestmentsMember
2021-09-30
0001164888
KBPH:InvestmentFairValueMember
us-gaap:OtherInvestmentsMember
2021-07-01
2021-09-30
0001164888
KBPH:InvestmentFairValueMember
2021-09-30
0001164888
KBPH:InvestmentFairValueMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:KitotechMedicalIncMember
2021-03-31
0001164888
KBPH:InvestmentFairValueMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:KitotechMedicalIncMember
2020-04-01
2021-03-31
0001164888
KBPH:InvestmentFairValueMember
us-gaap:ConvertibleDebtSecuritiesMember
2021-03-31
0001164888
KBPH:InvestmentFairValueMember
us-gaap:ConvertibleDebtSecuritiesMember
2020-04-01
2021-03-31
0001164888
srt:MinimumMember
KBPH:InvestmentFairValueMember
KBPH:ConvertibleDebtSecuritiesOtherMember
2021-03-31
0001164888
srt:MaximumMember
KBPH:InvestmentFairValueMember
KBPH:ConvertibleDebtSecuritiesOtherMember
2021-03-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesMember
KBPH:FemtoDXIncMember
2021-03-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesMember
KBPH:FemtoDXIncMember
2020-04-01
2021-03-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesMember
KBPH:NeuroflowIncMember
2021-03-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesMember
KBPH:NeuroflowIncMember
2020-04-01
2021-03-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesOtherMember
2021-03-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesOtherMember
2020-04-01
2021-03-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:CommonStockInPrivateCompaniesMember
2021-03-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:CommonStockInPrivateCompaniesMember
2020-04-01
2021-03-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:SafeMember
2021-03-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:SafeMember
2020-04-01
2021-03-31
0001164888
KBPH:InvestmentFairValueMember
us-gaap:OtherInvestmentsMember
2021-03-31
0001164888
KBPH:InvestmentFairValueMember
us-gaap:OtherInvestmentsMember
2020-04-01
2021-03-31
0001164888
KBPH:InvestmentFairValueMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel1Member
us-gaap:ConvertibleDebtSecuritiesMember
2021-09-30
0001164888
us-gaap:FairValueInputsLevel2Member
us-gaap:ConvertibleDebtSecuritiesMember
2021-09-30
0001164888
us-gaap:FairValueInputsLevel3Member
us-gaap:ConvertibleDebtSecuritiesMember
2021-09-30
0001164888
us-gaap:FairValueInputsLevel1Member
us-gaap:PreferredStockMember
2021-09-30
0001164888
us-gaap:FairValueInputsLevel2Member
us-gaap:PreferredStockMember
2021-09-30
0001164888
us-gaap:FairValueInputsLevel3Member
us-gaap:PreferredStockMember
2021-09-30
0001164888
us-gaap:FairValueInputsLevel1Member
KBPH:CommonStockInPrivateCompaniesMember
2021-09-30
0001164888
us-gaap:FairValueInputsLevel2Member
KBPH:CommonStockInPrivateCompaniesMember
2021-09-30
0001164888
us-gaap:FairValueInputsLevel3Member
KBPH:CommonStockInPrivateCompaniesMember
2021-09-30
0001164888
KBPH:CommonStockInPrivateCompaniesMember
2021-09-30
0001164888
us-gaap:FairValueInputsLevel1Member
KBPH:SafeMember
2021-09-30
0001164888
us-gaap:FairValueInputsLevel2Member
KBPH:SafeMember
2021-09-30
0001164888
us-gaap:FairValueInputsLevel3Member
KBPH:SafeMember
2021-09-30
0001164888
us-gaap:FairValueInputsLevel1Member
us-gaap:OtherInvestmentsMember
2021-09-30
0001164888
us-gaap:FairValueInputsLevel2Member
us-gaap:OtherInvestmentsMember
2021-09-30
0001164888
us-gaap:FairValueInputsLevel3Member
us-gaap:OtherInvestmentsMember
2021-09-30
0001164888
us-gaap:OtherInvestmentsMember
2021-09-30
0001164888
us-gaap:FairValueInputsLevel1Member
KBPH:PrivatePortfolioCompaniesMember
2021-09-30
0001164888
us-gaap:FairValueInputsLevel2Member
KBPH:PrivatePortfolioCompaniesMember
2021-09-30
0001164888
us-gaap:FairValueInputsLevel3Member
KBPH:PrivatePortfolioCompaniesMember
2021-09-30
0001164888
KBPH:PrivatePortfolioCompaniesMember
2021-09-30
0001164888
us-gaap:FairValueInputsLevel1Member
KBPH:CommonStockInPublicCompaniesMember
2021-09-30
0001164888
us-gaap:FairValueInputsLevel2Member
KBPH:CommonStockInPublicCompaniesMember
2021-09-30
0001164888
us-gaap:FairValueInputsLevel3Member
KBPH:CommonStockInPublicCompaniesMember
2021-09-30
0001164888
KBPH:CommonStockInPublicCompaniesMember
2021-09-30
0001164888
us-gaap:FairValueInputsLevel1Member
2021-09-30
0001164888
us-gaap:FairValueInputsLevel2Member
2021-09-30
0001164888
us-gaap:FairValueInputsLevel3Member
2021-09-30
0001164888
us-gaap:FairValueInputsLevel1Member
us-gaap:ConvertibleDebtSecuritiesMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel2Member
us-gaap:ConvertibleDebtSecuritiesMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel3Member
us-gaap:ConvertibleDebtSecuritiesMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel1Member
us-gaap:PreferredStockMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel2Member
us-gaap:PreferredStockMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel3Member
us-gaap:PreferredStockMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel1Member
KBPH:CommonStockInPrivateCompaniesMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel2Member
KBPH:CommonStockInPrivateCompaniesMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel3Member
KBPH:CommonStockInPrivateCompaniesMember
2021-03-31
0001164888
KBPH:CommonStockInPrivateCompaniesMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel1Member
KBPH:SafeMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel2Member
KBPH:SafeMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel3Member
KBPH:SafeMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel1Member
us-gaap:OtherInvestmentsMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel2Member
us-gaap:OtherInvestmentsMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel3Member
us-gaap:OtherInvestmentsMember
2021-03-31
0001164888
us-gaap:OtherInvestmentsMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel1Member
KBPH:PrivatePortfolioCompaniesMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel2Member
KBPH:PrivatePortfolioCompaniesMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel3Member
KBPH:PrivatePortfolioCompaniesMember
2021-03-31
0001164888
KBPH:PrivatePortfolioCompaniesMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel1Member
KBPH:CommonStockInPublicCompaniesMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel2Member
KBPH:CommonStockInPublicCompaniesMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel3Member
KBPH:CommonStockInPublicCompaniesMember
2021-03-31
0001164888
KBPH:CommonStockInPublicCompaniesMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel1Member
2021-03-31
0001164888
us-gaap:FairValueInputsLevel2Member
2021-03-31
0001164888
us-gaap:FairValueInputsLevel3Member
2021-03-31
0001164888
country:US
2021-04-01
2021-09-30
0001164888
country:CA
2021-04-01
2021-09-30
0001164888
KBPH:RestOfWorldMember
2021-04-01
2021-09-30
0001164888
country:US
2020-03-31
0001164888
country:CA
2020-03-31
0001164888
KBPH:RestOfWorldMember
2020-03-31
0001164888
country:US
2020-04-01
2020-09-30
0001164888
country:CA
2020-04-01
2020-09-30
0001164888
KBPH:RestOfWorldMember
2020-04-01
2020-09-30
0001164888
country:US
2020-09-30
0001164888
country:CA
2020-09-30
0001164888
KBPH:RestOfWorldMember
2020-09-30
0001164888
KBPH:FintechMember
2021-03-31
0001164888
KBPH:TechnologyMember
2021-03-31
0001164888
KBPH:LifeScienceMember
2021-03-31
0001164888
KBPH:FintechMember
2021-04-01
2021-09-30
0001164888
KBPH:TechnologyMember
2021-04-01
2021-09-30
0001164888
KBPH:LifeScienceMember
2021-04-01
2021-09-30
0001164888
KBPH:FintechMember
2021-09-30
0001164888
KBPH:TechnologyMember
2021-09-30
0001164888
KBPH:LifeScienceMember
2021-09-30
0001164888
KBPH:FintechMember
2020-03-31
0001164888
KBPH:TechnologyMember
2020-03-31
0001164888
KBPH:LifeScienceMember
2020-03-31
0001164888
KBPH:FintechMember
2020-04-01
2020-09-30
0001164888
KBPH:TechnologyMember
2020-04-01
2020-09-30
0001164888
KBPH:LifeScienceMember
2020-04-01
2020-09-30
0001164888
KBPH:FintechMember
2020-09-30
0001164888
KBPH:TechnologyMember
2020-09-30
0001164888
KBPH:LifeScienceMember
2020-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
2021-04-01
2021-09-30
0001164888
us-gaap:PreferredStockMember
2021-04-01
2021-09-30
0001164888
us-gaap:CommonStockMember
2021-04-01
2021-09-30
0001164888
KBPH:SafeMember
2021-04-01
2021-09-30
0001164888
KBPH:OtherOwnershipUnitsMember
2021-04-01
2021-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
2020-03-31
0001164888
us-gaap:PreferredStockMember
2020-03-31
0001164888
us-gaap:CommonStockMember
2020-03-31
0001164888
KBPH:SafeMember
2020-03-31
0001164888
KBPH:OtherOwnershipUnitsMember
2020-03-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
2020-04-01
2020-09-30
0001164888
us-gaap:PreferredStockMember
2020-04-01
2020-09-30
0001164888
us-gaap:CommonStockMember
2020-04-01
2020-09-30
0001164888
KBPH:SafeMember
2020-04-01
2020-09-30
0001164888
KBPH:OtherOwnershipUnitsMember
2020-04-01
2020-09-30
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
2020-09-30
0001164888
us-gaap:PreferredStockMember
2020-09-30
0001164888
us-gaap:CommonStockMember
2020-09-30
0001164888
KBPH:SafeMember
2020-09-30
0001164888
KBPH:OtherOwnershipUnitsMember
2020-09-30
0001164888
us-gaap:SeriesAPreferredStockMember
2021-04-01
2021-09-30
0001164888
us-gaap:SeriesAPreferredStockMember
2021-06-30
0001164888
KBPH:SeriesAOnePreferredStockMember
2021-09-30
0001164888
KBPH:SeriesAOnePreferredStockMember
2021-07-01
2021-09-30
0001164888
KBPH:SeriesAOneAndSeriesATwoPreferredStockMember
us-gaap:IPOMember
2021-07-01
2021-09-30
0001164888
KBPH:SeriesAOnePreferredStockMember
2021-04-01
2021-09-30
0001164888
KBPH:SeriesATwoPreferredStockMember
2021-04-01
2021-09-30
0001164888
us-gaap:SeriesBPreferredStockMember
2021-04-01
2021-09-30
0001164888
us-gaap:CommonStockMember
us-gaap:SeriesBPreferredStockMember
2021-03-02
0001164888
KBPH:SeriesBOnePreferredStockMember
2021-02-28
2021-03-02
0001164888
KBPH:SeriesBOneAndSeriesBTwoPreferredStockMember
us-gaap:IPOMember
2021-02-28
2021-03-02
0001164888
KBPH:SeriesBOnePreferredStockMember
2021-04-01
2021-09-30
0001164888
KBPH:SeriesBTwoPreferredStockMember
2021-04-01
2021-09-30
0001164888
KBPH:SeriesBOnePreferredStockMember
2021-07-01
2021-09-30
0001164888
KBPH:SeriesBThreePreferredStockMember
2021-09-30
0001164888
KBPH:SeriesBThreePreferredStockMember
2021-09-29
2021-09-30
0001164888
us-gaap:CommonStockMember
KBPH:AmendmentofPreferredStockMember
2021-07-01
2021-09-30
0001164888
us-gaap:CommonStockMember
KBPH:AmendmentofPreferredStockMember
2021-04-01
2021-09-30
0001164888
us-gaap:CommonStockMember
KBPH:AmendmentofPreferredStockMember
2021-03-31
0001164888
KBPH:TwoThousandAndEighteenStockOptionAndIncentivePlanMember
2018-04-28
2018-04-30
0001164888
KBPH:TwoThousandNineteenStockOptionAndIncentivePlanMember
2019-07-31
0001164888
KBPH:TwoThousandNineteenStockOptionAndIncentivePlanMember
2019-07-29
2019-07-31
0001164888
KBPH:TwoThousandAndTwentyStockOptionAndIncentivePlanMember
2020-12-31
0001164888
KBPH:NonQualifiedStockOptionsMember
2021-07-01
2021-09-30
0001164888
KBPH:NonQualifiedStockOptionsMember
2020-07-01
2020-09-30
0001164888
KBPH:NonQualifiedStockOptionsMember
2021-04-01
2021-09-30
0001164888
KBPH:NonQualifiedStockOptionsMember
2020-04-01
2020-09-30
0001164888
srt:MinimumMember
2021-03-31
0001164888
srt:MaximumMember
2021-03-31
0001164888
srt:MinimumMember
2021-04-01
2021-09-30
0001164888
srt:MaximumMember
2021-04-01
2021-09-30
0001164888
srt:MinimumMember
2020-04-01
2021-03-30
0001164888
srt:MaximumMember
2020-04-01
2021-03-30
0001164888
2020-04-01
2021-03-30
0001164888
us-gaap:WarrantMember
2020-03-31
0001164888
us-gaap:WarrantMember
2020-04-01
2020-09-30
0001164888
us-gaap:WarrantMember
2020-09-30
0001164888
us-gaap:WarrantMember
2019-04-01
2020-03-31
0001164888
us-gaap:WarrantMember
2021-03-31
0001164888
us-gaap:WarrantMember
2021-04-01
2021-09-30
0001164888
us-gaap:WarrantMember
2021-09-30
0001164888
us-gaap:WarrantMember
2020-04-01
2021-03-31
0001164888
2021-01-01
2021-09-30
0001164888
KBPH:SeriesBThreePreferredStockMember
us-gaap:SubsequentEventMember
2021-10-05
0001164888
us-gaap:SubsequentEventMember
KBPH:SeriesBThreePreferredStockMember
2021-11-12
2021-11-13
0001164888
us-gaap:SubsequentEventMember
2021-11-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
KBPH:Integer
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
10-Q
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE
ACT OF 1934
For
the quarterly period ended September 30, 2021
or
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE
ACT OF 1934
For
the transition period from: _____________ to _____________
KYTO
TECHNOLOGY AND LIFE SCIENCE, INC.
(Exact
name of registrant as specified in its charter)
delaware
|
|
000-50390
|
|
65-1086538
|
(State
or Other Jurisdiction |
|
(Commission
|
|
(I.R.S.
Employer |
of
Incorporation) |
|
File
Number) |
|
Identification
No.) |
13050
Paloma Road, Los Altos Hills, CA 94022
(Address
of Principal Executive Office) (Zip Code)
(650)
204 7896
(Registrant’s
telephone number, including area code)
(Former
name, former address and former fiscal year, if changed since last report)
Title
of each class |
|
Trading
Symbol |
|
Exchange |
Common
stock |
|
KBPH |
|
OTC
QB |
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (ss. 232.405 of this chapter) during the preceding 12 (or for such shorter period that the registrant was required
to submit such files). ☒ Yes No ☐
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
Large
accelerated filer |
☐ |
Accelerated
filer |
☐ |
|
Non-accelerated filer |
☐ |
Smaller
reporting company |
☒ |
|
Emerging
growth company |
☐ |
|
|
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ☐ Yes ☒ No
Indicate
the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
13,287,621
Common Shares - $.01 Par Value - as of November 15, 2021
KYTO
Technology and Life Science, Inc.
For
the quarterly period ended September 30, 2021
INDEX
PART
I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
Kyto
Technology and Life Science, Inc.
Condensed
Statements of Assets and Liabilities
| |
September 30, | | |
March 31, | |
| |
2021 | | |
2021 | |
| |
(Unaudited) | | |
| |
ASSETS | |
| | | |
| | |
Investments at fair value (cost of $7,904,636 and $5,686,545, respectively) | |
$ | 10,442,813 | | |
$ | 6,821,407 | |
Cash | |
| 316,124 | | |
| 1,437,868 | |
Other current assets | |
| 230,434 | | |
| 169,891 | |
Total Assets | |
$ | 10,989,371 | | |
$ | 8,429,166 | |
| |
| | | |
| | |
LIABILITIES | |
| | | |
| | |
| |
| | | |
| | |
Liabilities | |
| | | |
| | |
Accounts payable and accrued liabilities | |
$ | 84,477 | | |
$ | 193,141 | |
Accrued liabilities - related parties | |
| 87,000 | | |
| 51,420 | |
Common stock subscription liability | |
| - | | |
| 1,191,442 | |
Total Liabilities | |
| 171,477 | | |
| 1,436,003 | |
| |
| | | |
| | |
Commitments and Contingencies (Note 3) | |
| - | | |
| - | |
| |
| | | |
| | |
| |
| | | |
| | |
Net Assets | |
| | | |
| | |
Preferred stock authorized but not designated, $.01 par value 19,800,000 shares, none issued and outstanding as of September 30,
2021 and March 31, 2021, respectively | |
| - | | |
| - | |
Series A (including Series A-1 and A-2) preferred convertible stock, $0.01
par value, 4,200,000
shares designated, 4,200,000
issued and outstanding as of September 30, 2021 and March 31, 2021, respectively, aggregate liquidation preference of $6,720,000
at September 30, 2021 and March 31, 2021, respectively | |
| 42,001 | | |
| 42,001 | |
Series B (including Series B-1 and B-2) preferred convertible stock, $0.01
par value, 6,000,000
shares designated, 5,911,406
and 3,628,906
issued and outstanding as of September 30, 2021 and March 31, 2021, respectively, aggregate liquidation preference
of $9,458,250 at September 30, 2021 and $5,806,250 at March 31, 2021, respectively | |
| 59,114 | | |
| 36,289 | |
Preferred stock, value | |
| - | | |
| - | |
Common stock, $.01 par value, 40,000,000 shares authorized, 13,287,621 and 9,983,082 issued and
outstanding as of September 30, 2021 and March 31 2021, respectively | |
| 132,876 | | |
| 99,831 | |
Additional paid-in capital | |
| 42,878,748 | | |
| 39,772,228 | |
Accumulated deficit | |
| (32,294,845 | ) | |
| (32,957,186 | ) |
| |
| | | |
| | |
Total Net Assets | |
| 10,817,894 | | |
| 6,993,163 | |
| |
| | | |
| | |
Total Liabilities and Net Assets | |
$ | 10,989,371 | | |
$ | 8,429,166 | |
The
accompanying notes are an integral part of these condensed interim financial statements.
Kyto
Technology and Life Science, Inc.
Condensed
Statements of Operations
(Unaudited)
| |
2021 | | |
2020 | | |
2021 | | |
2020 | |
| |
For the Three months ended
September 30, | | |
For the Six months ended
September 30, | |
| |
2021 | | |
2020 | | |
2021 | | |
2020 | |
INVESTMENT INCOME | |
| | | |
| | | |
| | | |
| | |
| |
| | | |
| | | |
| | | |
| | |
Interest and other income | |
$ | - | | |
$ | - | | |
$ | - | | |
$ | 500 | |
| |
| | | |
| | | |
| | | |
| | |
Total investment income | |
| - | | |
| - | | |
| - | | |
| 500 | |
| |
| | | |
| | | |
| | | |
| | |
EXPENSES | |
| | | |
| | | |
| | | |
| | |
Professional fees | |
| 107,201 | | |
| 63,605 | | |
| 273,359 | | |
| 76,543 | |
Other operating expenses | |
| 245,519 | | |
| 96,506 | | |
| 466,027 | | |
| 122,936 | |
Interest and non operating expenses | |
| 1,596 | | |
| - | | |
| 1,588 | | |
| - | |
Total expenses | |
| 354,316 | | |
| 160,111 | | |
| 740,974 | | |
| 199,479 | |
| |
| | | |
| | | |
| | | |
| | |
Net investment loss | |
| (354,316 | ) | |
| (160,111 | ) | |
| (740,974 | ) | |
| (198,979 | ) |
| |
| | | |
| | | |
| | | |
| | |
Net change in unrealized gain from investments | |
| 1,350,449 | | |
| 478,248 | | |
| 1,403,315 | | |
| 478,248 | |
| |
| | | |
| | | |
| | | |
| | |
Net increase in net assets resulting from operations | |
$ | 996,133 | | |
$ | 318,137 | | |
$ | 662,341 | | |
$ | 279,269 | |
| |
| | | |
| | | |
| | | |
| | |
Basic earnings per Common Share, | |
| | | |
| | | |
| | | |
| | |
Net increase in net assets resulting from operations per common share | |
$ | 0.08 | | |
$ | 0.05 | | |
$ | 0.05 | | |
$ | 0.05 | |
| |
| | | |
| | | |
| | | |
| | |
Weighted average common shares outstanding | |
| 13,271,996 | | |
| 5,836,832 | | |
| 13,269,764 | | |
| 5,836,832 | |
| |
| | | |
| | | |
| | | |
| | |
Fully-diluted earnings per Common Share, | |
| | | |
| | | |
| | | |
| | |
Net increase in net assets resulting from operations per common share | |
$ | 0.04 | | |
$ | 0.02 | | |
$ | 0.03 | | |
$ | 0.02 | |
| |
| | | |
| | | |
| | | |
| | |
Weighted average common shares outstanding | |
| 27,338,695 | | |
| 17,987,040 | | |
| 26,263,218 | | |
| 17,058,856 | |
The
accompanying notes are an integral part of these condensed interim financial statements.
Kyto
Technology and Life Science, Inc.
Condensed
Statements of Changes in Net Assets for the Three and Six months ended September 30, 2021
(
Unaudited)
| |
| | |
Preferred
A | | |
| | |
Preferred
B | | |
| | |
Common | | |
Additional | | |
| | |
| |
| |
Preferred
A (Including Series A-1, A-2) | | |
Preferred
A
Stock
(Including Series A-1, A-2) | | |
Preferred
B (Including Series B-1, B-2) | | |
Preferred
B (Including Series B-1, B-2)
Stock | | |
Common | | |
Common
Stock | | |
Additional
Paid-in | | |
Accumulated | | |
| |
| |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Total | |
Three
months ended September 30, 2021 | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balance,
June 30, 2021 | |
| 4,200,000 | | |
$ | 42,001 | | |
| 4,320,156 | | |
$ | 43,202 | | |
| 13,268,871 | | |
$ | 132,689 | | |
$ | 41,610,332 | | |
$ | (33,290,978 | ) | |
$ | 8,537,246 | |
Net
increase in net assets resulting from operations | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 996,133 | | |
| 996,133 | |
Sale
of Series B-1 Preferred stock at $0.80
per share | |
| - | | |
| - | | |
| 1,591,250 | | |
| 15,912 | | |
| | | |
| | | |
| 1,257,088 | | |
| | | |
| 1,273,000 | |
Sale
of common stock at $0.40 per share | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Sale
of common stock at $0.40 per share, shares | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Exercise
of stock options | |
| | | |
| | | |
| | | |
| | | |
| 18,750 | | |
| 187 | | |
| 431 | | |
| | | |
| 618 | |
Compensation
expense from stock options | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 10,897 | | |
| | | |
| 10,897 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balance,
September 30, 2021 | |
| 4,200,000 | | |
$ | 42,001 | | |
| 5,911,406 | | |
$ | 59,114 | | |
| 13,287,621 | | |
$ | 132,876 | | |
$ | 42,878,748 | | |
$ | (32,294,845 | ) | |
$ | 10,817,894 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Six
months ended September 30, 2021 | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balance,
March 31, 2021 | |
| 4,200,000 | | |
$ | 42,001 | | |
| 3,628,906 | | |
$ | 36,289 | | |
| 9,983,082 | | |
$ | 99,831 | | |
$ | 39,772,228 | | |
$ | (32,957,186 | ) | |
$ | 6,993,163 | |
Net
increase in net assets resulting from operations | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 662,341 | | |
| 662,341 | |
Sale
of Series B-1 Preferred stock at $0.80
per share | |
| - | | |
| - | | |
| 2,282,500 | | |
| 22,825 | | |
| | | |
| | | |
| 1,803,176 | | |
| | | |
| 1,826,001 | |
Sale
of common stock at $0.40 per share | |
| | | |
| | | |
| | | |
| | | |
| 3,285,789 | | |
| 32,858 | | |
| 1,281,459 | | |
| | | |
| 1,314,317 | |
Exerrcise
of stock options | |
| | | |
| | | |
| | | |
| | | |
| 18,750 | | |
| 187 | | |
| 431 | | |
| | | |
| 618 | |
Compensation
expense from stock options | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| 21,454 | | |
| | | |
| 21,454 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balance,
September 30, 2021 | |
| 4,200,000 | | |
$ | 42,001 | | |
| 5,911,406 | | |
$ | 59,114 | | |
| 13,287,621 | | |
$ | 132,876 | | |
$ | 42,878,748 | | |
$ | (32,294,845 | ) | |
$ | 10,817,894 | |
The
accompanying notes are an integral part of these condensed interim financial statements.
Kyto
Technology and Life Science, Inc.
Condensed
Statements of Changes in Net Assets for the Three and Six months ended September 30, 2020
(
Unaudited)
| |
Preferred
A | | |
Preferred
A
Stock | | |
Preferred
B | | |
Preferred
B
Stock
| | |
Common | | |
Common
Stock | | |
Additional
Paid-in | | |
Accumulated | | |
| |
| |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Total | |
| |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| |
Three months ended September
30, 2020 | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balance, June
30, 2020 | |
| 42,000,000 | | |
$ | 42,001 | | |
| 1,281,250 | | |
$ | 12,188 | | |
| 5,836,832 | | |
$ | 58,368 | | |
$ | 36,315,354 | | |
$ | (33,423,120 | ) | |
$ | 3,004,791 | |
Net
increase in net assets resulting from operations | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 318,137 | | |
| 318,137 | |
Sale of Series B Preferred
stock at $0.80 per share | |
| - | | |
| - | | |
| 1,056,250 | | |
| 11,187 | | |
| - | | |
| - | | |
| 883,813 | | |
| - | | |
| 895,000 | |
Compensation expense from stock
options | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 12,803 | | |
| - | | |
| 12,803 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balance,
September 30, 2020 | |
| 42,000,000 | | |
$ | 42,001 | | |
| 2,337,500 | | |
$ | 23,375 | | |
| 5,836,832 | | |
$ | 58,368 | | |
$ | 37,211,970 | | |
$ | (33,104,983 | ) | |
$ | 4,230,731 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Six months ended September
30, 2020 | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balance, March 31, 2020 | |
| 42,000,000 | | |
$ | 42,001 | | |
| 812,500 | | |
$ | 8,125 | | |
| 5,836,832 | | |
$ | 58,368 | | |
$ | 35,943,369 | | |
$ | (33,384,252 | ) | |
$ | 2,667,611 | |
Balance | |
| 42,000,000 | | |
$ | 42,001 | | |
| 812,500 | | |
$ | 8,125 | | |
| 5,836,832 | | |
$ | 58,368 | | |
$ | 35,943,369 | | |
$ | (33,384,252 | ) | |
$ | 2,667,611 | |
Net
increase in net assets resulting from operations | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 279,269 | | |
| 279,269 | |
Sale of Series B Preferred
stock at $0.80 per share | |
| - | | |
| - | | |
| 1,525,000 | | |
| 15,250 | | |
| - | | |
| - | | |
| 1,254,750 | | |
| - | | |
| 1,270,000 | |
Compensation expense from stock
options | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 13,851 | | |
| - | | |
| 13,851 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balance,
September 30, 2020 | |
| 42,000,000 | | |
$ | 42,001 | | |
| 2,337,500 | | |
$ | 23,375 | | |
| 5,836,832 | | |
$ | 58,368 | | |
$ | 37,211,970 | | |
$ | (33,104,983 | ) | |
$ | 4,230,731 | |
Balance | |
| 42,000,000 | | |
$ | 42,001 | | |
| 2,337,500 | | |
$ | 23,375 | | |
| 5,836,832 | | |
$ | 58,368 | | |
$ | 37,211,970 | | |
$ | (33,104,983 | ) | |
$ | 4,230,731 | |
The
accompanying notes are an integral part of these condensed interim financial statements.
Kyto
Technology and Life Science, Inc.
Condensed
Statements of Cash Flows
(Unaudited)
| |
2021 | | |
2020 | |
| |
Six months months ended
September 30, | |
| |
2021 | | |
2020 | |
| |
| | |
| |
Operating activities: | |
| | | |
| | |
Net increase in net assets resulting from operations | |
$ | 662,341 | | |
$ | 279,269 | |
Adjustments to reconcile net increase (decrease) in net assets resulting from
operations to net cash used in operating activities | |
| | | |
| | |
Net change in unrealized gain on investments | |
| (1,403,315 | ) | |
| (478,248 | ) |
Stock option compensation expense | |
| 21,454 | | |
| 13,851 | |
Change in operating assets and liabilities | |
| | | |
| | |
Other current assets | |
| (60,543 | ) | |
| 500 | |
Accounts payable and accrued liabilities | |
| (108,664 | ) | |
| 15,064 | |
Accrued liabilities to related parties | |
| 35,580 | | |
| - | |
Purchase of investments | |
| (2,218,091 | ) | |
| (740,000 | ) |
Net cash used in operating activities | |
| (3,071,238 | ) | |
| (909,564 | ) |
| |
| | | |
| | |
Cash flows from financing activities: | |
| | | |
| | |
Sale of Common stock in connection with preference rights (see Note 6) | |
| 122,875 | | |
| - | |
Sale of Common stock from exercise of options stock | |
| 618 | | |
| - | |
Sale of Series B-1 Preferred stock | |
| 1,826,001 | | |
| 1,270,000 | |
Receipt of SBA loan | |
| - | | |
| 1,000 | |
Advances from related party | |
| - | | |
| 2,250 | |
Net cash provided by financing activities | |
| 1,949,494 | | |
| 1,273,250 | |
| |
| | | |
| | |
Net increase/(decrease) in cash | |
| (1,121,744 | ) | |
| 363,686 | |
Cash, beginning of period | |
| 1,437,868 | | |
| 33,756 | |
| |
| | | |
| | |
Cash, end of period | |
$ | 316,124 | | |
$ | 397,442 | |
| |
| | | |
| | |
Supplemental cash flow information | |
| | | |
| | |
Interest paid | |
$ | 1,588 | | |
$ | - | |
Taxes paid | |
$ | 800 | | |
$ | 800 | |
Supplemental schedule of noncash financing activities: | |
| | | |
| | |
Conversion of common stock subscription liability to common stock | |
$ | 1,191,442 | | |
$ | - | |
The
accompanying notes are an integral part of these condensed interim financial statements.
Kyto
Technology and Life Science, Inc.
Condensed
Schedule of Investments as of September 30, 2021
(Unaudited)
| |
Portfolio
Company |
| |
Industry | |
Investment | |
Cost | | |
Fair
value | | |
%
of net assets (a) | |
Convertible loan investments |
| |
| |
| |
| | | |
| | | |
| | |
| |
Abfero
Pharmaceuticals Inc |
| |
Life
science | |
Convertible
Note, 6% due, December 2022 | |
$ | 100,000 | | |
$ | 102,630 | | |
| 0.9 | % |
(
i ) | |
Achelios
Therapeutics Inc. |
| |
Life
science | |
Convertible
Note, 8% due, December 2021 | |
| 100,000 | | |
| 125,184 | | |
| 1.2 | % |
(
i ) | |
Achelios
Therapeutics Inc. |
| |
Life
science | |
Convertible
Note, 8% due December 2021 | |
| 25,000 | | |
| 30,036 | | |
| 0.3 | % |
(
i ) | |
Achelios
Therapeutics Inc. |
| |
Life
science | |
Convertible
Note, 8% due December 2021 | |
| 50,000 | | |
| 56,586 | | |
| 0.5 | % |
(
i ) | |
Achelios
Therapeutics Inc. |
| |
Life
science | |
Convertible
Note Sidecar, 25% discount. No interest | |
| 50,000 | | |
| 50,000 | | |
| 0.5 | % |
| |
AOA
DX Inc |
| |
Life
science | |
Convertible
Note, 4%, due May 2024 | |
| 100,000 | | |
| 101,567 | | |
| 0.9 | % |
| |
Avisi
Technologies Inc |
| |
Life
science | |
Convertible
Note, 8% due July 2022 | |
| 50,000 | | |
| 54,679 | | |
| 0.5 | % |
| |
Basepaws
Inc |
| |
Life
science | |
Convertible
Note, 1% due April 2020 | |
| 50,000 | | |
| 201,663 | | |
| 1.9 | % |
(
i ) | |
Beam
Semiconductor Inc |
*
| |
Technology | |
Convertible
Note, 8% due April 2022 | |
| 150,000 | | |
| 177,058 | | |
| 1.6 | % |
(
i ) | |
Beam
Semiconductor Inc |
*
| |
Technology | |
Convertible
Note, 8% due March 2021 | |
| 50,000 | | |
| 56,290 | | |
| 0.5 | % |
(
i ) | |
Beam
Semiconductor Inc |
*
| |
Technology | |
Convertible
Note, 8% due March 2022 | |
| 100,000 | | |
| 103,704 | | |
| 1.0 | % |
| |
CoLabs
Inc |
| |
Life
science | |
Convertible
Note, 6% due February 2023 | |
| 50,000 | | |
| 50,304 | | |
| 0.5 | % |
| |
Corinnova
Inc |
| |
Life
science | |
Convertible
Note, 6% due December 2024 | |
| 100,000 | | |
| 105,211 | | |
| 1.0 | % |
| |
Corinnova
Inc |
| |
Life
science | |
Convertible
Note, 6% due December 2024 | |
| 50,000 | | |
| 50,164 | | |
| 0.5 | % |
* | |
Cyberdontics
Inc |
*
| |
Life
science | |
Convertible
Note, 8% due September 2022 | |
| 30,000 | | |
| 34,971 | | |
| 0.3 | % |
* | |
Cyberdontics
Inc |
*
| |
Life
science | |
Convertible
Note, 8% due February 2023 | |
| 35,000 | | |
| 39,457 | | |
| 0.4 | % |
* | |
Cyberdontics
Inc |
*
| |
Life
science | |
Convertible
Note, 0% no due date | |
| 35,000 | | |
| 37,700 | | |
| 0.3 | % |
| |
Deep
Blue Medical Advances Inc |
| |
Life
science | |
Convertible
Note, 6% due June 2022 | |
| 50,000 | | |
| 52,351 | | |
| 0.5 | % |
| |
Every
Key Inc |
| |
Technology | |
Convertible
Note, 5% due December 2023 | |
| 100,000 | | |
| 109,027 | | |
| 1.0 | % |
| |
Identical
Inc |
| |
Life
science | |
Convertible
Note, 2% due May 2022 | |
| 100,000 | | |
| 101,775 | | |
| 0.9 | % |
* | |
INBay
Technology Inc |
| |
Technology | |
Convertible
Note, 12% due October 2020 | |
| 50,000 | | |
| 67,589 | | |
| 0.6 | % |
* | |
INBay
Technology Inc |
| |
Technology | |
Convertible
Note, 12% due July 2021 | |
| 30,000 | | |
| 38,028 | | |
| 0.4 | % |
* | |
INBay
Technology Inc |
| |
Technology | |
Convertible
Note, 12% due February 2022 | |
| 50,000 | | |
| 59,649 | | |
| 0.6 | % |
* | |
INBay
Technology Inc |
| |
Technology | |
Convertible
Note, 12% due December 2022 | |
| 40,000 | | |
| 43,958 | | |
| 0.4 | % |
* | |
INBay
Technology Inc |
| |
Technology | |
Convertible
Note, 12% due December 2023 | |
| 50,000 | | |
| 52,926 | | |
| 0.5 | % |
* | |
Iris
R&D Group Inc |
| |
Technology | |
Convertible
Note, 8% May 2023 | |
| 50,000 | | |
| 51,447 | | |
| 0.5 | % |
| |
Kiana
Analytics Inc |
| |
Technology | |
Convertible
Note, 3% December 2022 | |
| 100,000 | | |
| 102,326 | | |
| 0.9 | % |
| |
Kitotech
Medical Inc |
| |
Life
science | |
Convertible
Note, 6% due December 2020 | |
| 100,000 | | |
| 246,141 | | |
| 2.3 | % |
| |
Kitotech
Medical Inc |
| |
Life
science | |
Convertible
Note, 6% due November 2022 | |
| 75,000 | | |
| 85,896 | | |
| 0.8 | % |
| |
Lifewave
Biomedical Inc |
| |
Life
science | |
Convertible
Note, 6% due December 2020 | |
| 30,000 | | |
| 33,733 | | |
| 0.3 | % |
| |
Lifewave
Biomedical Inc |
| |
Life
science | |
Convertible
Note, 6% due December 2020 | |
| 70,000 | | |
| 76,916 | | |
| 0.7 | % |
| |
Lifewave
Biomedical Inc |
| |
Life
science | |
Convertible
Note, 6% due December 2021 | |
| 50,000 | | |
| 51,159 | | |
| 0.5 | % |
| |
Lowell
Therapeutics Inc |
| |
Life
science | |
Convertible
Note, 8% no due date | |
| 27,491 | | |
| 27,955 | | |
| 0.3 | % |
| |
mmTron
Inc |
| |
Technology | |
Convertible
Note, 4% due April 2023 | |
| 100,000 | | |
| 101,030 | | |
| 0.9 | % |
| |
Navaux
Inc |
| |
Life
science | |
Convertible
Note, 6% due December 2023 | |
| 60,000 | | |
| 62,841 | | |
| 0.6 | % |
| |
Neuro42
Inc. |
| |
Life
science | |
Convertible
Note, 8% due December 2023 | |
| 50,000 | | |
| 52,564 | | |
| 0.5 | % |
| |
Octagon
Therapeutics Inc |
| |
Life
science | |
Convertible
Note, 5% due June 2021 | |
| 50,000 | | |
| 52,349 | | |
| 0.5 | % |
| |
Octagon
Therapeutics Inc |
| |
Life
science | |
Convertible
Note, 5% due June 2021 | |
| 50,000 | | |
| 52,219 | | |
| 0.5 | % |
| |
Perikinetics
Inc |
| |
Life
science | |
Convertible
Note, 6% due May 2022 | |
| 100,000 | | |
| 105,326 | | |
| 1.0 | % |
| |
Preview
Medical Inc |
| |
Life
science | |
Convertible
Note, 7% due January 2023 | |
| 100,000 | | |
| 104,948 | | |
| 1.0 | % |
| |
Promaxo
Inc |
| |
Life
science | |
Convertible
note, 5% due July 2022 | |
| 100,000 | | |
| 183,876 | | |
| 1.7 | % |
| |
Rheos
Inc |
| |
Life
science | |
Convertible
note, 8% due August 2026 | |
| 100,000 | | |
| 101,074 | | |
| 0.9 | % |
| |
Saccharo
Inc |
| |
Life
science | |
Convertible
note, 7% due September 2022 | |
| 50,000 | | |
| 50,815 | | |
| 0.5 | % |
| |
SageMedic
Corp |
| |
Life
science | |
Convertible
Note, 8% April 2021 plus warrants | |
| 50,000 | | |
| 59,885 | | |
| 0.6 | % |
| |
SageMedic
Corp |
| |
Life
science | |
Convertible
Note, 8% December 2022 plus warrants | |
| 75,000 | | |
| 79,948 | | |
| 0.7 | % |
| |
Sensing
Electromagnetic Plus Corp |
| |
Technology | |
Convertible
Note, Fully reserved | |
| 50,000 | | |
| 1 | | |
| 0.0 | % |
| |
Sensing
Electromagnetic Plus Corp |
| |
Technology | |
Convertible
Note, Fully reserved | |
| 11,048 | | |
| 1 | | |
| 0.0 | % |
| |
Single
Pass Inc |
| |
Life
science | |
Convertible
Note, 6% April 2024 | |
| 50,000 | | |
| 50,970 | | |
| 0.5 | % |
* | |
Valfix
Medical Inc |
*
| |
Life
science | |
Convertible
Note, 8% December 2021 | |
| 50,000 | | |
| 54,515 | | |
| 0.5 | % |
* | |
Xpan
Inc |
*
| |
Life
science | |
Convertible
Note, 8% due March 2022 | |
| 50,000 | | |
| 56,301 | | |
| 0.5 | % |
* | |
Xpan
Inc |
*
| |
Life
science | |
Convertible
Note, 8% due June 2022 | |
| 25,000 | | |
| 27,548 | | |
| 0.3 | % |
* | |
Xpan
Inc |
*
| |
Life
science | |
Convertible
Note, 8% due June 2022 | |
| 25,000 | | |
| 27,542 | | |
| 0.3 | % |
Total
convertible loan investments |
| |
$ | 3,243,539 | | |
$ | 3,801,833 | | |
| 35.1 | % |
| |
United
States |
| |
| |
| |
$ | 2,423,539 | | |
$ | 2,873,150 | | |
| 26.6 | % |
| |
Canada |
| |
| |
| |
| 470,000 | | |
| 537,116 | | |
| 5.0 | % |
| |
Rest
of World |
| |
| |
| |
| 350,000 | | |
| 391,567 | | |
| 3.6 | % |
Total
convertible loan investments | |
$ | 3,243,539 | | |
$ | 3,801,833 | | |
| 35.1 | % |
Continued
on next page
The
accompanying notes are an integral part of these condensed interim financial statements.
Continued
from previous page
Kyto Technology and Life Science, Inc.
Condensed
Schedule of Investments as of September 30, 2021
(Unaudited)
| |
Portfolio
Company |
| |
Industry | |
Investment | |
Cost | | |
Fair
value | | |
%
of net assets (a) |
|
Preferred stock investments |
| |
| |
| |
| | | |
| | |
|
|
|
| |
Altis Biosystems |
| |
Life science | |
22,028 shares of Series Seed Preferred | |
$ | 50,000 | | |
$ | 50,000 | | |
0.5 |
% |
| |
Astrocyte Pharmaceuticals Inc |
| |
Life science | |
260,756 shares of Series A Preferred | |
| 100,000 | | |
| 100,000 | | |
0.9 |
% |
| |
Cnote Group, Inc |
| |
Fintech | |
84,655 shares of series Seed-2
Preferred (converted SAFE) | |
| 51,500 | | |
| 59,783 | | |
0.6 |
% |
| |
Cnote Group, Inc |
| |
Fintech | |
93,807 shares of Series Seed-3
Preferred (converted note) | |
| 50,000 | | |
| 66,247 | | |
0.6 |
% |
| |
Colabs Inc |
| |
Life science | |
147,058 shares of Series A-1 Preferred | |
| 50,000 | | |
| 50,000 | | |
0.5 |
% |
* | |
Connectus Services Ltd |
*
| |
Technology | |
31,348 shares of Series Seed Preferred | |
| 100,000 | | |
| 100,000 | | |
0.9 |
% |
| |
Deep Blue Medical Advances
Inc |
| |
Life science | |
10,474 shares of Series A Preferred | |
| 49,996 | | |
| 49,997 | | |
0.5 |
% |
| |
Eumentis Thereapeutics Inc |
| |
Life science | |
85,009 shares of Series A Preferred | |
| 100,000 | | |
| 100,000 | | |
0.9 |
% |
| |
FemtoDX Inc |
| |
Life science | |
42,436 shares of Series A Preferred | |
| 100,000 | | |
| 290,046 | | |
2.7 |
% |
| |
Healionics Corporation |
| |
Life science | |
35,075 of Series A-1 Preferred | |
| 100,000 | | |
| 100,000 | | |
0.9 |
% |
| |
i-Lumen Scientific Inc. |
| |
Life science | |
50,000 shares of Series A Preferred
plus warrants | |
| 50,000 | | |
| 50,000 | | |
0.5 |
% |
| |
i-Lumen Scientific Inc. |
| |
Life science | |
50,000 shares of Series A Preferred
plus warrants | |
| 50,000 | | |
| 50,000 | | |
0.5 |
% |
| |
Inhalon Biopharma Inc |
| |
Life science | |
18,843 shares of Series Seed Preferred | |
| 99,997 | | |
| 99,997 | | |
0.9 |
% |
| |
Light Line Medical Inc |
| |
Life science | |
62,849 shares of Series Seed
Preferred (converted note) | |
| 30,000 | | |
| 38,031 | | |
0.4 |
% |
| |
Light Line Medical Inc |
| |
Life science | |
141,871 shares of Series Seed
Preferred (converted note) | |
| 70,000 | | |
| 106,049 | | |
1.0 |
% |
| |
Light Line Medical Inc |
| |
Life science | |
40,323 shares of Series Seed preferred | |
| 25,000 | | |
| 25,000 | | |
0.2 |
% |
| |
Light Line Medical Inc |
| |
Life science | |
72,464 shares of Series A Preferred
plus warrants | |
| 50,000 | | |
| 50,000 | | |
0.5 |
% |
| |
Lowell Therapeutics Inc |
| |
Life science | |
20,000 shares of Series A Preferred | |
| 50,000 | | |
| 50,000 | | |
0.5 |
% |
| |
Lowell Therapeutics Inc |
| |
Life science | |
20,000 shares of Series A Preferred | |
| 50,000 | | |
| 50,000 | | |
0.5 |
% |
| |
Lowell Therapeutics Inc |
| |
Life science | |
25,000 shares of Series B Preferred | |
| 100,000 | | |
| 100,000 | | |
0.9 |
% |
| |
Makani Science Inc |
| |
Life science | |
172,413 shares of Series Seed Preferred | |
| 50,000 | | |
| 50,000 | | |
0.5 |
% |
| |
Micronic Technologies Inc |
| |
Technology | |
51,929 shares of Series Seed-1
Preferred plus warrants | |
| 100,000 | | |
| 100,000 | | |
0.9 |
% |
| |
Neuroflow Inc |
| |
Life science | |
98,684 shares of Series Seed -2 Preferred | |
| 150,000 | | |
| 224,998 | | |
2.1 |
% |
| |
Neuroflow Inc |
| |
Life science | |
20,429 shares of Series B Preferred | |
| 100,000 | | |
| 212,497 | | |
2.0 |
% |
| |
New View Surgical, Inc. |
| |
Life science | |
53,825 shares of Series A-1 Preferred | |
| 75,000 | | |
| 75,000 | | |
0.7 |
% |
| |
New View Surgical, Inc. |
| |
Life science | |
58,220 shares of Series A-1 Preferred | |
| 100,000 | | |
| 100,000 | | |
0.9 |
% |
* | |
Orion Biotechnology Inc |
*
| |
Life science | |
5,824 shares of Series A Preferred | |
| 100,000 | | |
| 100,000 | | |
0.9 |
% |
| |
Otomagnetics Inc |
| |
Life science | |
16,538 shares of Series A-1 Preferred | |
| 100,000 | | |
| 100,000 | | |
0.9 |
% |
| |
Partheous Inc |
| |
Life science | |
50,000 shares of Series A Preferred | |
| 50,000 | | |
| 50,000 | | |
0.5 |
% |
| |
Promaxo |
| |
Life science | |
104,248 shares of Series B-1
Preferred, (converted note) | |
| 250,000 | | |
| 1,034,684 | | |
9.6 |
% |
| |
Seal Rock Therapeutics, Inc. |
| |
Life science | |
68,075 shares of Series Seed
Preferred, (converted note) | |
| 78,000 | | |
| 199,112 | | |
1.8 |
% |
| |
Shyft (FKA Crater Group Inc) |
| |
Technology | |
42,657 shares of Series A-1
Preferred (converted note) | |
| 51,500 | | |
| 107,059 | | |
1.0 |
% |
| |
Shyft (FKA Crater Group Inc) |
| |
Technology | |
28,147 shares of Series A Preferred
(converted note) | |
| 50,000 | | |
| 91,771 | | |
0.8 |
% |
| |
Shyft (FKA Crater Group Inc) |
| |
Technology | |
21,774 shares of Series A-1
Preferred (plus warrants) | |
| 50,000 | | |
| 70,990 | | |
0.7 |
% |
( i ) | |
Trellis Bioscience LLC |
| |
Life science | |
50,000 shares of Series B Preferred
plus warrants | |
| 50,000 | | |
| 50,000 | | |
0.5 |
% |
( i ) | |
Trellis Bioscience LLC |
| |
Life science | |
50,000 shares of Series B Preferred
plus warrants | |
| 50,000 | | |
| 50,000 | | |
0.5 |
% |
( i ) | |
Trellis Bioscience LLC |
| |
Life science | |
100,000 shares of Series B
Preferred plus warrants | |
| 100,000 | | |
| 100,000 | | |
0.9 |
% |
* | |
Valfix Medical Inc |
*
| |
Life science | |
27,217 shares of Series Seed Preferred | |
| 50,000 | | |
| 50,000 | | |
0.5 |
% |
| |
Vesteck Inc |
| |
Life science | |
34,783 shares of Series A preferred | |
| 100,000 | | |
| 100,000 | | |
0.9 |
% |
| |
Visgenx Inc |
| |
Life science | |
7,833 shares of Series Seed-1
Preferred (converted note) | |
| 30,000 | | |
| 46,352 | | |
0.4 |
% |
| |
Visgenx Inc |
| |
Life science | |
4,132 shares of Series Seed
Preferred (converted note) | |
| 25,000 | | |
| 25,648 | | |
0.2 |
% |
| |
Visgenx
Inc |
| |
Life
science | |
2,480
shares of Series Seed Preferred (converted note) | |
| 15,003 | | |
| 15,392 | | |
0.1 |
% |
Total Preferred stock investments |
| |
$ | 3,050,997 | | |
$ | 4,538,653 | | |
42.0 |
% |
| |
United States |
| |
| |
| |
$ | 2,800,997 | | |
$ | 4,288,653 | | |
39.6 |
% |
| |
Canada |
| |
| |
| |
| 200,000 | | |
| 200,000 | | |
1.8 |
% |
| |
Rest of World |
| |
| |
| |
| 50,000 | | |
| 50,000 | | |
0.5 |
% |
Total
Preferred stock investments | |
| |
$ | 3,050,997 | | |
$ | 4,538,653 | | |
42.0 |
% |
| |
|
| |
| |
| |
| | | |
| | |
|
|
|
Common
stock investments | |
| |
| | | |
| | |
|
|
|
* | |
BendaRX Corp |
*
| |
Life science | |
12,500 Common shares | |
$ | 100,000 | | |
$ | 150,000 | | |
1.4 |
% |
* | |
BendaRX Corp |
*
| |
Life science | |
12,500 Common shares | |
| 100,000 | | |
| 150,000 | | |
1.4 |
% |
| |
Boardwalk Tech |
| |
Technology | |
75,000 Common shares | |
| 65,600 | | |
| 65,600 | | |
0.6 |
% |
| |
Boardwalk Tech |
| |
Technology | |
150,000 Common shares | |
| 73,500 | | |
| 91,995 | | |
0.9 |
% |
| |
Kuantsol Inc |
| |
Technology | |
133.333 Common shares | |
| 25,000 | | |
| 25,000 | | |
0.2 |
% |
Total
Common stock investments |
| |
$ | 464,100 | | |
$ | 956,327 | | |
4.2 |
% |
| |
United States |
| |
| |
| |
$ | 264,100 | | |
$ | 656,327 | | |
6.1 |
% |
| |
Canada |
| |
| |
| |
| 200,000 | | |
| 300,000 | | |
2.8 |
% |
| |
Rest of World |
| |
| |
| |
| - | | |
| - | | |
|
|
Total
Common stock investments |
| |
$ | 464,100 | | |
$ | 956,327 | | |
8.8 |
% |
| |
|
* | |
| |
| |
| | | |
| | |
|
|
|
SAFE
investments | |
| |
| | | |
| | |
|
|
|
* | |
Infinidome Ltd |
*
| |
Technology | |
SAFE | |
$ | 50,000 | | |
$ | 50,000 | | |
0.5 |
% |
* | |
Infinidome Ltd |
*
| |
Technology | |
SAFE | |
| 50,000 | | |
| 50,000 | | |
0.5 |
% |
* | |
Madorra Inc |
*
| |
Life science | |
SAFE | |
| 100,000 | | |
| 100,000 | | |
0.9 |
% |
| |
Mitre Medical Corp |
| |
Life science | |
SAFE | |
| 75,000 | | |
| 75,000 | | |
0.7 |
% |
| |
Mitre Medical Corp |
| |
Life science | |
SAFE | |
| 50,000 | | |
| 50,000 | | |
0.5 |
% |
* | |
Orion Biotechnology Inc. |
*
| |
Life science | |
SAFE | |
| 100,000 | | |
| 100,000 | | |
0.9 |
% |
* | |
Polymertal
Ltd |
*
| |
Technology | |
SAFE | |
| 150,000 | | |
| 150,000 | | |
1.4 |
% |
Total SAFE investments |
| |
$ | 575,000 | | |
$ | 575,000 | | |
5.3 |
% |
| |
United States |
| |
| |
| |
| 125,000 | | |
| 125,000 | | |
1.2 |
% |
| |
Canada |
| |
| |
| |
| 100,000 | | |
| 100,000 | | |
0.9 |
% |
| |
Rest of World |
| |
| |
| |
| 350,000 | | |
| 350,000 | | |
3.2 |
% |
Total
SAFE investments | |
| |
$ | 575,000 | | |
$ | 575,000 | | |
5.3 |
% |
Continued
on next page
The
accompanying notes are an integral part of these condensed interim financial statements.
Continued
from previous page
Kyto Technology and Life Science, Inc.
Condensed
Schedule of Investments as of September 30, 2021
(Unaudited)
| |
Portfolio
Company | |
Industry | |
Investment | |
Cost | | |
Fair
value | | |
%
of net assets (a) | |
Other
investments | |
| |
| |
| | | |
| | | |
| | |
| |
Enduralock LLC | |
Technology | |
34.1 Series A-1
Ownership Units | |
$ | 30,000 | | |
$ | 30,000 | | |
| 0.3 | % |
| |
Enduralock LLC | |
Technology | |
39.7 Series A-1 Ownership Units | |
| 35,000 | | |
| 35,000 | | |
| 0.3 | % |
( i ) | |
Exodos Life Sciences LP | |
Life science | |
Class A-1 Preferred Ownership
Units | |
| 206,000 | | |
| 206,000 | | |
| 1.9 | % |
| |
Green Sun Medical LLC | |
Life science | |
2,193 Class A-1 Ownership units | |
| 50,000 | | |
| 50,000 | | |
| 0.5 | % |
| |
Green Sun Medical LLC | |
Life science | |
1,096 Class A-1 Ownership units | |
| 25,000 | | |
| 25,000 | | |
| 0.2 | % |
| |
Green Sun Medical LLC | |
Life science | |
1,096 Class A-1 Ownership units | |
| 25,000 | | |
| 25,000 | | |
| 0.2 | % |
| |
Green Sun Medical LLC | |
Life science | |
4,386 Class A-1 Ownership units | |
| 100,000 | | |
| 100,000 | | |
| 0.9 | % |
| |
Riso Capital Fund I, LP | |
Technology | |
Ownership units | |
| 50,000 | | |
| 50,000 | | |
| 0.5 | % |
| |
Riso
Capital Fund I, LP | |
Technology | |
Ownership
units | |
| 50,000 | | |
| 50,000 | | |
| 0.5 | % |
Total
other investments | |
| |
| |
$ | 571,000 | | |
$ | 571,000 | | |
| 5.3 | % |
| |
United States | |
| |
| |
$ | 571,000 | | |
$ | 571,000 | | |
| 5.3 | % |
| |
Canada | |
| |
| |
| - | | |
| - | | |
| | |
| |
Rest of World | |
| |
| |
| - | | |
| - | | |
| | |
Total
other investments | |
| |
| |
$ | 571,000 | | |
$ | 571,000 | | |
| 5.3 | % |
| |
| |
| |
| |
| | | |
| | | |
| | |
Total
investments | |
| |
| |
$ | 7,904,636 | | |
$ | 10,442,813 | | |
| 96.5 | % |
| |
United States | |
| |
| |
$ | 6,184,636 | | |
$ | 8,514,130 | | |
| 78.7 | % |
| |
Canada | |
| |
| |
| 970,000 | | |
| 1,137,116 | | |
| 10.5 | % |
| |
Rest of World | |
| |
| |
| 750,000 | | |
| 791,567 | | |
| 7.3 | % |
Total
investments | |
| |
| |
$ | 7,904,636 | | |
$ | 10,442,813 | | |
| 96.5 | % |
| |
(a) based
on total net assets of | $ |
10,817,894 | |
| |
| | | |
| | | |
| | |
(
i ) Kyto representatives sit on the Board of Directors of these companies.
*
These companies are headquartered outside of the US.
The accompanying notes are an integral part of these condensed interim financial statements.
Kyto
Technology and Life Science, Inc.
Condensed
Schedule of Investments as of March 31, 2021
(Unaudited)
|
|
|
Portfolio
Company |
|
|
|
|
Industry |
|
Investment |
|
|
Cost |
|
|
Fair
value |
|
|
%
of net assets (a) |
|
Convertible
loan investments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(i) |
|
|
Achelios
Therapeutics Inc. |
|
|
|
|
|
Life science |
|
|
Convertible
Note, 8% due, December 2021 |
|
|
$ |
100,000 |
|
|
$ |
121,173 |
|
|
1.7 |
% |
(i) |
|
|
Achelios Therapeutics
Inc. |
|
|
|
|
|
Life science |
|
|
Convertible Note, 8%
due December 2021 |
|
|
|
25,000 |
|
|
|
29,033 |
|
|
0.4 |
% |
(i) |
|
|
Achelios Therapeutics
Inc. |
|
|
|
|
|
Life science |
|
|
Convertible Note, 8%
due December 2021 |
|
|
|
50,000 |
|
|
|
54,581 |
|
|
0.8 |
% |
|
|
|
Avisi Technologies Inc |
|
|
|
|
|
Life science |
|
|
Convertible Note, 8%
due July 2022 |
|
|
|
50,000 |
|
|
|
52,674 |
|
|
0.8 |
% |
|
|
|
Basepaws Inc |
|
|
|
|
|
Life science |
|
|
Convertible Note, 1%
due April 2020 |
|
|
|
50,000 |
|
|
|
162,319 |
|
|
2.3 |
% |
(i) |
|
|
Beam Semiconductor Inc |
|
|
* |
|
|
Technology |
|
|
Convertible Note, 8%
due April 2022 |
|
|
|
150,000 |
|
|
|
171,041 |
|
|
2.4 |
% |
(i) |
|
|
Beam Semiconductor Inc |
|
|
* |
|
|
Technology |
|
|
Convertible Note, 8%
due March 2021 |
|
|
|
50,000 |
|
|
|
54,285 |
|
|
0.8 |
% |
|
|
|
Corinnova Inc |
|
|
|
|
|
Life science |
|
|
Convertible Note, 6%
due December 2024 |
|
|
|
100,000 |
|
|
|
102,318 |
|
|
1.5 |
% |
|
|
|
Cyberdontics Inc |
|
|
* |
|
|
Life science |
|
|
Convertible Note, 8%
due September 2022 |
|
|
|
30,000 |
|
|
|
33,768 |
|
|
0.5 |
% |
|
|
|
Cyberdontics Inc |
|
|
* |
|
|
Life science |
|
|
Convertible Note, 8%
due February 2023 |
|
|
|
35,000 |
|
|
|
38,053 |
|
|
0.5 |
% |
|
|
|
Cyberdontics Inc |
|
|
* |
|
|
Life science |
|
|
Convertible Note, 0%
no due date |
|
|
|
35,000 |
|
|
|
36,296 |
|
|
0.5 |
% |
|
|
|
Deep Blue Medical Advances
Inc |
|
|
|
|
|
Life science |
|
|
Convertible Note, 6%
due June 2022 |
|
|
|
50,000 |
|
|
|
50,863 |
|
|
0.7 |
% |
|
|
|
Every Key Inc |
|
|
|
|
|
Technology |
|
|
Convertible Note, 5%
due December 2023 |
|
|
|
100,000 |
|
|
|
106,521 |
|
|
1.5 |
% |
|
|
|
Identical Inc |
|
|
|
|
|
Life science |
|
|
Convertible Note, 2%
due May 2022 |
|
|
|
100,000 |
|
|
|
100,844 |
|
|
1.4 |
% |
|
|
|
INBay Technology Inc |
|
|
* |
|
|
Technology |
|
|
Convertible Note, 12%
due October 2020 |
|
|
|
50,000 |
|
|
|
59,721 |
|
|
0.9 |
% |
|
|
|
INBay Technology Inc |
|
|
* |
|
|
Technology |
|
|
Convertible Note, 12%
due July 2021 |
|
|
|
30,000 |
|
|
|
34,149 |
|
|
0.5 |
% |
|
|
|
INBay Technology Inc |
|
|
* |
|
|
Technology |
|
|
Convertible Note, 12%
due February 2022 |
|
|
|
50,000 |
|
|
|
56,641 |
|
|
0.8 |
% |
|
|
|
INBay Technology Inc |
|
|
* |
|
|
Technology |
|
|
Convertible Note, 12%
due December 2022 |
|
|
|
40,000 |
|
|
|
41,552 |
|
|
0.6 |
% |
|
|
|
Kiana Analytics Inc |
|
|
|
|
|
Technology |
|
|
Convertible Note, 3%
December 2022 |
|
|
|
100,000 |
|
|
|
100,847 |
|
|
1.4 |
% |
|
|
|
Kitotech Medical Inc |
|
|
|
|
|
Life science |
|
|
Convertible Note, 6%
due December 2020 |
|
|
|
100,000 |
|
|
|
243,133 |
|
|
3.5 |
% |
|
|
|
Kitotech Medical Inc |
|
|
|
|
|
Life science |
|
|
Convertible Note, 6%
due November 2022 |
|
|
|
75,000 |
|
|
|
83,738 |
|
|
1.2 |
% |
|
|
|
Lifewave Biomedical Inc |
|
|
|
|
|
Life science |
|
|
Convertible Note, 6%
due December 2020 |
|
|
|
30,000 |
|
|
|
32,831 |
|
|
0.5 |
% |
|
|
|
Lifewave Biomedical Inc |
|
|
|
|
|
Life science |
|
|
Convertible Note, 6%
due December 2020 |
|
|
|
70,000 |
|
|
|
74,810 |
|
|
1.1 |
% |
|
|
|
Navaux Inc |
|
|
|
|
|
Life science |
|
|
Convertible Note, 6%
due December 2023 |
|
|
|
60,000 |
|
|
|
61,036 |
|
|
0.9 |
% |
|
|
|
Neuro42 Inc. |
|
|
|
|
|
Life science |
|
|
Convertible Note, 8%
due December 2023 |
|
|
|
50,000 |
|
|
|
50,559 |
|
|
0.7 |
% |
|
|
|
Octagon Therapeutics
Inc |
|
|
|
|
|
Life science |
|
|
Convertible Note, 5%
due June 2021 |
|
|
|
50,000 |
|
|
|
51,110 |
|
|
0.7 |
% |
|
|
|
Octagon Therapeutics
Inc |
|
|
|
|
|
Life science |
|
|
Convertible Note, 5%
due June 2021 |
|
|
|
50,000 |
|
|
|
50,966 |
|
|
0.7 |
% |
|
|
|
Perikinetics Inc |
|
|
|
|
|
Life science |
|
|
Convertible Note, 6%
due May 2022 |
|
|
|
100,000 |
|
|
|
102,318 |
|
|
1.5 |
% |
|
|
|
Preview Medical Inc |
|
|
|
|
|
Life science |
|
|
Convertible Note, 7%
due January 2023 |
|
|
|
100,000 |
|
|
|
101,918 |
|
|
1.5 |
% |
|
|
|
SageMedic Corp |
|
|
|
|
|
Life science |
|
|
Convertible Note, 8%
April 2021 plus warrants |
|
|
|
50,000 |
|
|
|
57,879 |
|
|
0.8 |
% |
|
|
|
SageMedic Corp |
|
|
|
|
|
Life science |
|
|
Convertible Note, 8%
December 2022 plus warrants |
|
|
|
75,000 |
|
|
|
77,088 |
|
|
1.1 |
% |
|
|
|
Sensing Electromagnetic
Plus Corp |
|
|
|
|
|
Technology |
|
|
Convertible Note, Fully
reserved |
|
|
|
50,000 |
|
|
|
1 |
|
|
0.0 |
% |
|
|
|
Sensing Electromagnetic
Plus Corp |
|
|
|
|
|
Technology |
|
|
Convertible Note, Fully
reserved |
|
|
|
11,048 |
|
|
|
1 |
|
|
0.0 |
% |
|
|
|
Valfix Medical Inc |
|
|
* |
|
|
Life science |
|
|
Convertible Note, 8%
December 2021 |
|
|
|
50,000 |
|
|
|
52,510 |
|
|
0.8 |
% |
|
|
|
Xpan Inc |
|
|
* |
|
|
Life science |
|
|
Convertible Note, 8%
due March 2022 |
|
|
|
50,000 |
|
|
|
54,296 |
|
|
0.8 |
% |
|
|
|
Xpan Inc |
|
|
* |
|
|
Life science |
|
|
Convertible Note, 8%
due June 2022 |
|
|
|
25,000 |
|
|
|
26,545 |
|
|
0.4 |
% |
|
|
|
Xpan Inc |
|
|
* |
|
|
Life science |
|
|
Convertible Note, 8%
due June 2022 |
|
|
|
25,000 |
|
|
|
26,540 |
|
|
0.4 |
% |
Total Convertible loan investments |
|
|
|
|
|
|
|
|
|
$ |
2,216,048 |
|
|
$ |
2,553,954 |
|
|
36.5 |
% |
|
|
|
United States |
|
|
|
|
|
|
|
|
|
|
|
$ |
1,596,048 |
|
|
$ |
1,868,557 |
|
|
26.7 |
% |
|
|
|
Canada |
|
|
|
|
|
|
|
|
|
|
|
|
370,000 |
|
|
|
407,561 |
|
|
5.8 |
% |
|
|
|
Rest of World |
|
|
|
|
|
|
|
|
|
|
|
|
250,000 |
|
|
|
277,836 |
|
|
4.0 |
% |
Total Convertible loan investments |
|
|
|
|
|
|
|
|
|
$ |
2,216,048 |
|
|
$ |
2,553,954 |
|
|
36.5 |
% |
Continued
on next page
The
accompanying notes are an integral part of these condensed interim financial statements.
Continued
from previous page
Kyto Technology and Life Science, Inc.
Condensed
Schedule of Investments as of March 31, 2021 - continued
(Unaudited)
Preferred stock investments |
| |
| |
| |
| | | |
| | |
|
|
|
| |
Altis Biosystems |
| |
Life science | |
22,028 shares of Series Seed Preferred | |
$ | 50,000 | | |
$ | 50,000 | | |
0.7 |
% |
| |
Astrocyte Pharmaceuticals Inc |
| |
Life science | |
260,756 shares of Series A Preferred | |
| 100,000 | | |
| 100,000 | | |
1.4 |
% |
| |
Cnote Group, Inc |
| |
Fintech | |
84,655 shares of series Seed-2
Preferred (converted SAFE) | |
| 51,500 | | |
| 59,783 | | |
0.9 |
% |
| |
Cnote Group, Inc |
| |
Fintech | |
93,807 shares of Series Seed-3
Preferred (converted note) | |
| 50,000 | | |
| 66,247 | | |
0.9 |
% |
| |
Colabs Inc |
| |
Life science | |
147,058 shares of Series A-1 Preferred | |
| 50,000 | | |
| 50,000 | | |
0.7 |
% |
| |
Connectus Services Ltd |
* | |
Technology | |
31,348 shares of Series Seed Preferred | |
| 100,000 | | |
| 100,000 | | |
1.4 |
% |
| |
Deep Blue Medical Advances
Inc |
| |
Life science | |
10,474 shares of Series A Preferred | |
| 49,997 | | |
| 49,997 | | |
0.7 |
% |
| |
Eumentis Thereapeutics Inc |
| |
Life science | |
85,009 shares of Series A Preferred | |
| 100,000 | | |
| 100,000 | | |
1.4 |
% |
| |
FemtoDX Inc |
| |
Life science | |
42,436 shares of Series A Preferred | |
| 100,000 | | |
| 159,835 | | |
2.3 |
% |
| |
i-Lumen Scientific Inc. |
| |
Life science | |
50,000 shares of Series A Preferred
plus warrants | |
| 50,000 | | |
| 50,000 | | |
0.7 |
% |
| |
i-Lumen Scientific Inc. |
| |
Life science | |
50,000 shares of Series A Preferred
plus warrants | |
| 50,000 | | |
| 50,000 | | |
0.7 |
% |
| |
Inhalon Biopharma Inc |
| |
Life science | |
18,843 shares of Series Seed Preferred | |
| 99,997 | | |
| 99,997 | | |
1.4 |
% |
| |
Light Line Medical Inc |
| |
Life science | |
62,849 shares of Series Seed
Preferred (converted note) | |
| 30,000 | | |
| 38,031 | | |
0.5 |
% |
| |
Light Line Medical Inc |
| |
Life science | |
141,871 shares of Series Seed
Preferred (converted note) | |
| 70,000 | | |
| 106,049 | | |
1.5 |
% |
| |
Light Line Medical Inc |
| |
Life science | |
40,323 shares of Series Seed preferred | |
| 25,000 | | |
| 25,000 | | |
0.4 |
% |
| |
Light Line Medical Inc |
| |
Life science | |
72,464 shares of Series A Preferred
plus warants | |
| 50,000 | | |
| 50,000 | | |
0.7 |
% |
| |
Lowell Therapeutics Inc |
| |
Life science | |
20,000 shares of Series A Preferred | |
| 50,000 | | |
| 50,000 | | |
0.7 |
% |
| |
Lowell Therapeutics Inc |
| |
Life science | |
20,000 shares of Series A Preferred | |
| 50,000 | | |
| 50,000 | | |
0.7 |
% |
| |
Micronic Technologies Inc |
| |
Technology | |
51,929 shares of Series Seed-1
Preferred plus warrants | |
| 100,000 | | |
| 100,000 | | |
1.4 |
% |
| |
Neuroflow Inc |
| |
Life science | |
98,684 shares of Series Seed -2 Preferred | |
| 150,000 | | |
| 224,998 | | |
3.2 |
% |
| |
Neuroflow Inc |
| |
Life science | |
20,429 shares of Series B Preferred | |
| 100,000 | | |
| 212,497 | | |
3.0 |
% |
| |
New View Surgical, Inc. |
| |
Life science | |
53,825 shares of Series A-1 Preferred | |
| 75,000 | | |
| 75,000 | | |
1.1 |
% |
| |
Otomagnetics Inc |
| |
Life science | |
16,538 shares of Series A-1
Preferred plus warrants | |
| 100,000 | | |
| 100,000 | | |
1.4 |
% |
| |
Promaxo |
| |
Life science | |
104,248 shares of Series B-1
Preferred, (converted note) | |
| 250,000 | | |
| 531,738 | | |
7.6 |
% |
| |
Seal Rock Therapeutics, Inc. |
| |
Life science | |
68,075 shares of Series Seed
Preferred, (converted note) | |
| 78,000 | | |
| 80,329 | | |
1.1 |
% |
| |
Shyft (FKA Crater Group Inc) |
| |
Technology | |
42,657 shares of Series A-1 Preferred | |
| 51,500 | | |
| 97,940 | | |
1.4 |
% |
| |
Shyft (FKA Crater Group Inc) |
| |
Technology | |
28,147 shares of Series A Preferred
(converted note) | |
| 50,000 | | |
| 64,626 | | |
0.9 |
% |
| |
Shyft (FKA Crater Group Inc) |
| |
Technology | |
21,774 shares of Series A-1
Preferred (converted note) | |
| 50,000 | | |
| 50,000 | | |
0.7 |
% |
(i) | |
Trellis Bioscience LLC |
| |
Life science | |
50,000 shares of Series B Preferred
plus warrants | |
| 50,000 | | |
| 50,000 | | |
0.7 |
% |
(i) | |
Trellis Bioscience LLC |
| |
Life science | |
50,000 shares of Series B Preferred
plus warrants | |
| 50,000 | | |
| 50,000 | | |
0.7 |
% |
(i) | |
Trellis Bioscience LLC |
| |
Life science | |
100,000 shares of Series B
Preferred plus warrants | |
| 100,000 | | |
| 100,000 | | |
1.4 |
% |
| |
Valfix Medical Inc |
* | |
Life science | |
27,217 shares of Series Seed Preferred | |
| 50,000 | | |
| 50,000 | | |
0.7 |
% |
| |
Visgenx Inc |
| |
Life science | |
7,833 shares of Series Seed-1
Preferred (converted note) | |
| 30,000 | | |
| 46,352 | | |
0.7 |
% |
| |
Visgenx Inc |
| |
Life science | |
4,132 shares of Series Seed
Preferred (converted note) | |
| 25,000 | | |
| 25,648 | | |
0.4 |
% |
| |
Visgenx
Inc |
| |
Life
science | |
2,480
shares of Series Seed Preferred (converted note) | |
| 15,003 | | |
| 15,392 | | |
0.2 |
% |
Total
Preferred stock investments |
| |
| |
| |
$ | 2,450,998 | | |
$ | 3,129,458 | | |
44.8 |
% |
| |
United States |
| |
| |
| |
$ | 2,300,998 | | |
$ | 2,979,458 | | |
42.6 |
% |
| |
Canada |
| |
| |
| |
| 100,000 | | |
| 100,000 | | |
1.4 |
% |
| |
Rest of World |
| |
| |
| |
| 50,000 | | |
| 50,000 | | |
0.7 |
% |
Total
Preferred stock investments |
| |
| |
| |
$ | 2,450,998 | | |
$ | 3,129,458 | | |
44.8 |
% |
| |
|
| |
| |
| |
| | | |
| | |
|
|
|
Common
stock investments |
| |
| |
| |
| | | |
| | |
|
|
|
| |
BendaRX Corp |
* | |
Life science | |
12,500 Common shares | |
$ | 100,000 | | |
$ | 150,000 | | |
2.1 |
% |
| |
BendaRX Corp |
* | |
Life science | |
12,500 Common shares | |
| 100,000 | | |
| 150,000 | | |
2.1 |
% |
| |
Boardwalk
Tech |
| |
Technology | |
150,000 Common shares | |
| 73,500 | | |
| 91,995 | | |
1.3 |
% |
Total
common stock investments |
| |
| |
| |
$ | 273,500 | | |
$ | 391,995 | | |
5.6 |
% |
| |
United States |
| |
| |
| |
$ | 73,500 | | |
$ | 91,995 | | |
1.3 |
% |
| |
Canada |
| |
| |
| |
| 200,000 | | |
| 300,000 | | |
4.3 |
% |
| |
Rest of World |
| |
| |
| |
| - | | |
| - | | |
|
|
Total
common stock investments |
| |
| |
| |
$ | 273,500 | | |
$ | 391,995 | | |
5.6 |
% |
| |
|
| |
| |
| |
| | | |
| | |
|
|
|
SAFE
investments |
| |
| |
| |
| | | |
| | |
|
|
|
| |
Infinidome Ltd |
* | |
Technology | |
SAFE | |
$ | 50,000 | | |
$ | 50,000 | | |
0.7 |
% |
| |
Infinidome Ltd |
* | |
Technology | |
SAFE | |
| 50,000 | | |
| 50,000 | | |
0.7 |
% |
| |
Mitre Medical Corp |
| |
Life science | |
SAFE | |
| 75,000 | | |
| 75,000 | | |
1.1 |
% |
| |
Mitre Medical Corp |
| |
Life science | |
SAFE | |
| 50,000 | | |
| 50,000 | | |
0.7 |
% |
| |
Orion
Biotechnology Inc. |
* | |
Life
science | |
SAFE | |
| 100,000 | | |
| 100,000 | | |
1.4 |
% |
Total
SAFE investments |
| |
| |
| |
$ | 325,000 | | |
$ | 325,000 | | |
4.6 |
% |
| |
United States |
| |
| |
| |
$ | 125,000 | | |
$ | 125,000 | | |
1.8 |
% |
| |
Canada |
| |
| |
| |
| 100,000 | | |
| 100,000 | | |
1.4 |
% |
| |
Rest of World |
| |
| |
| |
| 100,000 | | |
| 100,000 | | |
1.4 |
% |
Total
SAFE investments |
| |
| |
| |
$ | 325,000 | | |
$ | 325,000 | | |
4.6 |
% |
Continued
on next page
The
accompanying notes are an integral part of these condensed interim financial statements.
Continued
from previous page
Kyto
Technology and Life Science, Inc.
Condensed
Schedule of Investments as of March 31, 2021 - continued
(Unaudited)
Preferred
stock investments |
| |
| |
| |
| | | |
| | |
|
|
|
Other
investments |
| |
| |
| |
| | | |
| | |
|
|
|
| |
Enduralock LLC |
| |
Technology | |
34.1 Series A-1 Ownership Units | |
$ | 30,000 | | |
$ | 30,000 | | |
0.4 |
% |
| |
Enduralock LLC |
| |
Technology | |
39.7 Series A-1 Ownership Units | |
| 35,000 | | |
| 35,000 | | |
0.5 |
% |
(i) | |
Exodos Life Sciences LP |
| |
Life science | |
Class A-1 Preferred Ownership
Units | |
| 206,000 | | |
| 206,000 | | |
2.9 |
% |
| |
Green Sun Medical LLC |
| |
Life science | |
2,193 Class A-1 Ownership units | |
| 50,000 | | |
| 50,000 | | |
0.7 |
% |
| |
Green Sun Medical LLC |
| |
Life science | |
1,096 Class A-1 Ownership units | |
| 25,000 | | |
| 25,000 | | |
0.4 |
% |
| |
Green Sun Medical LLC |
| |
Life science | |
1,096 Class A-1 Ownership units | |
| 25,000 | | |
| 25,000 | | |
0.4 |
% |
| |
Riso
Capital Fund I, LP |
| |
Technology | |
Ownership
units | |
| 50,000 | | |
| 50,000 | | |
0.7 |
% |
Total
other investments |
| |
| |
| |
$ | 421,000 | | |
$ | 421,000 | | |
6.0 |
% |
| |
United States |
| |
| |
| |
$ | 421,000 | | |
$ | 421,000 | | |
6.0 |
% |
| |
Canada |
| |
| |
| |
| - | | |
| - | | |
|
|
| |
Rest of World |
| |
| |
| |
| - | | |
| - | | |
|
|
Total
Other investments |
| |
| |
| |
$ | 421,000 | | |
$ | 421,000 | | |
6.0 |
% |
| |
|
| |
| |
| |
| | | |
| | |
|
|
|
Total
investments |
| |
| |
| |
$ | 5,686,545 | | |
$ | 6,821,407 | | |
97.5 |
% |
| |
United States |
| |
| |
| |
$ | 4,516,546 | | |
$ | 5,486,011 | | |
78.4 |
% |
| |
Canada |
| |
| |
| |
| 770,000 | | |
| 907,560 | | |
13.0 |
% |
| |
Rest of World |
| |
| |
| |
| 400,000 | | |
| 427,836 | | |
6.1 |
% |
Total
investments |
| |
| |
| |
$ | 5,686,545 | | |
$ | 6,821,407 | | |
97.5 |
% |
| |
|
| |
| |
| |
| | | |
| | |
|
|
|
| |
(a) based
on total net assets of |
| $ |
6,993,163 | |
| |
| | | |
| | |
|
|
|
(
i ) |
|
* |
|
|
The
accompanying notes are an integral part of these condensed interim financial statements. |
KYTO
TECHNOLOGY AND LIFE SCIENCE INC.
NOTES
TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
September
30, 2021
NOTE
1 – DESCRIPTION OF BUSINESS
Kyto
Technology and Life Science, Inc. (the “Company”) was formed as a Florida corporation on March 5, 1999 under the name of
B Twelve, Inc. In August, 2002, the Company changed its name from B Twelve, Inc. to Kyto BioPharma Inc. and in May 2018, the name was
changed again to Kyto Technology and Life Science, Inc. In July 2019, the Company was re-incorporated as a Delaware company. The Company
operates virtually, from public locations or the homes of its officers, and does not currently lease any office space.
The
Company was originally formed to acquire and develop proprietary drugs for the treatment of cancer, arthritis, and other autoimmune diseases
and had been evaluating a number of strategies. As of March 31, 2018, the Company had accumulated a deficit of $32,380,746 from all prior
operations. In April 2018, the Board adopted a new business plan focused on the development of early-stage technology and life science
businesses through early-stage investment funding. The Company has recruited a number of experienced investment consultants from a network
that includes angel investors, corporate managers, sophisticated early-stage investors and successful entrepreneurs with experience across
a number of technology and life science products and markets, and relies on input from these advisors in conducting due diligence and
making investment decisions. In order to offset the risk in early-stage investing, the Company works with angel investment groups and
other sophisticated investors and participates only after these groups have completed due diligence and committed to invest, in effect
becoming lead investors. The Company then completes its own due diligence and invests under identical terms as the lead investors. The
Company will do follow-on investments in existing portfolio companies, assuming adequate progress, when portfolio companies initiate
new financing rounds. The Company currently does not typically invest more than $250,000 in any single investment. Generally, the Company’s
investments represent less than 5% ownership interests, and the Company therefore has no effective control or influence over the management
or commercial decisions of the companies in which it invests. The Company plans to generate revenue from realized gains from the sale
of the businesses in which it has invested, or some or all of its shareholdings in those cases where portfolio companies go public. Generally,
it is expected that investments will be realized from an exit within a period of four to five years following initial investment. Such
exits or liquidity events are outside the Company’s control and depend on merger and acquisition (“M&A”) transactions
or an initial public offering (“IPO”) which may result in cash or equity proceeds. Other than making its initial and, potentially,
follow-on investments in its portfolio companies, the Company does not provide any financial support to any of its investees.
The
Company has one regular employee – the CEO, Mr, Paul Russo. Prior to December 31, 2020, Mr. Russo was acting as a consultant to
the Company and did not receive contractual compensation for his services in the form of cash. As of January 1, 2021, Mr. Russo was engaged
as an employee of the Company at a salary of $400,000
per annum of which 60%
was paid monthly from January to April 2021, then 75%
from May 2021, with the balance being deferred to be paid once the Company lists and starts trading on the Nasdaq exchange. The full
terms of Mr. Russo’s employment are described in a Form 8-K filed on February 1, 2021, which was approved by the Compensation committee
of the Board of Directors on that date. During the three months and six months ended September 30, 2021, Mr. Russo received gross pay
of $90,000
and $170,000,
respectively. No consulting fees and no options were granted to him
during these periods. During the three months and six months ended September 30, 2020, Mr. Russo received no
payroll or consulting fees, however in the three
and six months ended September 30, 2020 he received a bonus of $50,000
and was granted options to purchase 215,000
shares of Common stock.
The
Company has created a portfolio of minority investments in early-stage start-up companies and derives its revenue opportunity from the
sale of those investments. Such sales are outside the Company’s control and depend on M&A transactions or IPOs which may result
in cash or equity proceeds. Accordingly, it is difficult to forecast revenue, net income, and cash flow. As of the date of this filing,
the Company had approximately $485,000 of cash to cover its operating expenses, and new investment requirements and is continuing to
raise additional funding on a recurring monthly basis. If successful, it will have sufficient funding for further investments and ongoing
operations. However, there is no assurance that the Company will be able to raise sufficient cash to cover its requirements on attractive
terms, if at all, and whether it will be able to continue as a going concern. These conditions raise substantial doubt about the Company’s
ability to continue as a going concern. The accompanying condensed interim financial statements have been prepared assuming the Company
will continue to operate as a going concern and do not include any adjustments that might result from the outcome of this uncertainty.
Stay at home orders and general economic uncertainties arising out of the current Covid-19 epidemic have created additional delays and
uncertainty. To date there has been no disruption to the Company’s business operations, although some of its portfolio investment
companies report delays in their programs.
At
March 31, 2020, management determined that the Company was an investment company for purposes of Accounting Standards Codification Topic
946, Financial Services—Investment Companies (ASC Topic 946) disclosure, and adopted the specialized accounting and reporting
guidance contained therein. Accordingly, a new company, Kyto Investments, Inc. (“KI”) was incorporated in Delaware in December
2020 in preparation for a restructuring and an N-2 Registration Statement filed in March 2021 for review by the SEC. KI is an internally
managed, closed-end investment company that has elected to be regulated as a business development company (“BDC”) under the
Investment Company Act of 1940, as amended (the “1940 Act”). Immediately upon effectiveness of this N-2 Registration Statement,
the Company will merge with KI and the Company will be the surviving entity. As of the completion of the merger, the Company will constitute
a “successor issuer” for the purposes of Rule 414 under the Securities Act and may continue the current offering by filing
post-effective amendments to the Registration Statements. Prior to the merger, the Company had fewer than 100 non affiliated investors
and filed under the 1934 Act relying on exemption Rule 3( c )(1).
As
a BDC, the Company will be required to comply with certain regulatory requirements. The Company also intends to elect to be treated for
U.S. federal income tax purposes as a regulated investment company (“RIC”) under Subchapter M of the Internal Revenue Code
of 1986, as amended (the “Code”). As a RIC, the Company is required to comply with additional regulatory requirements. The
Company has prepared and submitted sequentially two N-2 Registration Statements to the SEC for review but has not yet received final
approval of its registration as at the filing date of this report.
NOTE
2 - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES
(A)
BASIS OF PRESENTATION
The
accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles
(“U.S. GAAP”) for interim financial information with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly,
these unaudited condensed financial statements do not include all of the information and disclosures required by U.S. GAAP for complete
financial statements. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments
(consisting only of normal recurring adjustments), which the Company considers necessary, for a fair presentation of those financial
statements. The results of operations and cash flows for the three months and six months ended September 30, 2021 may not necessarily
be indicative of results that may be expected for any succeeding quarter or for the entire fiscal year. The condensed balance sheet as
of March 31, 2021 was derived from the audited financial statements at that date, but does not include all the information and footnotes
required by U.S. GAAP. The information contained in this Quarterly Report on Form 10-Q should be read in conjunction with the audited
financial statements of the Company for the year ended March 31, 2021, included in the Annual Report on Form 10-K as filed with the Securities
and Exchange Commission (the “SEC”) on August 10, 2021.
The
Company’s condensed interim financial statements are prepared in accordance with U.S. GAAP, which requires the use of estimates,
assumptions and the exercise of subjective judgment as to future uncertainties. Actual results could differ from those estimates, assumptions,
and judgments. Significant items subject to such estimates will include determining the fair value of investments, revenue recognition,
income tax uncertainties, stock-based compensation, and other contingencies.
The
Company’s financial statements are prepared using the specialized accounting principles of ASC Topic 946. In accordance
with this specialized accounting guidance, the Company recognizes and carries all of its investments at fair value with changes in fair
value recognized in earnings. Additionally, the Company will not apply consolidation or equity method of accounting to its investments.
The carrying amount of the Company’s financial instruments such as cash and payables approximates fair value due to the short maturity
of such instruments. Net assets are calculated as the carrying amounts of assets, including the fair value of investments, less the carrying
amounts of its liabilities.
(B)
INVESTMENT TRANSACTIONS AND NET REALIZED AND UNREALIZED GAIN OR LOSS ON INVESTMENTS
The
Company generates increases or decreases in its net assets from the sale of complete or partial investments following a merger or acquisition
(“M&A”) transaction or restructuring or from the revaluation of portfolio company investments to recognize changes in
their fair value, either upwards or downwards. As a minority early-stage investor, the Company does not have the ability to manage the
timing or acceptance of liquidity events that will realize its investments, nor the ability to predict when they may happen, although
as a general guideline, it would expect such events to occur approximately four to five years after its investments are made. The Company
records the realized gains and losses from investment activities upon completion of sale and receipt of net proceeds, after deducting
related transaction expenses. Realized gains or losses on the sale of investments, or upon the determination that an investment balance,
or portion thereof, is not recoverable, are calculated using the specific identification method. The Company measures realized gains
or losses by calculating the difference between the net proceeds from the repayment or sale and the cost basis of the investment. Net
change in unrealized appreciation or depreciation reflects the change in the fair values of the Company’s portfolio investments
during the reporting period, including any reversal of previously recorded unrealized appreciation or depreciation when gains or losses
are realized. The Company is in periodic contact with the management of its portfolio investment companies to provide a basis for valuation
changes. The Company does not expect to receive interest and principal repayments on its convertible notes and generally expects these
notes to convert into equity securities upon completion of qualified subsequent financings. Accrued interest is recorded as an adjustment
to the fair value of the convertible notes.
(C)
INCOME TAXES
The
Company accounts for income taxes under the Financial Accounting Standards Accounting Standard Codification Topic 740 “Accounting
for Income Taxes” (“Topic 740”). Under Topic 740, deferred tax assets and liabilities are recognized for the future
tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and
their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income
in the years in which those temporary differences are expected to be recovered or settled. Under Topic 740, the effect on deferred tax
assets and liabilities of a change in tax rates is recognized in income in the period, which includes the enactment date.
(D)
USE OF ESTIMATES
In
preparing financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and
liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during
the period presented. Actual results may differ from these estimates.
Significant
estimates during the three months and six months ended September 30, 2021 and September 30, 2020 include the valuation of the investment
portfolio, deferred tax assets, tax valuation allowance, stock options and warrants.
(E)
CASH AND CASH EQUIVALENTS
The
Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents.
There were no cash equivalents at September 30, 2021 and March 31, 2021, respectively.
(F)
CONCENTRATIONS
The
Company maintains its cash in bank checking and deposit accounts, which, at times, may exceed federally insured limits. As of September
30, 2021, and March 31, 2021, the Company’s bank balance exceeded the federally insured limit by approximately $70,000 and $1.2
million, respectively. The Company has not experienced any losses in such accounts through September 30, 2021.
(G)
STOCK-BASED COMPENSATION
Financial
Accounting Standards Board Accounting Standards Codification Topic 718, “Stock Compensation” requires generally that
all equity awards granted to employees and consultants be accounted for at fair value. This fair value is measured at grant date for
stock settled awards, and at subsequent exercise or settlement for cash-settled awards. Under this method, the Company records an expense
equal to the fair value of the options or warrants issued. The fair value is computed using the Black Scholes options pricing model.
The Company granted consultants and advisors 490,000 and 510,000 options during the three months ended September 30, 2021 and September
30, 2020, and 740,000 and 510,000 options during the six months ended September 30, 2021 and September 30, 2020, respectively.
(H)
NET EARNINGS PER COMMON SHARE
In
accordance with Statement of Financial Accounting Standards Accounting Standard Codification Topic 260, “Earnings per Share”,
basic earnings per common share is computed by dividing the net income less preferred dividends for the period by the weighted average
number of common shares outstanding. Diluted earnings per common share is computed by dividing net income less preferred dividends by
the weighted average number of common shares outstanding including the effect of common stock equivalents consisting of preferred stock,
stock options and warrants. The following table sets out the number of shares used in calculating fully- diluted earnings per common
share using the if-converted method.
Weighted
Average method
Number
of shares used in calculating fully- diluted earnings per common shares
SCHEDULE OF EARNINGS PER SHARE
| |
Three
months
ended
September 30,
2021 | | |
Six
months
ended September 30,
2021 | |
Common Stock | |
| 13,271,996 | | |
| 13,269,764 | |
Common stock subscribed not issued | |
| - | | |
| - | |
Series A preferred stock | |
| 4,200,000 | | |
| 4,200,000 | |
Series B preferred stock | |
| 5,307,240 | | |
| 4,361,525 | |
Options | |
| 2,962,792 | | |
| 2,835,262 | |
Warrants | |
| 1,596,667 | | |
| 1,596,667 | |
| |
| | | |
| | |
Total shares used in calculating fully-diluted earnings per common share | |
| 27,338,695 | | |
| 26,263,218 | |
| |
Three months
ended September 30,
2020 | | |
Six
months
ended September 30,
2020 | |
Common Stock issued | |
| 5,836,832 | | |
| 5,836,832 | |
Series A preferred stock | |
| 4,200,000 | | |
| 4,200,000 | |
Series B preferred stock | |
| 1,830,208 | | |
| 1,250,595 | |
Options | |
| 1,920,000 | | |
| 1,571,429 | |
Warrants | |
| 4,200,000 | | |
| 4,200,000 | |
| |
| | | |
| | |
Total shares used in calculating fully-diluted earnings per common share | |
| 17,987,040 | | |
| 17,058,856 | |
(I
) INVESTMENT AND VALUATION OF INVESTMENT AT FAIR VALUE
The
Company reviews the performance of its investments based on available information, including management reports, press releases, web
site announcements and progress reports, third party equity updates, management interviews and, where accessible, financial reports,
to determine their fair values. In the event that management considers the fair value of an investment to be greater or less than the
current book value, the difference will be reflected as unrealized gains or losses in investments in the statements of operations.
The
Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820,
“Fair Value Measurements and Disclosures”, for assets and liabilities measured at fair value on a recurring basis. ASC
820 establishes a common definition for fair value to be applied to existing U.S. GAAP that require the use of fair value measurements
which establishes a framework for measuring fair value and expands disclosure about such fair value measurements.
Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants. Fair value is an exchange price notion under which fair value is the price in an orderly transaction between market
participants to sell an asset or transfer a liability in the market in which the reporting entity would transact for the asset or liability.
The
Company has established procedures to estimate the fair value of its investments which the Company’s board of directors has reviewed
and approved. The Company uses observable market data to estimate the fair value of investments to the extent that market data is available.
In the absence of quoted market prices in active markets, or quoted market prices for similar assets or in markets that are not active,
the Company uses the valuation methodologies described below with unobservable data based on the best available information in the circumstances,
which incorporates the Company’s assumptions about the factors that a market participant would use to value the asset.
For
investments for which quoted market prices are not available, which comprise most of our investment portfolio, fair value is estimated
by using the income, market, or back-solve approach. The income approach is based on the assumption that value is created by the expectation
of future benefits discounted to a current value and the fair value estimate is the amount an investor would be willing to pay to receive
those future benefits. The market approach compares recent comparable transactions to the investment. The back solve method involves
comparing available data over a period of time and inferring a new valuation based on changes from a known starting point, for example
the cost of an investment. Adjustments are made for any dissimilarity between the comparable transactions and the investments. These
valuation methodologies involve a significant degree of judgment on the part of our management and board.
In
determining the appropriate fair value of an investment using these approaches, the most significant information and assumptions may
include, as applicable: available current market data, including relevant and applicable comparable market transactions, applicable market
yields and multiples, security covenants, call protection provisions, information rights, the nature and realizable value of any collateral,
the investment’s ability to make payments, its earnings and discounted cash flows, the markets in which the company does business,
comparisons of financial ratios of peer companies that are public, merger and acquisition comparables, the principal market and enterprise
values, environmental factors, subsequent financings by the portfolio investment, among other factors.
The
estimated fair values do not necessarily represent the amounts that may be ultimately realized due to the occurrence or nonoccurrence
of future circumstances that cannot be reasonably determined. Because of the inherent uncertainty of the valuation of the investments,
the estimate of fair values may differ significantly from the value that would have been used had a broader market for the investments
existed.
The
authoritative accounting guidance prioritizes the use of market-based inputs over entity-specific inputs and establishes a three-level
hierarchy for fair value measurements based upon the transparency of inputs to the valuation. The three levels of valuation hierarchy
are defined as follows:
Level
1: Observable inputs such as quoted market prices in active markets for identical assets or liabilities
Level
2: Observable market-based inputs or unobservable inputs that are corroborated by market data
Level
3: Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.
Most of the Company’s investments are Level 3.
Critical
accounting policies and practices are the policies that are both most important to the portrayal of the Company’s financial condition
and results, and require management’s most difficult, subjective, or complex judgments, often as a result of the need to make estimates
about matters that are inherently uncertain. These include estimates of the fair value of Level 3 investments and other estimates that
affect the reported amounts of assets and liabilities as of the date of the consolidated financial statements and the reported amounts
of certain revenues and expenses during the reporting period. It is likely that changes in these estimates will occur in the near term.
The Company’s estimates are inherently subjective in nature and actual results could differ materially from such estimates. See
“Note 1 – Significant Accounting Policies” to our financial statements as of March 31, 2021, as filed with the SEC
on August 10, 2021, for further detail regarding our critical accounting policies and recently issued or adopted accounting pronouncements.
(J)
RECENT ACCOUNTING PRONOUNCEMENTS
Management
does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect
on the accompanying financial statements.
(K)
OTHER CURRENT ASSETS
Other
current assets principally include deferred offering costs. Since April 2019, the Company has conducted a series of sales of common and
preferred stock to fund its ongoing investment program and cost of operations. Typically, it expects that raising capital through the
sale of any series of securities, from start to finish, may take from six to nine months and in order to match the cost and benefits
of this process, the Company adopted a policy of capitalizing direct expenses incurred in the course of raising capital, with the intention
of netting accumulated expenses against proceeds from sale of equity, and reporting the net funds raised at the close. Direct expenses
include legal fees, investor relations fees, investor roadshows and meeting expenses, and related filing and printing fees. At September
30, 2021 and March 31, 2021, the Company had deferred $230,434 and $169,891, respectively, of such expenses, relating to the preparation
and filing of an N-2 Registration Statement.
NOTE
3 – COMMITMENTS AND CONTINGENCIES
The
Company has no commitments or contingencies as of the date of this filing. The Company may be subject to litigation during the normal
course of business but has not received any such claims to date.
NOTE
4 - RELATED PARTY TRANSACTIONS
At
September 30, 2021 and March 31, 2021, the Company had accrued and owed $87,000 and $51,420, respectively, to officers of the Company
for deferred payroll and consulting service fees.
At
September 30, 2021, officers or directors of the Company held board positions at four portfolio companies: Beam Semiconductor Inc., Trellis
Bioscience Inc., Exodos Life Sciences LP, and Achelios Therapeutics Inc.
NOTE
5 – INVESTMENTS
The
following table summarizes the Company’s investment portfolio at September 30, 2021 and March 31, 2021.
SUMMARY OF INVESTMENT PORTFOLIO
| |
September 30, 2021 | | |
| | |
March 31, 2021 | | |
| |
Number of portfolio companies | |
| 66 | | |
| | | |
| 51 | | |
| | |
Fair value | |
$ | 10,442,813 | | |
| | | |
$ | 6,821,407 | | |
| | |
Cost | |
| 7,904,636 | | |
| | | |
| 5,686,545 | | |
| | |
| |
| | | |
| | | |
| | | |
| | |
% of portfolio at fair value | |
| | | |
| | | |
| | | |
| | |
Convertible notes | |
| 3,801,833 | | |
| 36.4 | % | |
| 2,553,954 | | |
| 37.4 | % |
Preferrred stock | |
| 4,538,653 | | |
| 43.5 | % | |
| 3,129,458 | | |
| 45.9 | % |
Common stock | |
| 956,327 | | |
| 9.2 | % | |
| 391,995 | | |
| 5.7 | % |
SAFE | |
| 575,000 | | |
| 5.5 | % | |
| 325,000 | | |
| 4.8 | % |
Other ownership units | |
| 571,000 | | |
| 5.5 | % | |
| 421,000 | | |
| 6.2 | % |
Total | |
$ | 10,442,813 | | |
| 100 | % | |
$ | 6,821,407 | | |
| 100 | % |
A
SAFE is a Simple Agreement for Future Equity in the form of a warrant to purchase equity stock in a future priced round.
Our
investment portfolio represents approximately 96% of our net assets at September 30, 2021 and 98% at March 31, 2021. Investments in early-stage
start-up private operating entities are valued based on available metrics, such as relevant market multiples and comparable company valuations,
company specific-financial data including subsequent financings, actual and projected results, and independent third-party valuation
estimates.
Significant
Unobservable Inputs for Level 3 Assets and Liabilities
In
accordance with FASB ASC 820, Fair Value Management, the tables below provide quantitative information about the Company’s
fair value measurements of its Level 3 assets as of September 30, 2021 and March 31, 2021. In addition to the techniques and inputs noted
in the tables above, according to the Company’s valuation policy, the Company may also use other valuation techniques and methodologies
when determining the Company’s fair value measurements. The tables below are not meant to be all-inclusive, but rather provide
information on the significant Level 3 inputs as they relate to the Company’s fair value measurements. To the extent an unobservable
input is not reflected in the tables below, such input is deemed insignificant with respect to the Company’s Level 3 fair value
measurements. Significant changes in the inputs in isolation would result in a significant change in the fair value measurement, depending
on the materiality of the investment.
The
following table summarizes the valuation techniques and significant unobservable inputs used for investments that are categorized within
Level 3 of the fair value hierarchy as of September 30, 2021 and March 31, 2021:
SCHEDULE OF INVESTMENTS
| |
As
of September 30, 2021 | |
| |
Fair
Value | | |
Valuation
Approach/ Technique | |
Unobservable
Inputs | |
Range/
Weighted Average |
| |
| | |
| |
| |
|
Convertible
notes: Basepaws Inc | |
$ | 201,663 | | |
Market
approach based on indicative term sheet and last round of financing | |
As
if converted note and Series A term sheet of $37.5 million | |
50:50
weight |
Convertible
notes: Promaxo Inc | |
| 183,876 | | |
Market
approach based on available comparables and financial performance | |
Conversion
prospects, market yield, remaining maturity | |
5%
yield |
Convertible
notes: Other | |
| 3,416,294 | | |
Market
approach based on available comparables and financial performance | |
Conversion
prospects, market yield, remaining maturity | |
1-12%
yield |
Preferred
stock in private companies” Shyft Moving Inc | |
| 269,820 | | |
Market
approach based on indicative term sheet and last round of financing | |
50/50
weighting to prior A-3 preferred and indicated pre Series B price. Forecast revenue from investor deck and 75% percentile for public
company peer valuation ratios | |
Based
on Series B valuation of $80 million |
Preferred
stock in private companies: Seal Rock Therapeutics Inc | |
| 199,112 | | |
Market
approach based on indicative term sheet and last round of financing | |
50/50
weighting to prior Series seed preferred and indicated Note price. 75% percentile for public company peer valuation ratios | |
Based
on new Note indication of $80 million |
Preferred
stock in private companies: Femto DX Inc | |
| 290,046 | | |
Market
approach based on indicative term sheet and last round of financing | |
50/50
weighting to prior Series B-2 preferred price and public market. 75% percentile for public company peer valuation ratios | |
Based
on Series B valuation of $170 million |
Preferred
stock in private companies: Promaxo Inc | |
| 1,034,984 | | |
Market
approach based on available comparables and financial performance | |
a) Last round of financing for series B-2 price, 118% change in enterprise value @75th percentile b) revenue multiples 2021 13.3X 2022 9.3x | |
0%-168.3%
0.6x - 27.7x 0.5x - 59.4x |
Preferred
stock in private companies: Other | |
| 2,744,691 | | |
Market
approach based on available comparables and financial performance | |
Market
approach based on available information from portfolio companies | |
Various |
Common
stock in private companies | |
| 325,000 | | |
Market
approach based on available comparables and financial performance | |
Historic
or projected revenue and/or EBITDA multiples discounted for lack of marketability | |
Various |
SAFE | |
| 575,000 | | |
Market
approach based on available comparables and financial performance | |
Precedent
and follow-on transactions adjusted for marketability | |
Various |
Other
investments | |
| 571,000 | | |
Market
approach based on available comparables and financial performance | |
Precedent
and follow-on transactions adjusted for marketability | |
Various |
Total
Investments | |
$ | 9,811,486 | | |
| |
| |
|
| |
As
of March 31, 2021 | |
| |
Fair
Value | | |
Valuation
Approach/ Technique | |
Unobservable
Inputs | |
Range/
Weighted Average |
| |
| | |
| |
| |
|
Convertible
notes: Kitotech Medical Inc | |
$ | 326,871 | | |
Market
approach based on available comparables and financial performance | |
Market
cap of $28.51 million a, Public company 75th percentile As if converted 2020 note | |
Range
: $28.514 million |
Convertible
notes | |
| 2,227,083 | | |
Market
approach based on available comparables and financial performance | |
Conversion
prospects, market yield, remaining maturity | |
1-12%
yield |
Preferred
stock in private companies: Femto DX Inc | |
| 159,835 | | |
Market
approach based on available comparables and financial performance | |
Based
on Series B financing and public company peer multiples using 50:50 percentile | |
Market
value of invested capital $58.66 million |
Preferred
stock in private companies: Neuroflow Inc | |
| 437,495 | | |
Market
approach based on available comparables and financial performance | |
Based
on Series Seed 2 and last round of financing - Series B | |
Market
value of invested capital $57.98 million |
Preferred
stock in private companies: other | |
| 2,532,128 | | |
Market
approach based on available comparables and financial performance | |
Market
approach based on available information from portfolio companies | |
Various |
Common
stock in private companies | |
| 300,000 | | |
Market
approach based on available comparables and financial performance | |
Historic
or projected revenue and/or EBITDA multiples | |
Various |
SAFE | |
| 325,000 | | |
Market
approach based on available comparables and financial performance | |
Precedent
and follow-on transactions adjusted for marketability | |
Various |
Other
investments | |
| 421,000 | | |
Market
approach based on available comparables and financial performance | |
Precedent
and follow-on transactions adjusted for marketability | |
Various |
Total
Investments | |
$ | 6,729,412 | | |
| |
| |
|
The
following table presents fair value measurements of investments, by major class, as of September 30, 2021, and March 31, 2021, according
to the fair value hierarchy:
SCHEDULE OF INVESTMENTS AT FAIR VALUE MEASUREMENTS OF INVESTMENTS
| |
As of September 30, 2021 | |
| |
Quoted prices in active markets for identical securities | | |
Significant other observable inputs | | |
Significant unobservable inputs | | |
| |
Description | |
(Level 1) | | |
(Level 2) | | |
(Level 3) | | |
Total | |
Investments at Fair Value | |
| | | |
| | | |
| | | |
| | |
Private Portfolio Companies | |
| | | |
| | | |
| | | |
| | |
Convertible notes | |
$ | - | | |
$ | - | | |
$ | 3,801,833 | | |
$ | 3,801,833 | |
Preferred stock | |
| - | | |
| - | | |
| 4,538,653 | | |
| 4,538,653 | |
Common stock | |
| - | | |
| - | | |
| 325,000 | | |
| 325,000 | |
SAFEs | |
| - | | |
| - | | |
| 575,000 | | |
| 575,000 | |
Other ownership interests | |
| - | | |
| - | | |
| 571,000 | | |
| 571,000 | |
| |
| - | | |
| - | | |
| 9,811,486 | | |
| 9,811,486 | |
Public Portfolio Companies | |
| | | |
| | | |
| | | |
| | |
Common stock | |
| 631,327 | | |
| - | | |
| - | | |
| 631,327 | |
| |
| | | |
| | | |
| | | |
| | |
Total Investments at Fair value | |
$ | 631,327 | | |
$ | - | | |
$ | 9,811,486 | | |
$ | 10,442,813 | |
| |
As of March 31, 2021 | |
Description | |
Level 1 | | |
Level 2 | | |
Level 3 | | |
Total | |
March 31, 2021 | |
| | |
| | |
| | |
| |
Investments at Fair Value | |
| | | |
| | | |
| | | |
| | |
Private Portfolio Companies | |
| | | |
| | | |
| | | |
| | |
Convertible notes | |
$ | - | | |
$ | - | | |
$ | 2,553,954 | | |
$ | 2,553,954 | |
Preferred stock | |
| - | | |
| - | | |
| 3,129,458 | | |
| 3,129,458 | |
Common stock | |
| - | | |
| - | | |
| 300,000 | | |
| 300,000 | |
SAFEs | |
| - | | |
| - | | |
| 325,000 | | |
| 325,000 | |
Other ownership interests | |
| - | | |
| - | | |
| 421,000 | | |
| 421,000 | |
| |
| - | | |
| - | | |
| 6,729,412 | | |
| 6,729,412 | |
| |
| | | |
| | | |
| | | |
| | |
Public Portfolio Companies | |
| | | |
| | | |
| | | |
| | |
Common stock | |
| 91,995 | | |
| - | | |
| - | | |
| 91,995 | |
| |
| | | |
| | | |
| | | |
| | |
Total Investments at Fair value | |
$ | 91,995 | | |
$ | - | | |
$ | 6,729,412 | | |
$ | 6,821,407 | |
As
of September 30, 2021, and March 31, 2021, all our investments were treated as Level 3 with the exception of two which are invested in
common stock of a public company and treated as Level 1.
We
focus on making our investments in the United States, Canada, and Israel. All investments are made and reported in U.S. dollars. Assets
that are denominated in foreign currencies are translated into U.S. dollars at closing rates of exchange on the date of valuation. Transactions
during the year are translated at the rate of exchange prevailing on the date of the transaction. The Company does not isolate that portion
of results of operations resulting from the changes in foreign exchange rates on securities from fluctuations resulting from changes
in market prices of such securities. Such foreign currency translation gains and losses are included in the net realized gains or losses
from investments and net changes in unrealized gain or losses from investments on the statement of operations.
SCHEDULE OF INVESTMENTS IN UNREALIZED GAIN OR LOSSES FOREIGN EXCHANGE RATES ON SECURITIES
| |
America | | |
Canada | | |
Rest of World | | |
Total | |
Fair value beginning of year March 31, 2021 | |
$ | 5,486,011 | | |
$ | 907,560 | | |
$ | 427,836 | | |
$ | 6,821,407 | |
New investments | |
| 1,668,091 | | |
| 200,000 | | |
| 350,000 | | |
| 2,218,091 | |
Proceeds from sale of investments | |
| - | | |
| - | | |
| - | | |
| - | |
Realized gains | |
| - | | |
| - | | |
| - | | |
| - | |
Net change in unrealized gains included in condensed Statements of Operations | |
| 1,360,028 | | |
| 29,556 | | |
| 13,731 | | |
| 1,403,315 | |
Fair value end of six months September 30, 2021 | |
$ | 8,514,130 | | |
$ | 1,137,116 | | |
$ | 791,567 | | |
$ | 10,442,813 | |
Changes in unrealized gains or losses for the period included in Condensed Statement of Operations for assets held at the end of the reporting period. | |
| | | |
| | | |
| | | |
$ | 1,403,315 | |
| |
America | | |
Canada | | |
Rest of World | | |
Total | |
Fair value beginning of year March 31, 2020 | |
$ | 2,170,499 | | |
$ | 245,000 | | |
$ | 250,000 | | |
$ | 2,665,499 | |
New investments | |
| 540,000 | | |
| 150,000 | | |
| 50,000 | | |
| 740,000 | |
Proceeds from sale of investments | |
| - | | |
| - | | |
| - | | |
| - | |
Realized gains | |
| - | | |
| - | | |
| - | | |
| - | |
Net change in unrealized gains included in condensed Statements of Operations | |
| 438,953 | | |
| 21,947 | | |
| 17,348 | | |
| 478,248 | |
Fair value end of six months September 30, 2020 | |
$ | 3,149,452 | | |
$ | 416,947 | | |
$ | 317,348 | | |
$ | 3,883,747 | |
Changes in unrealized gains or losses for the period included in Condensed Statement of Operations for assets held at the end of the reporting period. | |
| | | |
| | | |
| | | |
$ | 478,248 | |
Working
on the experience of our technical advisors, we limit our investments to fintech, technology, and life sciences.
| |
Fintech | | |
Technology | | |
Life science | | |
Total | |
Fair value beginning of year March 31, 2021 | |
$ | 126,030 | | |
$ | 1,394,318 | | |
$ | 5,301,059 | | |
$ | 6,821,407 | |
New investments | |
| - | | |
| 590,600 | | |
| 1,627,491 | | |
| 2,218,091 | |
Proceeds from sale of investments | |
| - | | |
| - | | |
| - | | |
| - | |
Realized gains | |
| - | | |
| - | | |
| - | | |
| - | |
Net change in unrealized gains included in condensed Statements of Operations | |
| - | | |
| 45,531 | | |
| 1,357,784 | | |
| 1,403,315 | |
Fair value end of six months September 30, 2021 | |
$ | 126,030 | | |
$ | 2,030,449 | | |
$ | 8,286,334 | | |
$ | 10,442,813 | |
Changes in unrealized gains or losses for the period included in Condensed Statement of Operations for assets held at the end of the reporting period. | |
| | | |
| | | |
| | | |
$ | 1,403,315 | |
| |
Fintech | | |
Technology | | |
Life science | | |
Total | |
Fair value beginning of year March 31, 2020 | |
$ | 101,500 | | |
$ | 685,002 | | |
$ | 1,878,997 | | |
$ | 2,665,499 | |
New investments | |
| - | | |
| - | | |
| 740,000 | | |
| 740,000 | |
Proceeds from sale of investments | |
| - | | |
| - | | |
| - | | |
| - | |
Realized gains | |
| - | | |
| - | | |
| - | | |
| - | |
Net change in unrealized gains included in condensed Statements of Operations | |
| 24,530 | | |
| 37,769 | | |
| 415,949 | | |
| 478,248 | |
Fair value end of six months September 30, 2020 | |
$ | 126,030 | | |
$ | 722,771 | | |
$ | 3,034,946 | | |
$ | 3,883,747 | |
Changes in unrealized gains or losses for the period included in Condensed Statement of Operations for assets held at the end of the reporting period. | |
| | | |
| | | |
| | | |
$ | 478,248 | |
We
invest in early-stage private companies developing products or solutions in the fields of fintech, technology and life sciences. Typically,
we are investing in interest bearing notes that may be convertible into equity securities upon the completion of qualified subsequent
financings, preferred stock, SAFEs or other forms of ownership. Typically notes carry a two-year term and are then rolled over for additional
periods if no other maturity triggers have been achieved. If a convertible note investment were, in our judgment, to become impaired,
we would reverse the accrued interest and adjust the valuation to reflect management’s assessment of fair value. If a convertible
note investment exceeds its maturity date we would request the portfolio company to document an extension, as well as consider whether
the overdue note, along with all other available performance data and management reviews lead us to consider whether there should be
an adjustment in fair value of the investment. There were no transfers into or out of Level 3 during the three and six months ended September
30, 2021 and September 30, 2020.
SCHEDULE OF ADJUSTMENT IN FAIR VALUE TO REFLECT IMPAIRMENT OF INVESTMENT
| |
Convertible notes | | |
Preferred stock | | |
Common stock | | |
SAFEs | | |
Other ownership interests | | |
Total | |
| |
| | |
| | |
| | |
| | |
| | |
| |
Fair value March 31, 2021 | |
$ | 2,553,954 | | |
$ | 3,129,458 | | |
$ | 391,995 | | |
$ | 325,000 | | |
$ | 421,000 | | |
$ | 6,821,407 | |
Conversions into preferred stock | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | |
New investments | |
| 1,027,491 | | |
| 600,000 | | |
| 190,600 | | |
| 250,000 | | |
| 150,000 | | |
| 2,218,091 | |
Proceeds from sale of investments | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | |
Realized gains | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | |
Unrealized gains included in condensed Statements of Operations | |
| 220,388 | | |
| 809,195 | | |
| 373,732 | | |
| - | | |
| - | | |
| 1,403,315 | |
Fair value September 30, 2021 | |
$ | 3,801,833 | | |
$ | 4,538,653 | | |
$ | 956,327 | | |
$ | 575,000 | | |
$ | 571,000 | | |
$ | 10,442,813 | |
| |
Convertible notes | | |
Preferred stock | | |
Common stock | | |
SAFEs | | |
Other ownership interests | | |
Total | |
| |
| | |
| | |
| | |
| | |
| | |
| |
Fair value March 31, 2020 | |
$ | 1,528,002 | | |
$ | 701,497 | | |
$ | 126,500 | | |
$ | 73,500 | | |
$ | 236,000 | | |
$ | 2,665,499 | |
Conversions into preferred stock | |
| (597,984 | ) | |
| 678,313 | | |
| - | | |
| (80,329 | ) | |
| - | | |
| - | |
New investments | |
| 100,000 | | |
| 440,000 | | |
| 100,000 | | |
| - | | |
| 100,000 | | |
| 740,000 | |
Proceeds from sale of investments | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | |
Realized gains | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | |
Unrealized gains included in condensed Statements of Operations | |
| 178,986 | | |
| 279,433 | | |
| (62,000 | ) | |
| 81,829 | | |
| - | | |
| 478,248 | |
Fair value September 30, 2020 | |
$ | 1,209,004 | | |
$ | 2,099,243 | | |
$ | 164,500 | | |
$ | 75,000 | | |
$ | 336,000 | | |
$ | 3,883,747 | |
NOTE
6– EQUITY
Series
A
The
Company has sold 4,200,000 Series A Stock Units (“Units”) consisting of one share of Series A Preferred Stock and one warrant
to purchase a share of Common Stock at $0.80 per share. The Units were sold in a private placement to accredited investors. The Series
A Preferred Stock will be converted into shares of Common Stock upon listing of the Company on Nasdaq or NYSE. In the event of any liquidation
or winding up of the Company, the holders of the Series A shall be entitled to receive in preference to the holders of shares of Common
Stock a per share amount equal to two times (2 X) their original purchase price plus any declared but unpaid dividends (the Liquidation
Preference). All share issuances and obligations are recognized on the books and stock register.
On
March 2, 2021, in preparation for an intended IPO, the Company made an offer to all its preferred shareholders to protect them against
the possibility that the IPO price might be less than their preferred stock price. Accordingly, Series A-1 and Series A-2 Preferred Stock
were created, and the holders of Series A Preferred Stock were granted an opportunity to purchase shares of Common Stock at $0.40 per
share. If shareholders purchased at least $6,000 of Common Stock, their shares of Series A Preferred Stock were exchanged for Series
A-1 which is guaranteed to convert into shares of Common Stock at the same price as the IPO price, and if shareholders purchased a pro-rated
amount of Common Stock their Series A Preferred Stock were exchanged for Series A-2 Preferred Stock which in turn is convertible into
shares of Common Stock at a discount of 10% to the IPO price. In all other respects the Series A-1 and Series A-2 Preferred Stock has
the same rights and obligations as the Series A Preferred Stock. As of September 30, 2021, 1,437,500 shares of Series A Preferred Stock
had been exchanged for Series A-1 Preferred Stock, and 2,212,500 shares of Series A Preferred Stock had been exchanged for Series A-2
Preferred Stock, respectively, leaving outstanding 550,000 shares of Series A Preferred Stock (“Series A”) designated at
a par value of $0.01 per share.
Series
B
There
were also 6,000,000 shares of Series B Preferred Stock (“Series B”) authorized designated at a par value of $0.01 per share.
The Series B can be converted into shares of Common Stock upon listing of the Company on Nasdaq. In the event of any liquidation or winding
up of the Company, the holders of the Series B shall be entitled to receive in preference to the holders of Common Shares and Series
A Preferred Stock, a per share amount equal to two times (2 X) their original purchase price plus any declared but unpaid dividends (the
Liquidation Preference). The holders of Series B shall be entitled to receive out of any funds of the Corporation at a time legally available
for the declaration of dividends, dividends at a cumulative rate of 10% under such terms and conditions as the Board shall prescribe,
provided, however, that in the event dividends shall be declared, dividends on issued and outstanding Series B shall be payable before
any dividends shall be declared or paid upon or set apart for the Common Stock.
On
March 2, 2021, in preparation for an intended future IPO, the Company made an offer to all its preferred shareholders to protect them
against the possibility that the IPO price might be less than their preferred stock price. Accordingly, Series B-1 and Series B-2 Preferred
Stock (“Series B-1” and “Series B-2”, respectively) were created, and the holders of the Series B were granted
an opportunity to purchase shares of Common Stock at $0.40 per share. If shareholders purchased at least $6,000 of Common Stock, their
Series B were exchanged for Series B-1 which is guaranteed to convert into shares of Common Stock at the same price as the IPO price,
and if shareholders purchased a pro-rated amount of Common Stock their Series B were exchanged for Series B-2 which converts into shares
of Common Stock at a discount of 10% to the IPO price. In all other respects, the Series B-1 and Series B-2 have the same rights and
obligations as the Series B. At September 30, 2021, 1,166,406 shares of Series B had been exchanged for Series B-1, and 2,176,250 shares
of Series B had been exchanged for Series B-2, respectively, leaving outstanding 286,250 shares of Series B. During the three and six
months ended September 30, 2021, the Company sold 1,591,250 and 2,282,500 shares of Series B-1 Preferred Stock for $1,273,000 and $1,826,001,
respectively.
As
of September 30, 2021, the Company authorized an additional 3,000,000 shares of Series B stock designated as Series B-3 Preferred (“Series
B-3”) bringing Series B to a total of 9,000,000 authorized shares with a par value of $0.01 per share. The Certificate of Designation
of the Series B-3 shares was filed with the Delaware Secretary of State on October 5, 2021. The Series B-3 will be offered for $0.80
per share and accrue a cumulative dividend of 10% per annum. The remaining terms and conditions are substantially the same as for all
other Series B shares, including mandatory conversion upon a majority vote of the Series B-3 shareholders, closing of a qualified financing
of at least $10 million, or listing on a public stock exchange.
B)
COMMON STOCK
The
Company has authorized 40,000,000 shares of common stock at a par value of $0.01 per share. As of September 30, 2021, and March 31, 2021
a total of 13,287,621 and 9,983,082 shares of the Company’s common stock were issued and outstanding, respectively.
During
the three and six months ended September 30, 2021, in connection with the amendment of Preferred Stock rights described in A above, the
Company sold 3,285,789 shares of Common Stock for $1,314,317 of which $1,191,442 was received and accrued as subscription liability at
March 31, 2021.
During
each of the three and six months ended September 30, 2021, the Company issued 18,750 shares of Common Stock for $618, respectively, in
connection with the exercise of stock options.
C)
STOCK OPTIONS
In
April 2018, the Board approved the introduction of the Kyto Technology and Life Science, Inc. Incentive Stock Option Plan (“the
2018 Plan”) reserving 2,697,085 shares for issuance to employees, consultants and directors, with the objective of securing the
benefit of services for stock options rather than cash salaries.
In
July 2019, the Board approved the introduction of the Kyto Technology and Life Science 2019 Stock Option and Incentive Plan (“2019
Plan”), and reserved 2 million shares for issuance to directors, officers, consultants and advisors. Options granted under the
2019 Plan expire May 21, 2029.
In
December 2020, the Board approved the introduction of the Kyto Technology and Life Science 2020 Non Qualified Stock Option Plan (“2020
Plan”), and reserved 2 million shares for issuance to directors, officers, consultants and advisors. Options granted under the
2020 Plan expire December 16, 2030.
During
the three months ended September 30, 2021, and September 30, 2020, the Company issued a total of 490,000 and 510,000 non-qualified stock
options, respectively, to consultants and advisors vesting over terms of two years. During the corresponding six months ended September
30, 2021, and September 30, 2020, the Company issued a total of 740,000 and 630,000 non-qualified stock options, respectively.
SCHEDULE OF OPTIONS VESTED
| |
Number of options granted | | |
Weighted average exercise price | | |
Weighted average remaining life years | |
Outstanding March 31, 2021 | |
| 2,634,250 | | |
$ | 0.05 | | |
| 8.13 | |
Granted | |
| 740,000 | | |
| 0.07 | | |
| 9.42 | |
Exercised | |
| (18,750 | ) | |
| (0.03 | ) | |
| - | |
Cancelled | |
| - | | |
| - | | |
| - | |
Outstanding September 30, 2021 | |
| 3,355,500 | | |
$ | 0.06 | | |
| 8.63 | |
| |
| | | |
| | | |
| | |
Exercisable September 30, 2021 | |
| 2,085,041 | | |
$ | 0.04 | | |
| 8.90 | |
In
connection with the grant of stock options the Company recognizes the value of the related option expense using the Black Scholes model,
with appropriate assumptions for option life, stock value, risk free interest rate, volatility, and cancellations.
SCHEDULE OF FAIR VALUE ASSUMPTIONS - STOCK OPTIONS
| |
September
30, 2021 | | |
March
31, 2021 | |
Stock Price at grant date | |
$ | 0.07 | | |
$ | 0.033
-
$ 0.078 | |
Exercise Price | |
$ | 0.07 | | |
$ | 0.033
-
$ 0.078 | |
Term in Years | |
| 0
-
2.00 | | |
| 0
-
2.00 | |
Volatility assumed | |
| 196 | % | |
| 71%
- 196 | % |
Annual dividend rate | |
| 0.0 | % | |
| 0.0 | % |
Risk free discount rate | |
| 0.12 | % | |
| 0.12%
- 2.0 | % |
The
compensation expense calculated at time of grant is recognized over the vesting period for the options granted. During the three and
six months ended September 30, 2021 the Company recognized $10,897
and $21,454,
respectively, as stock-based compensation expense. For the corresponding three and six months ended September 30, 2020, the Company recognized
$12,805 and
$13,851,
respectively.
The
intrinsic value of outstanding options at September 30, 2021 was $62,580,
and $56,987
of the option expense upon grant remained
unrecognized at September 30, 2021 with a remaining vesting period of 1.44
years.
D)
WARRANTS
In
conjunction with the sale of Series A Stock Units, the Company issued 4,200,000 warrants to purchase common stock at a price of $1.20
per share for a period of three years. The Company did not bifurcate the value of the warrants as the fair value of the warrant was determined
to be de minimis. The Company has not issued any warrants since September, 2019. At September 30, 2021 and March 31, 2021 the fair value
of the warrants was de minimis.
SCHEDULE OF WARRANTS
| |
Number of warrants | | |
Weighted average exercise price | | |
Weighted average remaining life
in years | |
Outstanding March 31, 2020 | |
| 4,200,000 | | |
$ | 1.20 | | |
| 2.9 | |
Granted | |
| - | | |
| - | | |
| - | |
Exercised | |
| (2,603,333 | ) | |
$ | 1.20 | | |
| - | |
Cancelled | |
| - | | |
| - | | |
| - | |
Outstanding September 30, 2020 | |
| 1,596,667 | | |
$ | 1.20 | | |
| 1.4 | |
| |
| | | |
| | | |
| | |
Exercisable March 31, 2020 | |
| 4,200,000 | | |
$ | 1.20 | | |
| 2.9 | |
Exercisable September 30, 2020 | |
| 1,596,667 | | |
$ | 1.20 | | |
| 1.4 | |
| |
Number of warrants | | |
Weighted average exercise price | | |
Weighted average remaining life
in years | |
Outstanding March 31, 2021 | |
| 1,596,667 | | |
$ | 1.20 | | |
| 1.4 | |
Granted | |
| - | | |
| | | |
| - | |
Exercised | |
| - | | |
| | | |
| - | |
Cancelled | |
| - | | |
| | | |
| - | |
Outstanding September 30, 2021 | |
| 1,596,667 | | |
$ | 1.20 | | |
| 1.1 | |
| |
| | | |
| | | |
| | |
Exercisable March 31, 2021 | |
| 1,596,667 | | |
$ | 1.20 | | |
| 1.4 | |
Exercisable September 30, 2021 | |
| 1,596,667 | | |
$ | 1.20 | | |
| 1.1 | |
The
Company values the warrants using the Black Scholes model, with appropriate assumptions for warrant life, stock value, risk free interest
rate, and volatility. The assumptions used for warrant valuation were as follows:
SCHEDULE OF FAIR VALUE ASSUMPTIONS - STOCK OPTIONS
Stock Price at grant date | |
$ | 0.006 | |
Exercise Price | |
$ | 1.200 | |
Term in Years | |
| 3.00 | |
Volatility assumed | |
| 73 | % |
Annual dividend rate | |
| 0.0 | % |
Risk free discount rate | |
| 1.79 | % |
NOTE
7 – FINANCIAL HIGHLIGHTS
SCHEDULE OF FINANCIAL HIGHLIGHTS
Per share data ( a) | |
Three months
ended | | |
Three months
ended | | |
Six months
ended | | |
Six months
ended | |
| |
September 30,
2021 | | |
September 30,
2020 | | |
September 30,
2021 | | |
September 30,
2020 | |
Net asset value | |
$ | 0.82 | | |
$ | 0.72 | | |
$ | 0.82 | | |
$ | 0.72 | |
Net investment loss | |
$ | (0.03 | ) | |
$ | (0.03 | ) | |
$ | (0.06 | ) | |
$ | (0.03 | ) |
Net unrealized gain on investments | |
$ | 0.10 | | |
$ | 0.05 | | |
$ | 0.11 | | |
$ | 0.08 | |
Net increase in net assets | |
$ | 0.08 | | |
$ | 0.05 | | |
$ | 0.05 | | |
$ | 0.05 | |
| |
| | | |
| | | |
| | | |
| | |
Ratios and Supplemental Data | |
| | | |
| | | |
| | | |
| | |
Net assets, end of period | |
$ | 10,817,894 | | |
$ | 4,230,731 | | |
$ | 10,817,894 | | |
$ | 4,230,731 | |
| |
| | | |
| | | |
| | | |
| | |
Weighted average common shares outstanding, end of period | |
| 13,271,996 | | |
| 5,836,832 | | |
| 13,269,764 | | |
| 5,836,832 | |
| |
| | | |
| | | |
| | | |
| | |
Total operating expenses/net assets | |
| 3.3 | % | |
| 3.8 | % | |
| 6.8 | % | |
| 4.7 | % |
| |
| | | |
| | | |
| | | |
| | |
Net investment loss/net assets | |
| 3.3 | % | |
| 3.8 | % | |
| 6.8 | % | |
| 4.7 | % |
| |
| | | |
| | | |
| | | |
| | |
Total return | |
| 9.2 | % | |
| 7.5 | % | |
| 6.1 | % | |
| 6.6 | % |
NOTE
8 - SUBSEQUENT EVENTS
On
October 5, 2021, the Company filed a Form 8-K announcing the Designation of 3,000,000 million shares of B-3 Preferred Stock. As of November
13, 2021, the Company has sold $546,000 of shares of Series B-3 Preferred Stock and invested $300,000 in three follow-on investments.
ITEM
2. |
MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS |
PLAN
OF OPERATIONS
Kyto
Technology and Life Science, Inc. (the “Company”) was formed as a Florida corporation on March 5, 1999 under the name of
B Twelve, Inc. In August, 2002, the Company changed its name from B Twelve, Inc. to Kyto BioPharma Inc. and in May 2018, the name was
changed again to Kyto Technology and Life Science, Inc. In July 2019, the Company was re-incorporated as a Delaware company. The Company
operates virtually, from public locations or the homes of its officers, and does not currently lease any office space.
The
Company was originally formed to acquire and develop proprietary drugs for the treatment of cancer, arthritis, and other autoimmune diseases
and had been evaluating a number of strategies. As of March 31, 2018, the Company had accumulated a deficit of $32,380,746 from all prior
operations. In April 2018, the Board adopted a new business plan focused on the development of early-stage technology and life science
businesses through early stage investment funding. The Company has recruited a number of experienced investment consultants from a network
that includes angel investors, corporate managers, sophisticated early stage investors and successful entrepreneurs with experience across
a number of technology and life science products and markets, and relies on input from these advisors in conducting due diligence and
making investment decisions. In order to offset the risk in early-stage investing, the Company works with angel investment groups and
other sophisticated investors and participates only after these groups have completed due diligence and committed to invest, in effect
becoming lead investors. The Company then completes its own due diligence and invests under identical terms as the lead investors. The
Company will do follow-on investments in existing portfolio companies, assuming adequate progress, when portfolio companies initiate
new financing rounds. The Company currently does not typically invest more than $250,000 in any single investment. Generally, the Company’s
investments represent less than 5% ownership interests, and the Company therefore has no effective control or influence over the management
or commercial decisions of the companies in which it invests. The Company plans to generate revenue from realized gains from the sale
of the businesses in which it has invested, or some or all of its shareholdings in those cases where portfolio companies go public. Generally,
it is expected that investments will be realized from an exit within a period of four to five years following initial investment. Such
exits or liquidity events are outside the Company’s control and depend on merger and acquisition (“M&A”) transactions
or an initial public offering (“IPO”) which may result in cash or equity proceeds. Accordingly, it is difficult to forecast
revenue, net income, and cash flow. Other than making its initial and, potentially, follow-on investments in its portfolio companies,
the Company does not provide any financial support to any of its investees.
The
Company has one regular employee – the CEO, Mr, Paul Russo. Prior to December 31, 2020, was acting as a consultant to the Company
and did not receive contractual compensation for his services in the form of cash. As of January 1, 2021, Mr. Russo was engaged as an
employee of the Company at a salary of $400,000 per annum of which 60% was paid monthly from January through April 2021, and 75% was
paid in subsequent months, with the balance deferred to be paid once the Company lists and starts trading on the Nasdaq exchange. The
full terms of Mr. Russo’s employment are described in a Form 8-K on February 1, 2021, incorporated by reference herein, which was
approved by the Compensation committee of the Board of Directors on that date. During the three months ended September 30, 2021, Mr.
Russo received $80,000 gross pay, no consulting fees and no options were granted. During the three months ended September 30, 2020, Mr.
Russo received no payroll or consulting fees, and no options were granted to him.
The
Company has created a portfolio of minority investments in early-stage start-up companies and derives its revenue opportunity from the
sale of those investments. Such sales are outside the Company’s control and depend on M&A transactions or IPOs which may result
in cash or equity proceeds. Accordingly, it is difficult to forecast revenue, net income, and cash flow. As of the date of this filing,
the Company had approximately $485,000 of cash to cover its operating expenses, and new investment requirements, and is continuing to
raise additional funding on a recurring monthly basis. If successful, it will have sufficient funding for further investments and ongoing
operations. However, there is no assurance that the Company will be able to raise sufficient cash to cover its requirements on attractive
terms, if at all, and whether it will be able to continue as a going concern. These conditions raise substantial doubt about the Company’s
ability to continue as a going concern. Stay at home orders and general economic uncertainties arising out of the current Covid-19 epidemic
have created additional delays and uncertainty. To date there has been no disruption to the Company’s business operations, although
some of its portfolio investment companies report delays in their programs.
At
March 31, 2020, management determined that the Company was an investment company for purposes of ASC 946 disclosure, and committed to
follow the specialized accounting and reporting guidance contained therein. Accordingly, a new company, Kyto Investments, Inc. (“KI”)
was incorporated in Delaware in December 2020 in preparation for a restructuring and an N-2 Registration Statement filed in March 2021
for review by the SEC. KI is an internally managed, closed-end investment company that has elected to be regulated as a business development
company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”). Immediately upon effectiveness
of this N-2 Registration Statement, the Company will merge with KI and the Company will be the surviving entity. As of the completion
of the merger, the Company will constitute a “successor issuer” for the purposes of Rule 414 under the Securities Act and
may continue the current offering by filing post-effective amendments to the Registration Statements. Prior to the merger, the Company
had fewer than 100 non-affiliated investors and filed under the 1934 Act relying on exemption Rule 3( c )(1).
As
a BDC, the Company will be required to comply with certain regulatory requirements. The Company also intends to elect to be treated for
U.S. federal income tax purposes as a regulated investment company (“RIC”) under Subchapter M of the Internal Revenue Code
of 1986, as amended (the “Code”). As a RIC, the Company is required to comply with additional regulatory requirements. The
Company has prepared and submitted sequentially two N-2 Registration Statements to the SEC for review but has not yet received final
approval of its registration as at the filing date of this report.
Results
of Operations
Revenue:
In the three months and six months ended September 30, 2021 the Company reported no realized investment income as there were no liquidity
events related to its investment portfolio. The Company reported $1,350,449 and $1,403,415 of unrealized gains from investments respectively,
in these periods. In the three months and six months ended September 30, 2020 the Company reported no realized investment income as there
were no liquidity events related to its investment portfolio. The Company reported $478,248 of unrealized gains from investments respectively,
in these same periods.
.
Professional
fees: In the three months and six months ended September 30, 2021, the Company reported $107,201 and $273,359, respectively, of professional
fees, mainly for legal and accounting services. In the corresponding three months and six months ended September 30, 2020 the Company
reported $63,605 and $76,543, respectively.
Other
Operating expenses: Other operating expenses include payroll, consulting, and travel and conference fees associated with raising capital
and review of investment deal-flow. In the three months and six months ended September 30, 2021, the Company incurred other operating
expenses of $245,519 and $466,127, respectively. In the corresponding three months and six months ended September 30, 2020, the Company
incurred other operating expenses of $96,506 and $122,936, respectively.
For
the three months and six months ended September 30, 2021, the Company’s net increase in net assets resulting from operations was
$996,133 and $662,341, respectively. For the corresponding three months and six months ended September 30, 2020, the Company’s
net increase in net assets resulting from operations was $318,137 and $279,269, respectively.
During
the three months ended September 30, 2021, the Company was subject to shelter in place regulations imposed by the State of California
in mitigation of the spread of the Corona 19 virus. Since the Company does not have any dedicated office space and works virtually from
the homes of its officers, there was no major disruption in working routines which continued by video and teleconference. Uncertainty
arising from Covid 19 created a slow-down in the rate at which the Company was able to raise Series B funding, and thereby continue to
make investments, however the Company did see a reduction in travel and investor relations expenses during the period. The Company has
more than 60 discrete investments in a range of different industry and geographic segments, many of which are in the life science and
medical space. While there is clearly a risk that our portfolio companies may be adversely affected in their ability to raise future
funding or do business, there have been no management reports revealing major problems and some of our portfolio companies may actually
benefit from new opportunities created. We believe that our policy of spreading our investments in relatively small amounts over a large
number of portfolio companies helps mitigate some of the risk that might be suffered by any of our investments.
Liquidity
and Capital Resources
The
Company had net assets of $10,817,894 and $6,993,163 at September 30, 2021 and March 31, 2021, respectively. Cash was $316,124 and $1,437,868
at September 30, 2021 and March 31, 2021, respectively.
Cash
from operating activities
The
Company used net cash of $3,071,238 in operating activities during the six months ended September 30, 2021 compared to $909,564 used
for the six months ended September 30, 2020. Main reasons for the higher level in 2021 were an increase in investments in portfolio companies
and increased professional fees and operating expenses.
Cash
from investing activities
No
cash was used in investing activities.
Cash
from financing activities
The
Company had a net cash inflow from financing activities of $1,949,494 in the six months ended September 30, 2021 compared to $1,273,250
in the three months ended September 30, 2020. This inflow included $1,826,001 proceeds from the sale of Series B preferred stock, and
$122,875 proceeds from the sale of common stock, respectively, in the six months ended September 30, 2021, compared to $1,270,000 from
the sale of Series B preferred stock in the corresponding six month prior period ended September 30, 2020.
The
Company’s plan of operations for the next twelve months is to continue to focus its efforts on finding new sources of capital by
means of private placements, and to use this capital to fund additional investments as they become available, and to cover operating
expenses. The Company is planning to uplift from OTC to the NASDAQ market, and raise additional funding from an initial public offering
(“IPO)” for which as an initial step it has submitted an N-2 filing to the SEC for review.
CRITICAL
ACCOUNTING POLICIES
USE
OF ESTIMATES
In
preparing financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and
liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during
the period presented. Actual results may differ from these estimates.
Significant
estimates at September 30, 2021 and March 31, 2021 include the valuation of investments, deferred tax assets, tax allowance, stock options
and warrants.
INVESTMENT
AND VALUATION OF INVESTMENT AT FAIR VALUE
The
Company reviews the performance of its investments based on available information, including management reports, press releases, web
site announcements and progress reports, third party equity updates, management interviews and, where accessible, financial reports,
to determine their fair values. In the event that Management considers the fair value of an investment to be greater or less than the
current book value, the difference will be reflected as unrealized gains or losses in investments in the statements of operations.
The
Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820,
“Fair Value Measurements and Disclosures”, for assets and liabilities measured at fair value on a recurring basis. ASC
820 establishes a common definition for fair value to be applied to existing GAAP that require the use of fair value measurements which
establishes a framework for measuring fair value and expands disclosure about such fair value measurements.
Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants. Fair value is an exchange price notion under which fair value is the price in an orderly transaction between market
participants to sell an asset or transfer a liability in the market in which the reporting entity would transact for the asset or liability.
The
Company has established procedures to estimate the fair value of its investments which the Company’s board of directors has reviewed
and approved. The Company uses observable market data to estimate the fair value of investments to the extent that market data is available.
In the absence of quoted market prices in active markets, or quoted market prices for similar assets or in markets that are not active,
the Company uses the valuation methodologies described below with unobservable data based on the best available information in the circumstances,
which incorporates the Company’s assumptions about the factors that a market participant would use to value the asset.
For
investments for which quoted market prices are not available, which comprise most of our investment portfolio, fair value is estimated
by using the income, market, or back-solve approach. The income approach is based on the assumption that value is created by the expectation
of future benefits discounted to a current value and the fair value estimate is the amount an investor would be willing to pay to receive
those future benefits. The market approach compares recent comparable transactions to the investment. The back solve method involves
comparing available data over a period of time and inferring a new valuation based on changes from a known starting point, for example
the cost of an investment. Adjustments are made for any dissimilarity between the comparable transactions and the investments. These
valuation methodologies involve a significant degree of judgment on the part of our management and board.
In
determining the appropriate fair value of an investment using these approaches, the most significant information and assumptions may
include, as applicable: available current market data, including relevant and applicable comparable market transactions, applicable market
yields and multiples, security covenants, call protection provisions, information rights, the nature and realizable value of any collateral,
the investment’s ability to make payments, its earnings and discounted cash flows, the markets in which the company does business,
comparisons of financial ratios of peer companies that are public, merger and acquisition comparables, the principal market and enterprise
values, environmental factors, subsequent financings by the portfolio investment, among other factors.
The
estimated fair values do not necessarily represent the amounts that may be ultimately realized due to the occurrence or nonoccurrence
of future circumstances that cannot be reasonably determined. Because of the inherent uncertainty of the valuation of the investments,
the estimate of fair values may differ significantly from the value that would have been used had a broader market for the investments
existed.
RECENT
ACCOUNTING PRONOUNCEMENTS
Management
does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect
on the accompanying financial statements.
OFF-BALANCE
SHEET ARRANGEMENTS
As
of the date of this Quarterly Report on Form 10-Q, we do not have any off-balance sheet arrangements that have or are reasonably likely
to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations,
liquidity, capital expenditures or capital resources that are material to investors.
IMPACT
OF INFLATION
The
Company does not foresee any implications being created by the current rate of inflation.
CONTRACTUAL
OBLIGATION
The
Company has no contractual obligations outside the normal course of business with its vendors, advisors, and consultants.
ITEM
3. |
QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK |
Not
required for smaller reporting company.
ITEM
4. |
CONTROLS
AND PROCEDURES |
Evaluation
of Disclosure Controls and Procedures
We
maintain disclosure controls and procedures that are designed to ensure that material information required to be disclosed in our periodic
reports filed under the Securities Exchange Act of 1934, as amended, or 1934 Act, is recorded, processed, summarized, and reported within
the time periods specified in the SEC’s rules and forms and to ensure that such information is accumulated and communicated to
our management, including our chief executive officer/chief financial officer (principal financial officer) as appropriate, to allow
timely decisions regarding required disclosure. During the three months ended September 30, 2021 we carried out an evaluation, under
the supervision and with the participation of our management, including the principal executive officer and the principal financial officer
(principal financial officer), of the effectiveness of the design and operation of our disclosure controls and procedures, as defined
in Rule 13(a)-15(e) under the 1934 Act. Based on this evaluation, because of the Company’s limited resources and limited number
of employees, management concluded that our disclosure controls and procedures were ineffective as of September 30, 2021. Notwithstanding
this conclusion, we believe that our unaudited condensed financial statements contained in this Quarterly Report fairly present our financial
position, results of operations and cash flows for the periods covered thereby in all material respects.
Management’s
Report on Internal Control over Financial Reporting
With
the participation of our Chief Executive Officer and Chief Financial Officer (principal financial officer), our management conducted
an evaluation of the effectiveness of our internal control over financial reporting as of September 30, 2021 based on the framework in
Internal Controls—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”).
Based on our evaluation and the material weaknesses described below, management concluded that the Company did not maintain effective
internal control over financial reporting as of September 30, 2021 based on the COSO framework criteria. Management has identified control
deficiencies regarding the lack of segregation of duties and the need for a stronger internal control environment. Management of the
Company believes that these material weaknesses are due to the small size of the Company’s accounting staff. The small size of
the Company’s accounting staff may prevent adequate controls in the future, such as segregation of duties, due to the cost/benefit
of such remediation. To mitigate the current limited resources and limited employees, we rely heavily on direct management oversight
of transactions, along with the use of external legal and accounting professionals. As we grow, we expect to increase our number of employees,
which will enable us to implement adequate segregation of duties within the internal control framework. In addition, we have identified
the following material weaknesses: (i) the Company utilizes accounting software that does not prevent erroneous or unauthorized changes
to previous reporting periods and/or can be adjusted so as not to provide an adequate audit trail of entries made in the accounting software,
and (ii) we have identified a material weakness in our internal controls relating to the accounting of transactions that are either highly
complex and/or unusual in nature. In such instances, we seek to augment our internal accounting capabilities by obtaining assistance
from third-parties who have greater expertise in such areas.
These
control deficiencies could result in a misstatement of account balances that would result in a reasonable possibility that a material
misstatement to our financial statements may not be prevented or detected on a timely basis. Accordingly, we have determined that these
control deficiencies as described above together constitute a material weakness. However, management believes that despite our material
weaknesses, our financial statements for the three and six month periods ended September 30, 2021 are fairly stated, in all material
respects, in accordance with US GAAP.
Limitations
on Effectiveness of Controls and Procedures
Our
management, including our Chief Executive Officer and Chief Financial Officer (principal financial officer), does not expect that our
disclosure controls and procedures or our internal controls will prevent all errors and all fraud. A control system, no matter how well
conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further,
the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered
relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance
that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include, but
are not limited to, the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error
or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or
by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the
likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential
future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies
or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or
fraud may occur and not be detected.
PART
II. OTHER INFORMATION
ITEM
1. |
LEGAL
PROCEEDINGS |
None
Not
required for smaller reporting company.
ITEM
2. |
UNREGISTERED
SALES OF EQUITY SECURITIES AND USE OF PROCEEDS. |
The
Corporation filed a certificate of Designation in April 2021 for the issue of up to 3,200,000 shares of Series B-1 Preferred stock to
accredited investors under Section 4(2) or Rule 506 of Regulation D of the Securities Act 1933. As of the filing date, the Corporation
had sold a total of 5,911,416 shares of Series B Preferred stock to accredited investors. The Company will use the net proceeds
for investment purposes and operating expenses.
ITEM
3. |
DEFAULTS
UPON SENIOR SECURITIES |
None
ITEM
4. |
MINE
SAFETY DISCLOSURES |
Not
applicable
ITEM
5. |
OTHER
INFORMATION |
None
Index
to Exhibits on page 13
INDEX
TO EXHIBITS
* |
Filed
as Exhibit to Company’s Form 10-SB on September 12, 2003 with the Securities and Exchange Commission. |
** |
Previously
filed with Form 8-K on July 17, 2019. |
*** |
Filed
as Exhibit with Form 10-K on July 2, 2020. |
SIGNATURES
In
accordance with the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.
|
Kyto
Technology and Life Science, Inc. |
|
|
|
|
By:
|
/s/
Paul Russo |
|
|
Paul
Russo
Chief
Executive Officer, principal executive officer, |
Date:
November 18, 2021
SIGNATURES
In
accordance with the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.
|
Kyto
Technology and Life Science, Inc. |
|
|
|
|
By:
|
/s/
Simon Westbrook |
|
|
Simon
Westbrook
Principal
financial and accounting officer |
Date:
November 18, 2021